

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number  
**WO 02/086075 A2**

(51) International Patent Classification<sup>7</sup>: C12N

(21) International Application Number: PCT/US02/12635

(22) International Filing Date: 19 April 2002 (19.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/285,030 19 April 2001 (19.04.2001) US  
60/355,514 6 February 2002 (06.02.2002) US

(71) Applicant (for all designated States except US): THE  
SCRIPPS RESEARCH INSTITUTE [US/US]; 10550  
North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHULTZ, Peter  
[US/US]; 1650 La Jolla Ranch Road, La Jolla, CA 92037  
(US). WANG, Lei [CN/US]; 8730 Costa Verde Blvd., #  
2320, San Diego, CA 92122 (US). ANDERSON, John,  
Christopher [US/US]; 3922 8th Avenue, Apt. 11, San  
Diego, CA 92103 (US). CHIN, Jason, W. [GB/US]; 4249  
Nobel Drive #23, San Diego, CA 92122 (US). LIU, David,  
R. [US/US]; 1 Fox Run Lane, Lexington, MA 02420 (US).  
MAGLIERY, Thomas, J. [US/US]; 333 Mill Rd., North  
Haven, CT 06473 (US). MEGGERS, Eric, L. [DE/US];  
1534 Pine Street, Apt. 2F, Philadelphia, PA 19102 (US).  
MEHL, Ryan, Aaron [US/US]; 3576 31st Street, San  
Diego, CA 92104 (US). PASTRNAK, Miro [SK/US];  
11686 Carmel Creek Road, Apt. 107, San Diego, CA

92130 (US). SANTORO, Stephen, William [US/US];  
12668-63 Carmel Country Rd., San Diego, CA 92130  
(US). ZHANG, Zhiwen [CN/US]; 7045 Charmant Drive,  
#33, San Diego, CA 92122 (US).

(74) Agents: QUINE, Jonathan, Alan et al.; Quine Intellec-  
tual Property Law Group, P.C, P.O. Box 458, Alameda, CA  
94501 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



WO 02/086075 A2

(54) Title: METHODS AND COMPOSITION FOR THE PRODUCTION OF ORTHOGONAL TRNA-AMINOACYL-TRNA SYN-  
THETASE PAIRS

(57) Abstract: This invention provides compositions and methods for generating components of protein biosynthetic machinery including orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases. Methods for identifying orthogonal pairs are also provided. These components can be used to incorporate unnatural amino acids into proteins in vivo.

METHODS AND COMPOSITION FOR THE PRODUCTION OF  
ORTHOGANAL tRNA-AMINOACYL tRNA SYNTHETASE PAIRS

**CROSS-REFERENCE TO RELATED APPLICATIONS**

- 5    [0001]        This application claims priority to United States provisional patent application Serial No. 60/285,030, filed April 19, 2001, and United States patent application Serial No. 60/355,514, filed February 6, 2002, the specifications of which are incorporated herein in their entirety.

10                    **STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY  
                         SPONSORED RESEARCH AND DEVELOPMENT**

- [0002]        The invention was made with United States Government support under Grant No. 6502573 from the Office of Naval Research and Grant No. GM2159 from the National Institutes. The United States Government has certain rights in the invention.

**FIELD OF THE INVENTION**

- 15    [0003]        The invention relates to the field of translation biochemistry. In particular, the invention relates to methods for producing mutated orthogonal tRNAs, mutated orthogonal aminoacyl-tRNA synthetases, and pairs thereof. The invention also provides methods for identifying orthogonal pairs, which are used for the incorporation of unnatural amino acids into proteins in vivo, and related compositions.

20                    **BACKGROUND OF THE INVENTION**

- [0004]        Proteins carry out virtually all of the complex processes of life, from photosynthesis to signal transduction and the immune response. To understand and control these intricate activities, a better understanding of the relationship between the structure and function of proteins is needed.
- 25    [0005]        Unlike small organic molecule synthesis wherein almost any structural change can be made to influence functional properties of a compound, the synthesis of

proteins is limited to changes encoded by the twenty natural amino acids. The genetic code of every known organism, from bacteria to human, encodes the same twenty common amino acids. These amino acids can be modified by post-translational modification of proteins, e.g., glycosylation, phosphorylation or oxidation, or in rarer instances, by the enzymatic modification of aminoacylated suppressor tRNAs, e.g., in the case of selenocysteine. Nonetheless, polypeptides, which are synthesized from only these 20 simple building blocks, carry out all of the complex processes of life.

[0006] Both site-directed and random mutagenesis, in which specific amino acids in a protein can be replaced with any of the other nineteen common amino acids, have become important tools for understanding the relationship between the structure and function of proteins. These methodologies have made possible the generation of proteins with enhanced properties, including stability, catalytic activity and binding specificity. Nevertheless, changes in proteins are limited to the 20 common amino acids, most of which have simple functional groups. *See Knowles, J. R. Tinkering with enzymes: what are we learning? Science*, 236:1252-1258 (1987); and, Zoller, M. J., Smith, M. *Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors, Methods Enzymol*, 100:468-500 (1983). By expanding the genetic code to include additional amino acids with novel biological, chemical or physical properties, the properties of proteins, e.g., the size, acidity, nucleophilicity, hydrogen-bonding, hydrophobic properties, etc., can be modified as compared to a protein composed of only amino acids from the 20 common amino acids, e.g., as in a naturally occurring protein.

[0007] Several strategies have been employed to introduce unnatural amino acids into proteins. The first experiments involved the derivatization of amino acids with reactive side-chains such as Lys, Cys and Tyr, for example, the conversion of lysine to N<sup>ε</sup>-acetyl-lysine. Chemical synthesis also provides a straightforward method to incorporate unnatural amino acids, but routine solid-phase peptide synthesis is generally limited to small peptides or proteins with less than 100 residues. With the recent development of enzymatic ligation and native chemical ligation of peptide fragments, it is possible to make larger proteins, but such methods are not easily scaled. *See, e.g., P. E. Dawson and S. B. H. Kent, Annu. Rev. Biochem.*, 69:923 (2000). A general in vitro biosynthetic method in which a suppressor tRNA chemically acylated with the desired unnatural amino acid is added to an in vitro extract capable of supporting protein biosynthesis, has been

used to site-specifically incorporate over 100 unnatural amino acids into a variety of proteins of virtually any size. *See, e.g.*, V. W. Cornish, D. Mendel and P. G. Schultz, Angew. Chem. Int. Ed. Engl., 1995, 34:621 (1995); C. J. Noren, S.J. Anthony-Cahill, M.C. Griffith, P. G. Schultz, *A general method for site-specific incorporation of unnatural amino acids into proteins*, Science 244 182-188 (1989); and, J. D. Bain, C. G. Glabe, T. A. Dix, A. R. Chamberlin, E. S. Diala, *Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide*, J. Am. Chem. Soc. 111 8013-8014 (1989). A broad range of functional groups has been introduced into proteins for studies of protein stability, protein folding, enzyme mechanism, and signal transduction. Although these studies demonstrate that the protein biosynthetic machinery tolerates a wide variety of amino acid side chains, the method is technically demanding, and yields of mutant proteins are low.

[0008] Over 50 years ago, it was found that many analogs of natural amino acids inhibit the growth of bacteria. Analysis of the proteins produced in the presence of these amino acid analogs revealed that they had been substituted for their natural counterparts to various extents. *See, e.g.*, M. H. Richmond, Bacteriol. Rev., 26:398 (1962). This occurs because the aminoacyl-tRNA synthetase, the enzyme responsible for the attachment of the correct amino acid to its cognate tRNA, cannot rigorously distinguish the analog from the corresponding natural amino acid. For instance, norleucine is charged by methionyl-tRNA synthetase, and *p*-fluorophenylalanine is charged by phenylalanine-tRNA synthetase. *See*, D. B. Cowie, G. N. Cohen, E. T. Bolton and H. de Robichon-Szulmajster, Biochim. Biophys. Acta, 1959, 34:39 (1959); and, R. Munier and G. N. Cohen, Biochim. Biophys. Acta, 1959, 31:378 (1959).

[0009] An in vivo method, termed selective pressure incorporation, was later developed to exploit the promiscuity of wild-type synthetases. *See, e.g.*, N. Budisa, C. Minks, S. Alefelder, W. Wenger, F. M. Dong, L. Moroder and R. Huber, FASEB J., 13:41 (1999). An auxotrophic strain, in which the relevant metabolic pathway supplying the cell with a particular natural amino acid is switched off, is grown in minimal media containing limited concentrations of the natural amino acid, while transcription of the target gene is repressed. At the onset of a stationary growth phase, the natural amino acid is depleted and replaced with the unnatural amino acid analog. Induction of expression of the recombinant protein results in the accumulation of a protein containing the unnatural

analog. For example, using this strategy, *o*, *m* and *p*-fluorophenylalanines have been incorporated into proteins, and exhibit two characteristic shoulders in the UV spectrum which can be easily identified, *see, e.g.*, C. Minks, R. Huber, L. Moroder and N. Budisa, Anal. Biochem., 284:29 (2000); trifluoromethionine has been used to replace methionine in bacteriophage  $\lambda$  lysozyme to study its interaction with chitooligosaccharide ligands by  $^{19}\text{F}$  NMR, *see, e.g.*, H. Duewel, E. Daub, V. Robinson and J. F. Honek, Biochemistry, 36:3404 (1997); and trifluoroleucine has been inserted in place of leucine, resulting in increased thermal and chemical stability of a leucine-zipper protein. *See, e.g.*, Y. Tang, G. Ghirlanda, W. A. Petka, T. Nakajima, W. F. DeGrado and D. A. Tirrell, Angew. Chem. Int. Ed. Engl., 40:1494 (2001). Moreover, selenomethionine and telluromethionine are incorporated into various recombinant proteins to facilitate the solution of phases in X-ray crystallography. *See, e.g.*, W. A. Hendrickson, J. R. Horton and D. M. Lemaster, EMBO J., 9:1665 (1990); J. O. Boles, K. Lewinski, M. Kunkle, J. D. Odom, B. Dunlap, L. Lebioda and M. Hatada, Nat. Struct. Biol., 1:283 (1994); N. Budisa, B. Steipe, P. Demange, C. Eckerskorn, J. Kellermann and R. Huber, Eur. J. Biochem., 230:788 (1995); and, N. Budisa, W. Karnbrock, S. Steinbacher, A. Humm, L. Prade, T. Neuefeind, L. Moroder and R. Huber, J. Mol. Biol., 270:616 (1997). Methionine analogs with alkene or alkyne functionalities have also been inserted efficiently, allowing for additional modification of proteins by chemical means. *See, e.g.*, J. C. M. van Hest and D. A. Tirrell, FEBS Lett., 428:68 (1998); J. C. M. van Hest, K. L. Kiick and D. A. Tirrell, J. Am. Chem. Soc., 122:1282 (2000); and, K. L. Kiick and D. A. Tirrell, Tetrahedron, 56:9487 (2000).

[0010] The success of this method depends on the recognition of the unnatural amino acid analogs by aminoacyl-tRNA synthetases, which, in general, requires high selectivity to insure the fidelity of protein translation. Therefore, the range of chemical functionality accessible via this route is limited. For instance, although thiaproline can be incorporated quantitatively into proteins, oxaproline and selenoproline cannot. *See*, N. Budisa, C. Minks, F. J. Medrano, J. Lutz, R. Huber and L. Moroder, Proc. Natl. Acad. Sci. U S A, 95:455 (1998). One way to expand the scope of this method is to relax the substrate specificity of aminoacyl-tRNA synthetases, which has been achieved in a limited number of cases. For example, it was found that replacement of Ala<sup>294</sup> by Gly in *Escherichia coli* phenylalanyl-tRNA synthetase (PheRS) increases the size of substrate binding pocket, and results in the acylation of tRNA<sup>Phe</sup> by *p*-Cl-phenylalanine (*p*-Cl-Phe). *See*, M. Ibba, P. Kast and H. Hennecke, Biochemistry, 33:7107 (1994). *An Escherichia*

*coli* strain harboring this mutant PheRS allows the incorporation of *p*-Cl-phenylalanine or *p*-Br-phenylalanine in place of phenylalanine. *See, e.g.*, M. Ibba and H. Hennecke, FEBS Lett., 364:272 (1995); and, N. Sharma, R. Furter, P. Kast and D. A. Tirrell, FEBS Lett., 467:37 (2000). Similarly, a point mutation Phe130Ser near the amino acid binding site of

5 *Escherichia coli* tyrosyl-tRNA synthetase was shown to allow azatyrosine to be incorporated more efficiently than tyrosine. *See*, F. Hamano-Takaku, T. Iwama, S. Saito-Yano, K. Takaku, Y. Monden, M. Kitabatake, D. Soll and S. Nishimura, J. Biol. Chem., 275:40324 (2000).

[0011] The fidelity of aminoacylation is maintained both at the level of substrate

10 discrimination and proofreading of non-cognate intermediates and products. Therefore, an alternative strategy to incorporate unnatural amino acids into proteins in vivo is to modify synthetases that have proofreading mechanisms. These synthetases cannot discriminate and therefore activate amino acids that are structurally similar to the cognate natural amino acids. This error is corrected at a separate site, which deacylates the mischarged amino

15 acid from the tRNA to maintain the fidelity of protein translation. If the proofreading activity of the synthetase is disabled, structural analogs that are misactivated may escape the editing function and be incorporated. This approach has been demonstrated recently with the valyl-tRNA synthetase (ValRS). *See*, V. Doring, H. D. Mootz, L. A. Nangle, T. L. Hendrickson, V. de Crecy-Lagard, P. Schimmel and P. Marliere, Science, 292:501

20 (2001). ValRS can misaminoacylate tRNA<sup>Val</sup> with Cys, Thr, or aminobutyrate (Abu); these noncognate amino acids are subsequently hydrolyzed by the editing domain. After random mutagenesis of the *Escherichia coli* chromosome, a mutant *Escherichia coli* strain was selected that has a mutation in the editing site of ValRS. This edit-defective ValRS incorrectly charges tRNA<sup>Val</sup> with Cys. Because Abu sterically resembles Cys (–SH

25 group of Cys is replaced with –CH<sub>3</sub> in Abu), the mutant ValRS also incorporates Abu into proteins when this mutant *Escherichia coli* strain is grown in the presence of Abu. Mass spectrometric analysis shows that about 24% of valines are replaced by Abu at each valine position in the native protein.

[0012] At least one major limitation of the methods described above is that all sites

30 corresponding to a particular natural amino acid throughout the protein are replaced. The extent of incorporation of the natural and unnatural amino acid may also vary – only in rare cases can quantitative substitution be achieved since it is difficult to completely

deplete the cognate natural amino acid inside the cell. Another limitation is that these strategies make it difficult to study the mutant protein in living cells, because the multi-site incorporation of analogs often results in toxicity. Finally, this method is applicable in general only to close structural analogs of the common amino acids, again because

5 substitutions must be tolerated at all sites in the genome.

[0013] Solid-phase synthesis and semi-synthetic methods have also allowed for the synthesis of a number of small proteins containing novel amino acids. For example, see the following publications and references cited within: Crick, F.J.C., Barrett, L. Brenner, S. Watts-Tobin, R. *General nature of the genetic code for proteins*. Nature, 192:1227-1232 (1961); Hofmann, K., Bohn, H. *Studies on polypeptides. XXXVI. The effect of pyrazole-imidazole replacements on the S-protein activating potency of an S-peptide fragment*, J. Am. Chem., 5914-5919 (1966); Kaiser, E. T. *Synthetic approaches to biologically active peptides and proteins including enzymes*, Acc. Chem. Res., 47-54 (1989); Nakatsuka, T., Sasaki, T., Kaiser, E. T. *Peptide segment coupling catalyzed by the semisynthetic enzyme thiosubtilisin*, J. Am. Chem. Soc., 109:3808-3810 (1987); Schnolzer, M., Kent, S B H. *Constructing proteins by dovetailing unprotected synthetic peptides: backbone-engineered HIV protease*, Science, 256(5054):221-225 (1992); Chaiken, I. M. *Semisynthetic peptides and proteins*, CRC Crit. Rev. Biochem., 11(3):255-301 (1981); Offord, R. E. *Protein engineering by chemical means?* Protein Eng., 1(3):151-157 (1987); and, Jackson, D. Y., Burnier, J., Quan, C., Stanley, M., Tom, J., Wells, J. A. *A Designed Peptide Ligase for Total Synthesis of Ribonuclease A with Unnatural Catalytic Residues*, Science, 266(5183):243-247(1994).

10  
15  
20

[0014] Chemical modification has been used to introduce a variety of unnatural side chains, including cofactors, spin labels and oligonucleotides into proteins in vitro. See, e.g., Corey, D. R., Schultz, P. G. *Generation of a hybrid sequence-specific single-stranded deoxyribonuclease*, Science, 283(4832):1401-1403 (1987); Kaiser, E. T., Lawrence D. S., Rokita, S. E. *The chemical modification of enzymatic specificity*, Rev. Biochem., 54:565-595 (1985); Kaiser, E. T., Lawrence, D. S. *Chemical mutation of enzyme active sites*, Science, 226(4674):505-511 (1984); Neet, K. E., Nanci A, Koshland, D. E. *Properties of thiol-subtilisin*, J. Biol. Chem., 243(24):6392-6401 (1968); Polgar, L. B., M. L. *A new enzyme containing a synthetically formed active site. Thiol-subtilisin*. J. Am. Chem. Soc., 88:3153-3154 (1966); and, Pollack, S.J., Nakayama, G. Schultz, P. G.

25  
30

*Introduction of nucleophiles and spectroscopic probes into antibody combining sites, Science*, 242(4881):1038-1040 (1988).

- [0015] Alternatively, biosynthetic methods that employ chemically modified aminoacyl-tRNAs have been used to incorporate several biophysical probes into proteins synthesized in vitro. See the following publications and references cited within: Brunner, J. *New Photolabeling and crosslinking methods*, Annu. Rev. Biochem., 62:483-514 (1993); and, Krieg, U. C., Walter, P., Hohnson, A. E. *Photocrosslinking of the signal sequence of nascent preprolactin of the 54-kilodalton polypeptide of the signal recognition particle*, Proc. Natl. Acad. Sci., 83(22):8604-8608 (1986).
- 10 [0016] Previously, it has been shown that unnatural amino acids can be site-specifically incorporated into proteins in vitro by the addition of chemically aminoacylated suppressor tRNAs to protein synthesis reactions programmed with a gene containing a desired amber nonsense mutation. Using these approaches, one can substitute a number of the common twenty amino acids with close structural homologues, e.g.,
- 15 fluorophenylalanine for phenylalanine, using strains auxotrophic for a particular amino acid. See, e.g., Noren, C. J., Anthony-Cahill, Griffith, M.C., Schultz, P. G. *A general method for site-specific incorporation of unnatural amino acids into proteins*, Science, 244:182-188 (1989); M. W. Nowak, et al., Science 268:439-42 (1995); Bain, J.D., Glabe, C. G., Dix, T. A., Chamberlin, A. R., Diala, E. S. *Biosynthetic site-specific Incorporation of a non-natural amino acid into a polypeptide*, J. Am. Chem. Soc., 111:8013-8014 (1989); N. Budisa et al., FASEB J. 13:41-51 (1999); Ellman, J. A., Mendel, D., Anthony-Cahill, S., Noren, C. J., Schultz, P. G. *Biosynthetic method for introducing unnatural amino acids site-specifically into proteins*, Methods in Enz., 301-336 (1992); and, Mendel, D., Cornish, V.W. & Schultz, P. G. *Site-Directed Mutagenesis with an Expanded Genetic*
- 20 *Code*, Annu. Rev. Biophys. Biomol. Struct. 24, 435-62 (1995).
- [0017] For example, a suppressor tRNA was prepared that recognized the stop codon UAG and was chemically aminoacylated with an unnatural amino acid. Conventional site-directed mutagenesis was used to introduce the stop codon TAG, at the site of interest in the protein gene. See, e.g., Sayers, J. R., Schmidt, W. Eckstein, F. 5', 3'
- 30 *Exonuclease in phosphorothioate-based oligonucleotide-directed mutagenesis*, Nucleic Acids Res., 16(3):791-802 (1988). When the acylated suppressor tRNA and the mutant gene were combined in an in vitro transcription/translation system, the unnatural amino



acid was incorporated in response to the UAG codon which gave a protein containing that amino acid at the specified position. Experiments using [<sup>3</sup>H]-Phe and experiments with α-hydroxy acids demonstrated that only the desired amino acid is incorporated at the position specified by the UAG codon and that this amino acid is not incorporated at any other site in the protein. See, e.g., Noren, et al, *supra*; and, Ellman, J. A., Mendel, D., Schultz, P. G. *Site-specific incorporation of novel backbone structures into proteins*, Science, 197-200 (1992).

[0018] In general, these in vitro approaches are limited by difficulties in achieving site-specific incorporation of the amino acids, by the requirement that the amino acids be simple derivatives of the common twenty amino acids or problems inherent in the synthesis of large proteins or peptide fragments.

[0019] Microinjection techniques have also been used to incorporate unnatural amino acids into proteins. See, e.g., M. W. Nowak, P. C. Kearney, J. R. Sampson, M. E. Saks, C. G. Labarca, S. K. Silverman, W. G. Zhong, J. Thorson, J. N. Abelson, N. Davidson, P. G. Schultz, D. A. Dougherty and H. A. Lester, Science, 268:439 (1995); and, D. A. Dougherty, Curr. Opin. Chem. Biol., 4:645 (2000). A *Xenopus* oocyte was coinjected with two RNA species made in vitro: an mRNA encoding the target protein with a UAG stop codon at the amino acid position of interest and an amber suppressor tRNA aminoacylated with the desired unnatural amino acid. The translational machinery of the oocyte then inserted the unnatural amino acid at the position specified by UAG. This method has allowed in vivo structure-function studies of integral membrane proteins, which are generally not amenable to in vitro expression systems. Examples include the incorporation of a fluorescent amino acid into tachykinin neurokinin-2 receptor to measure distances by fluorescence resonance energy transfer, see, e.g., G. Turcatti, K. Nemeth, M. D. Edgerton, U. Meseth, F. Talabot, M. Peitsch, J. Knowles, H. Vogel and A. Chollet, J. Biol. Chem., 271:19991 (1996); the incorporation of biotinylated amino acids to identify surface-exposed residues in ion channels, see, e.g., J. P. Gallivan, H. A. Lester and D. A. Dougherty, Chem. Biol., 4:739 (1997); the use of caged tyrosine analogs to monitor conformational changes in an ion channel in real time, see, e.g., J. C. Miller, S. K. Silverman, P. M. England, D. A. Dougherty and H. A. Lester, Neuron, 20:619 (1998); and, the use of α-hydroxy amino acids to change ion channel backbones for probing their gating mechanisms, see, e.g., P. M. England, Y. Zhang, D. A. Dougherty and H. A. Lester,

Cell, 96:89 (1999); and, T. Lu, A. Y. Ting, J. Mainland, L. Y. Jan, P. G. Schultz and J. Yang, Nat. Neurosci., 4:239 (2001).

5 [0020] However, there are limitations microinjection method, e.g., the suppressor tRNA has to be chemically aminoacylated with the unnatural amino acid in vitro, and the acylated tRNA is consumed as a stoichiometric reagent during translation and cannot be regenerated. This limitation results in poor suppression efficiency and low protein yields, necessitating highly sensitive techniques to assay the mutant protein, such as electrophysiological measurements. Moreover, this method is only applicable to cells that can be microinjected.

10 [0021] The ability to incorporate unnatural amino acids directly into proteins in vivo offers the advantages of high yields of mutant proteins, technical ease, the potential to study the mutant proteins in cells or possibly in living organisms and the use of these mutant proteins in therapeutic treatments. The ability to include unnatural amino acids with various sizes, acidities, nucleophilicities, hydrophobicities, and other properties into  
15 proteins can greatly expand our ability to rationally and systematically manipulate the structures of proteins, both to probe protein function and create new proteins or organisms with novel properties. However, the process is difficult, because the complex nature of tRNA-synthetase interactions that are required to achieve a high degree of fidelity in protein translation. Therefore, improvements to the process are needed to provide more  
20 efficient and effective methods to alter the biosynthetic machinery of the cell. The present invention addresses these and other needs, as will be apparent upon review of the following disclosure.

### SUMMARY OF THE INVENTION

[0022] The present invention provides compositions of components used in protein  
25 biosynthetic machinery, which include orthogonal tRNA-aminoacyl-tRNA synthetase pairs and the individual components of the pairs. Methods for generating and selecting orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and pairs thereof that can use an unnatural amino acid are also provided. Compositions of the invention include novel orthogonal tRNA-aminoacyl-tRNA synthetase pairs, e.g., mutRNATyr-mutTyrRS pairs,  
30 mutRNA<sup>Leu</sup>-mutLeuRS pairs, mutRNAThr-mutThrRS pairs, mutRNA<sup>Glu</sup>-mutGluRS pairs, and the like. The novel orthogonal pairs can be use to incorporate an unnatural

amino acid in a polypeptide in vivo. Other embodiments of the invention include selecting orthogonal pairs.

[0023] Compositions of the present invention include an orthogonal aminoacyl-tRNA synthetase (O-RS), where the O-RS preferentially aminoacylates an orthogonal  
5 tRNA (O-tRNA) with an unnatural amino acid, optionally, in vivo. In one embodiment, the O-RS comprises a nucleic acid comprising a polynucleotide sequence selected from the group consisting of: SEQ ID NO: 4-34 (*see*, Table 5) and a complementary polynucleotide sequence thereof. In another embodiment, the O-RS has improved or enhanced enzymatic properties, e.g., the  $K_m$  is higher or lower, the  $k_{cat}$  is higher or lower,  
10 the value of  $k_{cat}/K_m$  is higher or lower or the like, for the unnatural amino acid compared to a naturally occurring amino acid, e.g., one of the 20 known amino acids.

[0024] The unnatural amino acids of the present invention encompass a variety of substances. For example, they optionally include (but are not limited to) such molecules as: an O-methyl-L-tyrosine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-  
15 4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAc $\beta$ -serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a *p*-azido-L-phenylalanine, a *p*-acyl-L-phenylalanine, a *p*-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphoserine, a phosphotyrosine, a *p*-iodo-phenylalanine, a *p*-bromophenylalanine, a *p*-amino-L-phenylalanine, and an isopropyl-L-phenylalanine. Additionally, other  
20 examples optionally include (but are not limited to) an unnatural analogue of a tyrosine amino acid; an unnatural analogue of a glutamine amino acid; an unnatural analogue of a phenylalanine amino acid; an unnatural analogue of a serine amino acid; an unnatural analogue of a threonine amino acid; an alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkynyl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde,  
25 hydroxylamine, keto, or amino substituted amino acid, or any combination thereof; an amino acid with a photoactivatable cross-linker; a spin-labeled amino acid; a fluorescent amino acid; an amino acid with a novel functional group; an amino acid that covalently or noncovalently interacts with another molecule; a metal binding amino acid; a metal-  
30 containing amino acid; a radioactive amino acid; a photocaged amino acid; a photoisomerizable amino acid; a biotin or biotin-analogue containing amino acid; a glycosylated or carbohydrate modified amino acid; a keto containing amino acid; an

amino acid comprising polyethylene glycol; an amino acid comprising polyether; a heavy atom substituted amino acid; a chemically cleavable or photocleavable amino acid; an amino acid with an elongated side chain; an amino acid containing a toxic group; a sugar substituted amino acid, e.g., a sugar substituted serine or the like; a carbon-linked sugar-  
5 containing amino acid; a redox-active amino acid; an  $\alpha$ -hydroxy containing acid; an amino thio acid containing amino acid; an  $\alpha,\alpha$  disubstituted amino acid; a  $\beta$ -amino acid; and a cyclic amino acid other than proline.

[0025] The present invention also includes a polypeptide comprising an amino acid sequence encoded by a coding polynucleotide sequence which is selected from: a  
10 coding polynucleotide sequence selected from SEQ ID NO: 4-34 (*see*, Table 5 for sequences); a coding polynucleotide sequence encoding a polypeptide selected from SEQ ID NO: 35-66 a polynucleotide sequence which hybridizes under highly stringent conditions over substantially the entire length of such polynucleotide sequences; and complementary sequences of any of such sequences. Additionally, such polypeptide  
15 optionally encodes an orthogonal aminoacyl tRNA synthetase and/or an amino acid sequence selected from SEQ ID NO:35 to SEQ ID NO:66.

[0026] The present invention also includes a nucleic acid comprising a polynucleotide sequence selected from the group consisting of: a polynucleotide sequence selected from SEQ ID NO:1 to SEQ ID NO:3 (or a complementary polynucleotide  
20 sequence thereof) and a polynucleotide sequence which hybridizes under highly stringent conditions over substantially the entire length of such polynucleotide sequences. Such nucleic acids also include wherein the polynucleotide sequence comprises an orthogonal tRNA and/or wherein the polynucleotide sequence forms a complementary pair with an orthogonal aminoacyl-tRNA synthetase (which optionally is selected from the those  
25 whose sequence is listed in SEQ ID NO:35 to SEQ ID NO:66.

[0027] Compositions of an orthogonal tRNA (O-tRNA) are also included, where the O-tRNA recognizes a selector codon and wherein the O-tRNA is preferentially aminoacylated with an unnatural amino acid by an orthogonal aminoacyl-tRNA synthetase. In one embodiment, the O-tRNA comprises a nucleic acid comprising a  
30 polynucleotide sequence selected from the group consisting of: SEQ ID NO: 1-3 (*see*, Table 5) and a complementary polynucleotide sequence thereof.

[0028] Selector codons of the present invention expand the genetic codon framework of protein biosynthetic machinery. For example, a selector codon includes, e.g., a unique three base codon (composed of natural or unnatural bases), a nonsense codon (such as a stop codon, e.g., an amber codon, or an opal codon), an unnatural codon, a rare codon, a codon comprising at least four bases, a codon comprising at least five bases, a codon comprising at least six bases, or the like.

[0029] In one embodiment, the O-tRNA (optionally comprising within compositions) can include an orthogonal aminoacyl-tRNA synthetase (O-RS), e.g., where the O-tRNA and the O-RS are complementary, e.g., an O-tRNA/O-RS pair. In one embodiment, a pair comprises e.g., a mutRNATyr-mutTyrRS pair, such as mutRNATyr-SS12TyrRS pair, a mutRNALeu-mutLeuRS pair, a mutRNAThr-mutThrRS pair, a mutRNAGlu-mutGluRS pair, or the like. In another embodiment, the pair is other than a mutRNAGln-mutGlnRS derived from *Escherichia coli*, a mutRNAAsp-mutAspRS derived from yeast or a mutRNAPheCUA-mutphenylalanineRS from yeast, where these pairs do not possess the properties of the pairs of the present invention.

[0030] The O-tRNA and the O-RS can be derived by mutation of a naturally occurring tRNA and RS from a variety of organisms. In one embodiment, the O-tRNA and O-RS are derived from at least one organism, where the organism is a prokaryotic organism, e.g., *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Halobacterium*, *Escherichia coli*, *A. fulgidus*, *P. furiosus*, *P. horikoshii*, *A. pernix*, *T. thermophilus*, or the like. Optionally, the organism is a eukaryotic organism, e.g., plants (e.g., complex plants such as monocots, or dicots), algae, fungi (e.g., yeast, etc), animals (e.g., mammals, insects, arthropods, etc.), insects, protists, or the like. Optionally, the O-tRNA is derived by mutation of a naturally occurring tRNA from a first organism and the O-RS is derived by mutation of a naturally occurring RS from a second organism. In one embodiment, the O-tRNA and O-RS can be derived from a mutated tRNA and mutated RS.

[0031] The O-tRNA and the O-RS also can optionally be isolated from a variety of organisms. In one embodiment, the O-tRNA and O-RS are isolated from at least one organism, where the organism is a prokaryotic organism, e.g., *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Halobacterium*, *Escherichia coli*, *A. fulgidus*, *P. furiosus*, *P. horikoshii*, *A. pernix*, *T. thermophilus*, or the like. Optionally, the organism is

a eukaryotic organism, e.g., plants (e.g., complex plants such as monocots, or dicots), algae, fungi (e.g., yeast, etc), animals (e.g., mammals, insects, arthropods, etc.), insects, protists, or the like. Optionally, the O-tRNA is isolated from a naturally occurring tRNA from a first organism and the O-RS is isolated from a naturally occurring RS from a second organism. In one embodiment, the O-tRNA and O-RS can be isolated from one or more library (which optionally comprises one or more O-tRNA and/or O-RS from one or more organism (including those comprising prokaryotes and/or eukaryotes).

[0032] In another aspect, the compositions of the present invention can be in a cell. Optionally, the compositions of the present invention can be in an in vitro translation system.

[0033] Methods for generating components of the protein biosynthetic machinery, such as O-RSs, O-tRNAs, and orthogonal O-tRNA/O-RS pairs that can be used to incorporate an unnatural amino acid are provided in the present invention. Methods for selecting an orthogonal tRNA-tRNA synthetase pair for use in in vivo translation system of an organism are also provided. The unnatural amino acids and selectors codons used in the methods are described above and below.

[0034] Methods for producing at least one recombinant orthogonal aminoacyl-tRNA synthetase (O-RS) comprise: (a) generating a library of (optionally mutant) RSs derived from at least one aminoacyl-tRNA synthetase (RS) from a first organism, e.g., a prokaryotic organism, such as *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Halobacterium*, *Escherichia coli*, *A. fulgidus*, *P. furiosus*, *P. horikoshii*, *A. pernix*, *T. thermophilus*, or the like; (b) selecting (and/or screening) the library of RSs (optionally mutant RSs) for members that aminoacylate an orthogonal tRNA (O-tRNA) in the presence of an unnatural amino acid and a natural amino acid, thereby providing a pool of active (optionally mutant) RSs; and/or, (c) selecting (optionally through negative selection) the pool for active RSs (e.g., mutant RSs) that preferentially aminoacylate the O-tRNA in the absence of the unnatural amino acid, thereby providing the at least one recombinant O-RS; wherein the at least one recombinant O-RS preferentially aminoacylates the O-tRNA with the unnatural amino acid.

Recombinant O-RSs produced by the methods are also included in the present invention.

[0035] In one embodiment, the RS is an inactive RS. The inactive RS can be generated by mutating an active RS. For example, the inactive RS can be generated by

mutating at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, or at least about 10 or more amino acids to different amino acids, e.g., alanine.

5 [0036] Libraries of mutant RSs can be generated using various mutagenesis techniques known in the art. For example, the mutant RSs can be generated by site-specific mutations, random mutations, diversity generating recombination mutations, chimeric constructs, and by other methods described herein or known in the art.

[0037] In one embodiment, selecting (and/or screening) the library of RSs (optionally mutant RSs) for members that are active, e.g., that aminoacylate an orthogonal  
10 tRNA (O-tRNA) in the presence of an unnatural amino acid and a natural amino acid, includes: introducing a positive selection or screening marker, e.g., an antibiotic resistance gene, or the like, and the library of (optionally mutant) RSs into a plurality of cells, wherein the positive selection and/or screening marker comprises at least one selector codon, e.g., an amber, ochre, or opal codon; growing the plurality of cells in the presence  
15 of a selection agent; identifying cells that survive (or show a specific response) in the presence of the selection and/or screening agent by suppressing the at least one selector codon in the positive selection or screening marker, thereby providing a subset of positively selected cells that contains the pool of active (optionally mutant) RSs. Optionally, the selection and/or screening agent concentration can be varied.

20 [0038] In one aspect, the positive selection marker is a chloramphenicol acetyltransferase (CAT) gene and the selector codon is an amber stop codon in the CAT gene. Optionally, the positive selection marker is a  $\beta$ -lactamase gene and the selector codon is an amber stop codon in the  $\beta$ -lactamase gene. In another aspect the positive screening marker comprises a fluorescent or luminescent screening marker or an affinity  
25 based screening marker (e.g., a cell surface marker).

[0039] In one embodiment, negatively selecting or screening the pool for active RSs (optionally mutants) that preferentially aminoacylate the O-tRNA in the absence of the unnatural amino acid includes: introducing a negative selection or screening marker with the pool of active (optionally mutant) RSs from the positive selection or screening  
30 into a plurality of cells of a second organism, wherein the negative selection or screening marker comprises at least one selector codon (e.g., an antibiotic resistance gene, e.g., a chloramphenicol acetyltransferase (CAT) gene); and, identifying cells that survive or show

a specific screening response in a 1st media supplemented with the unnatural amino acid and a screening or selection agent, but fail to survive or to show the specific response in a 2nd media not supplemented with the unnatural amino acid and the selection or screening agent, thereby providing surviving cells or screened cells with the at least one recombinant O-RS. For example, a CAT identification protocol optionally acts as a positive selection and/or a negative screening in determination of appropriate O-RS recombinants. For instance, a pool of clones is optionally replicated on growth plates containing CAT (which comprises at least one selector codon) either with or without one or more unnatural amino acid. Colonies growing exclusively on the plates containing unnatural amino acids are thus regarded as containing recombinant O-RS. In one aspect, the concentration of the selection (and/or screening) agent is varied. In some aspects the first and second organisms are different. Thus, the first and/or second organism optionally comprises: a prokaryote, a eukaryote, a mammal, an *Escherichia coli*, a fungi, a yeast, an archaeobacterium, a eubacterium, a plant, an insect, a protist, etc. In other embodiments, the screening marker comprises a fluorescent or luminescent screening marker or an affinity based screening marker.

[0040] In another embodiment, screening or selecting (e.g., negatively selecting) the pool for active (optionally mutant) RSs includes: isolating the pool of active mutant RSs from the positive selection step (b); introducing a negative selection or screening marker, wherein the negative selection or screening marker comprises at least one selector codon (e.g., a toxic marker gene, e.g., a ribonuclease barnase gene, comprising at least one selector codon), and the pool of active (optionally mutant) RSs into a plurality of cells of a second organism; and identifying cells that survive or show a specific screening response in a 1st media not supplemented with the unnatural amino acid, but fail to survive or show a specific screening response in a 2nd media supplemented with the unnatural amino acid, thereby providing surviving or screened cells with the at least one recombinant O-RS, wherein the at least one recombinant O-RS is specific for the unnatural amino acid. In one aspect, the at least one selector codon comprises about two or more selector codons. Such embodiments optionally can include wherein the at least one selector codon comprises two or more selector codons, and wherein the first and second organism are different (e.g., each organism is optionally, e.g., a prokaryote, a eukaryote, a mammal, an *Escherichia coli*, a fungi, a yeast, an archaeobacteria, a eubacteria, a plant, an insect, a protist, etc.). Also, some aspects include wherein the negative selection marker comprises a ribonuclease



barnase gene (which comprises at least one selector codon). Other aspects include wherein the screening marker optionally comprises a fluorescent or luminescent screening marker or an affinity based screening marker. In the embodiments herein, the screenings and/or selections optionally include variation of the screening and/or selection stringency.

5 [0041] In one embodiment, the methods for producing at least one recombinant orthogonal aminoacyl-tRNA synthetase (O-RS) can further comprise: (d) isolating the at least one recombinant O-RS; (e) generating a second set of O-RS (optionally mutated) derived from the at least one recombinant O-RS; and, (f) repeating steps (b) and (c) until a  
10 tRNA. Optionally, steps (d)-(f) are repeated, e.g., at least about two times. In one aspect, the second set of mutated O-RS derived from at least one recombinant O-RS can be generated by mutagenesis, e.g., random mutagenesis, site-specific mutagenesis, recombination or a combination thereof.

[0042] The stringency of the selection/screening steps, e.g., the positive  
15 selection/screening step (b), the negative selection/screening step (c) or both the positive and negative selection/screening steps (b) and (c), in the above-described methods, optionally includes varying the selection/screening stringency. In another embodiment, the positive selection/screening step (b), the negative selection/screening step (c) or both the positive and negative selection/screening steps (b) and (c) comprise using a reporter,  
20 wherein the reporter is detected by fluorescence-activated cell sorting (FACS) or wherein the reporter is detected by luminescence. Optionally, the reporter is displayed on a cell surface, on a phage display or the like and selected based upon affinity or catalytic activity involving the unnatural amino acid or an analogue. In one embodiment, the mutated synthetase is displayed on a cell surface, on a phage display or the like.

25 [0043] The methods embodied herein optionally comprise wherein the unnatural amino acid is selected from, e.g.: an O-methyl-L-tyrosine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAc $\beta$ -serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a *p*-azido-L-phenylalanine, a *p*-acyl-L-phenylalanine, a *p*-benzoyl-L-phenylalanine, an L-  
30 phosphoserine, a phosphoserine, a phosphonotyrosine, a *p*-iodo-phenylalanine, a *p*-bromophenylalanine, a *p*-amino-L-phenylalanine, and an isopropyl-L-phenylalanine. A

recombinant O-RS produced by the methods herein is also included in the current invention.

**[0044]** Methods for producing a recombinant orthogonal tRNA (O-tRNA) include:

- (a) generating a library of mutant tRNAs derived from at least one tRNA, e.g., a  
5 suppressor tRNA, from a first organism; (b) selecting (e.g., negatively selecting) or  
screening the library for (optionally mutant) tRNAs that are aminoacylated by an  
aminoacyl-tRNA synthetase (RS) from a second organism in the absence of a RS from the  
first organism, thereby providing a pool of tRNAs (optionally mutant); and, (c) selecting  
or screening the pool of tRNAs (optionally mutant) for members that are aminoacylated by  
10 an introduced orthogonal RS (O-RS), thereby providing at least one recombinant O-tRNA;  
wherein the at least one recombinant O-tRNA recognizes a selector codon and is not  
efficiency recognized by the RS from the second organism and is preferentially  
aminoacylated by the O-RS. In some embodiments the at least one tRNA is a suppressor  
tRNA and/or comprises a unique three base codon of natural and/or unnatural bases, or is  
15 a nonsense codon, a rare codon, an unnatural codon, a codon comprising at least 4 bases,  
an amber codon, an ochre codon, or an opal stop codon. In one embodiment, the  
recombinant O-tRNA possesses an improvement of orthogonality. It will be appreciated  
that in some embodiments, O-tRNA is optionally imported into a first organism from a  
second organism without the need for modification. In various embodiments, the first and  
20 second organisms are either the same or different and are optionally chosen from, e.g.,  
prokaryotes (e.g., *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*,  
*Escherichia coli*, *Halobacterium*, etc.), eukaryotes, mammals, fungi, yeasts,  
archaeobacteria, eubacteria, plants, insects, protists, etc. Additionally, the recombinant  
tRNA is optionally aminoacylated by an unnatural amino acid, wherein the unnatural  
25 amino acid is biosynthesized in vivo either naturally or through genetic manipulation. The  
unnatural amino acid is optionally added to a growth medium for at least the first or  
second organism.

- [0045]** In one aspect, selecting (e.g., negatively selecting) or screening the library  
for (optionally mutant) tRNAs that are aminoacylated by an aminoacyl-tRNA synthetase  
30 (step (b)) includes: introducing a toxic marker gene, wherein the toxic marker gene  
comprises at least one of the selector codons (or a gene that leads to the production of a  
toxic or static agent or a gene essential to the organism wherein such marker gene

comprises at least one selector codon) and the library of (optionally mutant) tRNAs into a plurality of cells from the second organism; and, selecting surviving cells, wherein the surviving cells contain the pool of (optionally mutant) tRNAs comprising at least one orthogonal tRNA or nonfunctional tRNA. For example, surviving cells can be selected by  
5 using a comparison ratio cell density assay.

[0046] In another aspect, the toxic marker gene can include two or more selector codons. In another embodiment of the methods, the toxic marker gene is a ribonuclease barnase gene, where the ribonuclease barnase gene comprises at least one amber codon. Optionally, the ribonuclease barnase gene can include two or more amber codons.

10 [0047] In one embodiment, selecting or screening the pool of (optionally mutant) tRNAs for members that are aminoacylated by an introduced orthogonal RS (O-RS) can include: introducing a positive selection or screening marker gene, wherein the positive marker gene comprises a drug resistance gene (e.g.,  $\beta$ -lactamase gene, comprising at least one of the selector codons, such as at least one amber stop codon) or a gene essential to the  
15 organism, or a gene that leads to detoxification of a toxic agent, along with the O-RS, and the pool of (optionally mutant) tRNAs into a plurality of cells from the second organism; and, identifying surviving or screened cells grown in the presence of a selection or screening agent, e.g., an antibiotic, thereby providing a pool of cells possessing the at least one recombinant tRNA, where the at least recombinant tRNA is aminoacylated by the O-  
20 RS and inserts an amino acid into a translation product encoded by the positive marker gene, in response to the at least one selector codons. In another embodiment, the concentration of the selection and/or screening agent is varied. Recombinant O-tRNAs produced by the methods of the present invention are also included.

[0048] Methods for generating specific O-tRNA/O-RS pairs are provided.  
25 Methods include: (a) generating a library of mutant tRNAs derived from at least one tRNA from a first organism; (b) negatively selecting or screening the library for (optionally mutant) tRNAs that are aminoacylated by an aminoacyl-tRNA synthetase (RS) from a second organism in the absence of a RS from the first organism, thereby providing a pool of (optionally mutant) tRNAs; (c) selecting or screening the pool of (optionally mutant)  
30 tRNAs for members that are aminoacylated by an introduced orthogonal RS (O-RS), thereby providing at least one recombinant O-tRNA. The at least one recombinant O-tRNA recognizes a selector codon and is not efficiency recognized by the RS from the

second organism and is preferentially aminoacylated by the O-RS. The method also includes (d) generating a library of (optionally mutant) RSs derived from at least one aminoacyl-tRNA synthetase (RS) from a third organism; (e) selecting or screening the library of mutant RSs for members that preferentially aminoacylate the at least one recombinant O-tRNA in the presence of an unnatural amino acid and a natural amino acid, thereby providing a pool of active (optionally mutant) RSs; and, (f) negatively selecting or screening the pool for active (optionally mutant) RSs that preferentially aminoacylate the at least one recombinant O-tRNA in the absence of the unnatural amino acid, thereby providing the at least one specific O-tRNA/O-RS pair, wherein the at least one specific O-tRNA/O-RS pair comprises at least one recombinant O-RS that is specific for the unnatural amino acid and the at least one recombinant O-tRNA. Specific O-tRNA/O-RS pairs produced by the methods are included. For example, the specific O-tRNA/O-RS pair can include, e.g., a mutRNATyr-mutTyrRS pair, such as a mutRNATyr-SS12TyrRS pair, a mutRNALeu-mutLeuRS pair, a mutRNAThr-mutThrRS pair, a mutRNAGlu-mutGluRS pair, or the like. Additionally, such methods include wherein the first and third organism are the same (e.g., *Methanococcus jannaschii*).

[0049] Methods for selecting an orthogonal tRNA-tRNA synthetase pair for use in an in vivo translation system of a second organism are also included in the present invention. The methods include: introducing a marker gene, a tRNA and an aminoacyl-tRNA synthetase (RS) isolated or derived from a first organism into a first set of cells from the second organism; introducing the marker gene and the tRNA into a duplicate cell set from a second organism; and, selecting for surviving cells in the first set that fail to survive in the duplicate cell set or screening for cells showing a specific screening response that fail to give such response in the duplicate cell set, wherein the first set and the duplicate cell set are grown in the presence of a selection or screening agent, wherein the surviving or screened cells comprise the orthogonal tRNA-tRNA synthetase pair for use in the in vivo translation system of the second organism. In one embodiment, comparing and selecting or screening includes an in vivo complementation assay. The concentration of the selection or screening agent can be varied.

[0050] The organisms of the present invention comprise a variety of organism and a variety of combinations. For example, the first and the second organisms of the methods of the present invention can be the same or different. In one embodiment, the organisms

are optionally a prokaryotic organism, e.g., *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Halobacterium*, *Escherichia coli*, *A. fulgidus*, *P. furiosus*, *P. horikoshii*, *A. pernix*, *T. thermophilus*, or the like. Alternatively, the organisms optionally comprise a eukaryotic organism, e.g., plants (e.g., complex plants such as monocots, or  
5 dicots), algae, protists, fungi (e.g., yeast, etc), animals (e.g., mammals, insects, arthropods, etc.), or the like. In another embodiment, the second organism is a prokaryotic organism, e.g., *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Halobacterium*, *Escherichia coli*, *A. fulgidus*, *Halobacterium*, *P. furiosus*, *P. horikoshii*, *A. pernix*, *T. thermophilus*, or the like. Alternatively, the second organism can be a  
10 eukaryotic organism, e.g., a yeast, a animal cell, a plant cell, a fungus, a mammalian cell, or the like. In various embodiments the first and second organisms are different.

[0051] The various methods of the invention (above) optionally comprise wherein selecting or screening comprises one or more positive or negative selection or screening, e.g., a change in amino acid permeability, a change in translation efficiency, and a change  
15 in translational fidelity. Additionally, the one or more change is optionally based upon a mutation in one or more gene in an organism in which an orthogonal tRNA-tRNA synthetase pair are used to produce such protein. Selecting and/or screening herein optionally comprises wherein at least 2 selector codons within one or more selection gene or within one or more screening gene are use. Such multiple selector codons are  
20 optionally within the same gene or within different screening/selection genes. Additionally, the optional multiple selector codons are optionally different selector codons or comprise the same type of selector codons.

[0052] Kits are an additional feature of the invention. For example, the kits can include one or more translation system as noted above (e.g., a cell), one or more unnatural  
25 amino acid, e.g., with appropriate packaging material, containers for holding the components of the kit, instructional materials for practicing the methods herein and/or the like. Similarly, products of the translation systems (e.g., proteins such as EPO analogues comprising unnatural amino acids) can be provided in kit form, e.g., with containers for holding the components of the kit, instructional materials for practicing the methods herein  
30 and/or the like.

## BRIEF DESCRIPTION OF THE DRAWINGS

- [0053] **Figure 1** schematically illustrates site-specific incorporation of unnatural amino acids into proteins in vivo. An orthogonal aminoacyl-tRNA synthetase aminoacylates an orthogonal tRNA with an unnatural amino acid. The acylated orthogonal tRNA inserts the unnatural amino acid at the position specified by a selector codon, e.g., a unique codon, which is introduced into the gene encoding a protein of interest.
- [0054] **Figure 2, Panel A and Panel B**, schematically illustrates examples of selection methods for active synthetases that aminoacylate with unnatural amino acids.
- 10 **Panel A** illustrates the general selection/screen for aminoacyl-tRNA synthetases with unnatural amino acid specificities. In the positive selection, active synthetases with either natural or unnatural amino acid specificities are identified; in the negative selection, synthetases with natural amino acid specificities are eliminated. Only synthetases charging the orthogonal tRNA with the unnatural amino acid can survive both
- 15 selections/screens. **Panel B** schematically illustrates one embodiment of the selection/screen for synthetases preferentially aminoacylating an O-tRNA with an unnatural amino acid. For example, expression vectors containing an orthogonal suppressor tRNA and a member of a library of mutated RS with a positive selection marker, e.g.,  $\beta$ -lactamase, with a selector codon, e.g., an amber codon, are introduced into
- 20 an organism and grown in the presence a selector agent, e.g., ampicillin. The expression of the positive selection marker allows the cell to survive in the selection agent. Survivors encode synthetases capable of charging any natural or unnatural amino acid (aa) onto the O-tRNA. The active synthetases are transformed into a second strain in the expression vector, and an expression vector with a negative selection marker, e.g., a toxic gene, such
- 25 as barnase, that when expressed kills the cells, with one or more selector codons, e.g., TAG. The cells are grown without the unnatural amino acid. If the synthetase provided aminoacylates the O-tRNA with a natural amino acid, the negative selection marker is expressed and the cell dies. If the synthetase preferentially aminoacylates the O-tRNA, no negative selection marker is expressed, because there is no unnatural amino acid and the
- 30 cell lives. This provides at least one orthogonal synthetase that preferentially aminoacylates the O-tRNA with the desired unnatural codon.

[0055] **Figure 3** illustrates site-specific mutations to generate directed libraries for tyrosine analogues.

[0056] **Figure 4** illustrates a consensus sequence for pentafluorophenylalanine selection to generate directed libraries for these analogues.

5 [0057] **Figure 5** schematically illustrates the transplantation of one domain, e.g., the CPI domain, from one organism, e.g., *Escherichia coli*, to the synthetase of other organism, e.g., *Methanococcus jannaschii* TyrRS.

[0058] **Figure 6** schematically illustrates the construction of chimeric *Methanococcus jannaschii*/*Escherichia coli* synthetases.

10 [0059] **Figure 7** schematically illustrates the generation of a library of chimeric synthetases, e.g., *Methanococcus jannaschii*/*Escherichia coli* synthetases.

[0060] **Figure 8** schematically illustrates an example for selection of suppressor tRNAs that are poor substrates for an endogenous synthetases, e.g., an *Escherichia coli* synthetase, and that are charged efficiently by a cognate synthetase of interest. Expression  
15 vectors that contain a member of a mutated tRNA library and another vector with a negative selection marker, e.g., a toxic gene, such as barnase, with one or more selector codons are introduced into a cell of an organism. Survivors of the negative selection encode mutated tRNAs that are either orthogonal to the organism or non-functional. The vectors from the survivors are isolated and transformed into other cells along with a  
20 positive selection marker, e.g.,  $\beta$ -lactamase gene, with a selector codon. The cells are grown in the presence of a selection agent, e.g., ampicillin, and an RS from an organism from the same source, e.g., *Methanococcus jannaschii*, as the tRNA. Survivors of this selection encode mutant tRNA that are orthogonal to the cell's synthetases, e.g., *Escherichia coli*'s synthetases, and aminoacylated by RS from the same source as the  
25 tRNA.

[0061] **Figure 9, Panel A and B**, schematically illustrates a mutated anticodon-loop tRNA library, **Panel A**, and a mutated all-loop library, **Panel B**, from *Methanococcus jannaschii* tRNA<sub>TyrCUA</sub>. Randomly mutated nucleotides (N) are shaded in black.

[0062] **Figure 10** schematically illustrates examples of structures of unnatural base  
30 pairs which pair by forces other than hydrogen bonding (PICS:PICS, 3MN:3MN, 7AI:7AI, Dipic:Py).

- [0063] **Figure 11** is a graph of results of a negative selection method for suppressor tRNAs, which shows the percentage of surviving cells containing one of three constructs, for a given amount of time based on the suppression of two amber codons in the barnase gene introduced by a vector, e.g., plasmid pSCB2. This plasmid encodes the barnase gene containing two amber codons. Selections are carried out in GMMML liquid medium, and 20 mM of arabinose is used to induce barnase expression. Three constructs are indicated by the following: (1) a circle which represents a control plasmid with no suppressor tRNA; (2) a triangle which represents a suppressor tRNA on plasmid, pAC-YYG1; and, (3) a square which represents a suppressor tRNA on plasmid, pAC-JY.
- 10 [0064] **Figure 12** displays growth histograms, illustrating positive selection based on the suppression of an amber codon in the  $\beta$ -lactamase gene. A vector encoding a suppressor tRNA, e.g., pAC plasmid, is cotransformed with a vector encoding a synthetase, e.g., pBLAM-JYRS, in an organism, e.g., *Escherichia coli* DH10B cells. The growth of cells harboring synthetase and different pAC plasmids in liquid 2X YT medium with various concentrations of ampicillin, e.g., 0, 100 and 500  $\mu$ g/ml, is shown in **Panel A**, where pAC is a control plasmid with no suppressor tRNA, where pAC-YYG1 is a plasmid with a suppressor tRNA, and where pAC-JY is a plasmid with a suppressor tRNA. **Panel B** shows positive selection of the same constructs using 2X YT agar plates with 500 $\mu$ g/ml ampicillin. Three constructs are indicated by the following: (1) a circle which represents a control plasmid with no suppressor tRNA; (2) a triangle which represents a suppressor tRNA on plasmid, pAC-YYG1; and, (3) a square which represents a suppressor tRNA on plasmid, pAC-JY.

- [0065] **Figure 13** illustrates DNA sequences of mutant suppressor tRNAs selected from anticodon-loop and all-loop library. JY stands for the wild-type *Methanococcus jannaschii* tRNACUATyrCUA.

- [0066] **Figure 14** schematically illustrates a stereo view of the active site of TyrRS. Residues from *B. stearothermophilus* TyrRS are illustrated in the figure. Corresponding residues from *Methanococcus jannaschii* TyrRS are Tyr<sup>32</sup>(Tyr<sup>34</sup>), Glu<sup>107</sup>(Asn<sup>123</sup>), Asp<sup>158</sup>(Asp<sup>176</sup>), Ile<sup>159</sup>(Phe<sup>177</sup>), and Leu<sup>162</sup>(Leu<sup>180</sup>) with residues from *B. stearothermophilus* TyrRS in parentheses.

- [0067] **Figure 15** schematically illustrates a view of the active site of TyrRS. Residues from *B. stearothermophilus* TyrRS are illustrated in the figure. Corresponding



residues from *Methanococcus jannaschii* TyrRS are Tyr<sup>32</sup>(Tyr<sup>34</sup>), Asp<sup>158</sup>(Asp<sup>176</sup>), Ile<sup>159</sup>(Phe<sup>177</sup>), Leu<sup>162</sup>(Leu<sup>180</sup>) and Ala<sup>167</sup>(Gln<sup>189</sup>) with residues from *B. stearothermophilus* TyrRS in parentheses.

[0068] **Figure 16, Panel A and Panel B** schematically illustrate an example of FACS-based selection and screening methods used to generate a component of the present invention, e.g., orthogonal synthetase. **Panel A** schematically illustrates vectors, e.g., plasmids, for expression of orthogonal synthetase library and O-tRNA (library plasmid) and for the T7 RNA polymerase/GFP reporter system (reporter plasmid), with one or more selector codons, e.g., TAG. **Panel B** schematically illustrates positive selection/negative screen scheme, where the cells are grown the presence and absence of the unnatural amino acid, the presence and absence of a selection agent, and screened for fluorescing cells and non-fluorescing cells in the screening process, where the "+" and empty circles correspond to fluorescing and non-fluorescing cells, respectively.

[0069] **Figure 17, Panel A, Panel B, Panel C and Panel D** illustrates an amplifiable fluorescence reporter system. **Panel A** schematically illustrates vectors that can be used in the screen, e.g., plasmids, such as pREP, where T7 RNA polymerase transcription is controlled by the ara promoter; protein expression depends on suppression of amber codons at varying locations in the gene. Reporter expression, e.g., GFPuv expression is controlled by T7 RNA polymerase. The reporter vector, e.g., plasmid pREP, is compatible for use with a vector for expressing an orthogonal synthetase/tRNA pair, e.g., a ColE1 plasmid. **Panel B** illustrates compositions and fluorescence enhancement of T7 RNA polymerase gene constructs within pREP (1-12). The construct number is indicated to the left of each. Fluorescence enhancements, indicated to the right of each construct, are calculated as the cell concentration-corrected ratio of fluorescence, as measured fluorimetrically, of cells containing pREP(1-12) and pQ or pQD. The position of the amber mutations within a gene are indicated. **Panel C** illustrates cytometric analysis of cells containing pREP (10) and either pQD (top) or pQ (bottom). **Panel D** illustrates fluorimetric analyses of cells containing pREP (10) and expressing various *Escherichia coli* suppressor tRNAs. "None" indicates that the cells contain no suppressor tRNA.

[0070] **Figure 18** schematically illustrates phage-based selection for the incorporation of unnatural amino acids into a surface epitope. For example, *Escherichia*

*coli* carrying the mutant synthetase library are infected by phage with a stop codon in a gene encoding a surface protein. Phage containing an active synthetase display the unnatural amino acid on the phage surface and are selected with immobilized monoclonal antibodies.

5 [0071] Figure 19 schematically illustrates an example of a molecule, e.g., immobilized aminoalkyl adenylate analog of the aminoacyl adenylate intermediate, used to screen displayed synthetases, e.g., phage-displayed synthetases, with unnatural amino acid specificity.

[0072] Figure 20 is a graph illustrating ampicillin resistance of various orthogonal  
10 pairs from a variety of organisms. The figure illustrates an example of finding an orthogonal pair using a reporter constructs, each containing a reporter gene, e.g., a  $\beta$ -lactamase gene, with a selector codon, e.g., an amber codon, and a suppressor tRNA (with a selector anticodon), where the suppressor tRNA can be from a variety of organisms, e.g., *A. fulgidus*, *Halobacterium NRC-1*, *P. furiosus*, *P. horikoshii*, and *Methanococcus*  
15 *jannaschii*. The reporter constructs and cloned synthetases from different organisms, e.g., *M. thermoautotrophicum*, *Methanococcus jannaschii*, *P. horikoshii*, *A. pernix*, *A. fulgidus*, *Halobacterium NRC-1*, and *Escherichia coli* are transformed into a cell. Cells are grown in various concentrations of a selector agent, e.g., ampicillin. Cells possessing an orthogonal tRNA/RS pair are selected, e.g., using an in vivo complementation assay. As  
20 shown, two systems showed suppression levels significant higher than was observed with *Escherichia coli* synthetase. They are *M. thermoautotrophicum* and *Methanococcus jannaschii*.

[0073] Figure 21, Panel A and Panel B, illustrates mutated amber suppressor tRNAs from a *Halobacterium NRC-1*, which are generated by mutating, e.g., randomizing,  
25 the anticodon loop of the leucyl tRNA and selecting (Panel B) for more efficient suppression of a selector codon, e.g., an amber codon in a reporter gene(s), e.g., using a combination of selection steps, such as selection based on  $\beta$ -lactamase and selection based on barnase. Panel B illustrates IC<sub>50</sub> values in  $\mu\text{g/ml}$  of ampicillin for a  $\beta$ -lactamase amber suppression system with three mutant tRNA constructs, original amber mutant, optimized anticodon loop, and optimized acceptor stem, alone or with an RS, e.g., MtLRS. The  
30 optimized anticodon and optimized acceptor stem gave the highest values in the  $\beta$ -lactamase selection step.

[0074] **Figure 22** illustrates a tRNA suppressor for a base codon. The tRNA suppressor illustrated in this figure was isolated from a library derived from the *Halobacterium NRC-1* TTG tRNA, where the anticodon loop was randomized with 8 nucleotides and subjected to ampicillin selection with a reporter construct containing a  $\beta$ -lactamase gene with an AGGA codon at the A184 site.

[0075] **Figure 23 Panels A-D**, illustrates the activity of the dominant synthetase variant from each successful evolution experiment. **Figure 23A** is a photograph illustrating long-wavelength ultraviolet illumination of cells containing pREP/YC-JYCUA and the indicated synthetase variant, grown in either the presence (+) or absence (-) of the corresponding unnatural amino acid. **Figure 23B** illustrates a fluorimetric analysis of cells containing pREP/YC-JYCUA and the indicated synthetase variant, grown in either the presence (left) or absence (right) of the corresponding unnatural amino acid. **Figure 23C** is a table that illustrates a  $\text{Cm IC}_{50}$  analysis of cells containing pREP/YC-JYCUA and the indicated synthetase variant, grown in either the presence or absence of the corresponding unnatural amino acid. **Figure 23D** illustrates a protein expression analysis from cells containing pBAD/JYAMB-4TAG and the indicated synthetase variant, grown in either the presence (+) or absence (-) of the corresponding unnatural amino acid.

[0076] **Figure 24**, illustrates activity comparisons of OAY-RS variants derived using a negative FACS-based screen (OAY-RS(1,3,5)) or negative barnase-based selection (OAY-RS(B)). Cells containing pREP/YC-JYCUA and the indicated synthetase variant were grown in either the presence (solid block, left) or absence (solid block, right) of the corresponding unnatural amino acid and analyzed fluorimetrically. Fluorescence enhancement (bar, back) is calculated as the cell concentration-corrected ratio of fluorescence of cells grown in the presence versus the absence of unnatural amino acid.

[0077] **Figure 25, Panels A-B**, illustrate components of the multipurpose reporter plasmid system for directing the evolution of *M. jannaschii* TyrRS. **Figure 25A** illustrates plasmid pREP/YC-JYCUA. Plasmid pREP/YC-JYCUA is compatible for use with plasmid pBK and variants. **Figure 25B** illustrates structures of unnatural amino acids used as targets for the evolution of *M. jannaschii* TyrRS.

[0078] **Figure 26** illustrates the strategy for the evolution of an aminoacyl-tRNA synthetase using plasmid pREP/YC-JYCUA. Fluorescent and non-fluorescent cells are shown in black and white, respectively.

[0079] Figure 27 illustrates a threonyl-tRNA synthetase from *Thermus thermophilus*.

[0080] Figure 28 illustrates the generation of an orthogonal tRNA for a *T. thermophilus* orthogonal threonyl-tRNA/RS.

5 [0081] Figure 29 illustrates exemplary unnatural amino acids as utilized in the current invention.

[0082] Figure 30 illustrates exemplary unnatural amino acids as utilized in the current invention.

10 [0083] Figure 31 illustrates exemplary unnatural amino acids as utilized in the current invention.

## DETAILED DESCRIPTION

### [0084] Introduction

[0085] Proteins are at the crossroads of virtually every biological process, from photosynthesis and vision to signal transduction and the immune response. These  
15 complex functions result from a polyamide based polymer consisting of twenty relatively simple building blocks arranged in a defined primary sequence.

[0086] The present invention includes methods and composition for use in the site-specific incorporation of unnatural amino acids directly into proteins in vivo. Importantly, the unnatural amino acid is added to the genetic repertoire, rather than substituting for one  
20 of the common 20 amino acids. The present invention provides methods for generating, methods for identifying and compositions comprising the components used by the biosynthetic machinery to incorporate an unnatural amino acid into a protein. The present invention, e.g., (i) allows the site-selective insertion of one or more unnatural amino acids at any desired position of any protein, (ii) is applicable to both prokaryotic and eukaryotic  
25 cells, (iii) enables in vivo studies of mutant proteins in addition to the generation of large quantities of purified mutant proteins, and (iv) is adaptable to incorporate any of a large variety of non-natural amino acids, into proteins in vivo. Thus, in a specific polypeptide sequence a number of different site-selective insertions of unnatural amino acids is possible. Such insertions are optionally all of the same type (e.g., multiple examples of  
30 one type of unnatural amino acid inserted at multiple points in a polypeptide) or are

optionally of diverse types (e.g., different unnatural amino acid types are inserted at multiple points in a polypeptide).

**[0087] DEFINITIONS**

**[0088]** Before describing the present invention in detail, it is to be understood that this invention is not limited to particular compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a molecule” optionally includes a combination of two or more such molecules, and the like.

**[0089]** Unless defined otherwise, all scientific and technical terms are understood to have the same meaning as commonly used in the art to which they pertain. For the purpose of the present invention, the following terms are defined below.

**[0090]** As used herein, proteins and/or protein sequences are “homologous” when they are derived, naturally or artificially, from a common ancestral protein or protein sequence. Similarly, nucleic acids and/or nucleic acid sequences are homologous when they are derived, naturally or artificially, from a common ancestral nucleic acid or nucleic acid sequence. For example, any naturally occurring nucleic acid can be modified by any available mutagenesis method to include one or more selector codon. When expressed, this mutagenized nucleic acid encodes a polypeptide comprising one or more unnatural amino acid. The mutation process can, of course, additionally alter one or more standard codon, thereby changing one or more standard amino acid in the resulting mutant protein as well. Homology is generally inferred from sequence similarity between two or more nucleic acids or proteins (or sequences thereof). The precise percentage of similarity between sequences that is useful in establishing homology varies with the nucleic acid and protein at issue, but as little as 25% sequence similarity is routinely used to establish homology. Higher levels of sequence similarity, e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% or more can also be used to establish homology. Methods for determining sequence similarity percentages (e.g., BLASTP and BLASTN using default parameters) are described herein and are generally available.

- [0091] The term “preferentially aminoacylates” refers to an efficiency, e.g., about 70% efficient, about 75% efficient, about 85% efficient, about 90%, about 95%, about 99% or more efficient, at which an O-RS aminoacylates an O-tRNA with an unnatural amino acid compared to a naturally occurring tRNA or starting material used to generate the O-tRNA. The unnatural amino acid is then incorporated into a growing polypeptide chain with high fidelity, e.g., at greater than about 75% efficiency for a given selector codon, at greater than about 80% efficiency for a given selector codon, at greater than about 90% efficiency for a given selector codon, greater than about 95 % efficiency for a given selector codon, or greater than about 99% efficiency for a given selector codon.
- [0092] The term “selector codon” refers to codons recognized by the O-tRNA in the translation process and not recognized by an endogenous tRNA. The O-tRNA anticodon loop recognizes the selector codon on the mRNA and incorporates its amino acid, e.g., an unnatural amino acid, at this site in the polypeptide. Selector codons can include, e.g., nonsense codons, such as, stop codons, e.g., amber, ochre, and opal codons; four or more base codons; codons derived from natural or unnatural base pairs and the like. For a given system, a selector codon can also include one of the natural three base codons, wherein the endogenous system does not use said natural three base codon, e.g., a system that is lacking a tRNA that recognizes the natural three base codon or a system wherein the natural three base codon is a rare codon.
- [0093] As used herein, the term “orthogonal” refers to a molecule (e.g., an orthogonal tRNA (O-tRNA) and/or an orthogonal aminoacyl tRNA synthetase (O-RS)) that is used with reduced efficiency by a system of interest (e.g., a translational system, e.g., a cell). Orthogonal refers to the inability or reduced efficiency, e.g., less than 20% efficient, less than 10% efficient, less than 5% efficient, or e.g., less than 1% efficient, of an orthogonal tRNA and/or orthogonal RS to function in the translation system of interest. For example, an orthogonal tRNA in a translation system of interest aminoacylates any endogenous RS of a translation system of interest with reduced or even zero efficiency, when compared to aminoacylation of an endogenous tRNA by the endogenous RS. In another example, an orthogonal RS aminoacylates any endogenous tRNA in the translation system of interest with reduced or even zero efficiency, as compared to aminoacylation of the endogenous tRNA by an endogenous RS. “Improvement in

orthogonality” refers to enhanced orthogonality compared to a starting material or a naturally occurring tRNA or RS.

[0094] The term “complementary” refers to components of an orthogonal pair, O-tRNA and O-RS that can function together, e.g., the O-RS aminoacylates the O-tRNA.

5 [0095] The term “derived from” refers to a component that is isolated from an organism or isolated and modified, or generated, e.g., chemically synthesized, using information of the component from the organism.

[0096] The term “translation system” refers to the components necessary to incorporate a naturally occurring amino acid into a growing polypeptide chain (protein).

10 For example, components can include ribosomes, tRNAs, synthetases, mRNA and the like. The components of the present invention can be added to a translation system, in vivo or in vitro.

[0097] The term “inactive RS” refers to a synthetase that have been mutated so that it no longer can aminoacylate its cognate tRNA with an amino acid.

15 [0098] The term “selection agent” refers to an agent that when present allows for a selection of certain components from a population, e.g., an antibiotic, wavelength of light, an antibody, a nutrient or the like. The selection agent can be varied, e.g., such as concentration, intensity, etc.

[0099] The term “positive selection marker” refers to a marker than when present, 20 e.g., expressed, activated or the like, results in identification of an organism with the positive selection marker from those without the positive selection marker.

[0100] The term “negative selection marker” refers to a marker than when present, e.g., expressed, activated or the like, allows identification of an organism that does not possess the desired property (e.g., as compared to an organism which does possess the 25 desired property).

[0101] The term “reporter” refers to a component that can be used to select components described in the present invention. For example, a reporter can include a green fluorescent protein, a firefly luciferase protein, or genes such as  $\beta$ -gal/lacZ ( $\beta$ -galactosidase), Adh (alcohol dehydrogenase) or the like.

[0102] The term “not efficiently recognized” refers to an efficiency, e.g., less than about 10%, less than about 5%, or less than about 1%, at which a RS from one organism aminoacylates O-tRNA.

5 [0103] The term “eukaryote” refers to organisms belonging to the phylogenetic domain Eucarya such as animals (e.g., mammals, insects, reptiles, birds, etc.), ciliates, plants, fungi (e.g., yeasts, etc.), flagellates, microsporidia, protists, etc. Additionally, the term “prokaryote” refers to non-eukaryotic organisms belonging to the Eubacteria (e.g., *Escherichia coli*, *Thermus thermophilus*, etc.) and Archaea (e.g., *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Halobacterium* such as *Haloferax*  
10 *volcanii* and *Halobacterium* species *NRC-1*, *A. fulgidus*, *P. furiosus*, *P. horikoshii*, *A. pernix*, etc.) phylogenetic domains

[0104] A “suppressor tRNA” is a tRNA that alters the reading of a messenger RNA (mRNA) in a given translation system. A suppressor tRNA can read through, e.g., a stop codon, a four base codon, or a rare codon.

15 [0105] **DISCUSSION**

[0106] The present invention relates to methods and compositions for new components of biosynthetic translational machinery that allows for the incorporation of unnatural amino acids into proteins in vivo. Specifically, compositions comprising and methods for generating orthogonal tRNAs and orthogonal-RS and orthogonal  
20 tRNAs/orthogonal-RS pairs are provided. These components, when introduced into a host cell, can be used in the translation system of the cell to incorporate an unnatural amino acid in vivo into a polypeptide (protein) of interest. For example, this can provide site-specific unnatural amino acid mutagenesis; or, optionally, random unnatural amino acid mutagenesis. The orthogonal tRNA delivers the unnatural amino acid in response to a  
25 selector codon and the orthogonal synthetase preferentially aminoacylates an orthogonal tRNA with the unnatural amino acid. The O-RS does not efficiently aminoacylate the orthogonal tRNA with any of the common twenty amino acids. Methods for making and identifying orthogonal pairs are also provided.

[0107] The site-specific incorporation of unnatural amino acids into proteins in  
30 vivo is schematically illustrated in **Figure 1**. A selector codon, e.g., a unique codon, is introduced into a gene of interest. The gene is transcribed into mRNA and conventional



translation begins on the ribosome. Endogenous synthetases aminoacylate endogenous tRNAs with natural amino acids (aa) in the presence of ATP. An orthogonal tRNA is enzymatically aminoacylated by an orthogonal synthetase with an unnatural amino acid in the presence of ATP. When the ribosome encounters a selector codon, an orthogonal tRNA, which is modified to contain a selector anticodon, e.g., a unique anticodon, it is able to decode the mutation as an unnatural amino acid, and translation proceeds to the full-length product with the incorporated unnatural amino acid.

[0108]        **Orthogonal aminoacyl tRNA synthetase, O-RS**

[0109]        In order to specifically incorporate an unnatural amino acid in vivo, the substrate specificity of the synthetase is altered so that only the desired unnatural amino acid, but not any common 20 amino acids are charged to the tRNA. If the orthogonal synthetase is promiscuous, it will result in mutant proteins with a mixture of natural and unnatural amino acids at the target position. For instance, in an attempt to site-specifically incorporate *p*-F-Phe, a yeast amber suppressor tRNA<sup>Phe</sup>CUA /phenylalanyl-tRNA synthetase pair was used in a *p*-F-Phe resistant, Phe auxotrophic *Escherichia coli* strain. See, e.g., R. Furter, Protein Sci., 7:419 (1998). Because yeast PheRS does not have high substrate specificity for *p*-F-Phe, the mutagenesis site was translated with 64-75% *p*-F-Phe and the remainder as Phe and Lys even in the excess of *p*-F-Phe added to the growth media. In addition, at the Phe codon positions, 7% *p*-F-Phe was found, indicating that the endogenous *Escherichia coli* PheRS incorporates *p*-F-Phe in addition to Phe. Because of its translational infidelity, this approach is not generally applicable to other unnatural amino acids. Modification of the substrate specificity of a synthetase was expected to be difficult due to the high intrinsic fidelity of the natural synthetases and the fact that unnatural amino acids are not required for any cellular function. The present invention solves this problem and provides composition of, and methods for, generating synthetases that have modified substrate specificity, such as an unnatural amino acid. Using the components of the present invention, the efficiency of incorporation of an unnatural amino acid into is, e.g., greater than about 75%, greater than about 85%, greater than about 95%, greater than about 99% or more.

30

[0110]        Compositions of the present invention include an orthogonal aminoacyl-tRNA synthetase (O-RS), where the O-RS preferentially aminoacylates an orthogonal

tRNA (O-tRNA) with an unnatural amino acid, optionally, in vivo. In one embodiment, the O-RS comprises a nucleic acid comprising a polynucleotide sequence selected from the group consisting of: SEQ ID NO: 4-34 (*see*, Table 5) and a complementary polynucleotide sequence thereof. In another embodiment, the O-RS has improved or enhanced enzymatic properties, e.g., the  $K_m$  is lower, the  $k_{cat}$  is higher, the value of  $k_{cat}/K_m$  is higher or the like, for the unnatural amino acid compared to a naturally occurring amino acid, e.g., one of the 20 known amino acids. Sequences of exemplary O-tRNA and O-RS molecules can be found in Example 10.

[0111] Methods for producing an O-RS are based on generating a pool of mutant synthetases from the framework of a wild-type synthetase, and then selecting for mutated RSs based on their specificity for an unnatural amino acid relative to the common twenty. To isolate such a synthetase, the selection methods of the present invention are: (i) sensitive, as the activity of desired synthetases from the initial rounds can be low and the population small; (ii) "tunable", since it is desirable to vary the selection stringency at different selection rounds; and, (iii) general, so that it can be used for different unnatural amino acids.

[0112] The present invention provides methods to generate an orthogonal aminoacyl tRNA synthetase by mutating the synthetase, e.g., at the active site in the synthetase, at the editing mechanism site in the synthetase, at different sites by combining different domains of synthetases, or the like, and applying a selection process. **Figure 2, Panel A** schematically illustrates an in vivo selection/screen strategy, which is based on the combination of a positive selection followed by a negative selection. In the positive selection, suppression of the selector codon introduced at a nonessential position(s) of a positive marker allows cells to survive under positive selection pressure. In the presence of both natural and unnatural amino acids, survivors thus encode active synthetases charging the orthogonal suppressor tRNA with either a natural or unnatural amino acid. In the negative selection, suppression of a selector codon introduced at a nonessential position(s) of a negative marker removes synthetases with natural amino acid specificities. Survivors of the negative and positive selection encode synthetases that aminoacylate (charge) the orthogonal suppressor tRNA with unnatural amino acids only. These synthetases can then be subjected to further mutagenesis, e.g., DNA shuffling or other recursive mutagenesis methods. Of course, in other embodiments, the invention optionall

cn utilize different orders of steps to identify (e.g., O-RS, O-tRNA, pairs, etc.), e.t., negative selection/screening followed by positive selection/screening or vice verse or any such combinations thereof.

[0113] For example, *see*, **Figure 2, Panel B**. In **Figure 2, Panel B**, a selector  
5 codon, e.g., an amber codon, is placed in a reporter gene, e.g., an antibiotic resistance  
gene, such as  $\beta$ -lactamase, with a selector codon, e.g., TAG. This is placed in an  
expression vector with members of the mutated RS library. This expression vector along  
with an expression vector with an orthogonal tRNA, e.g., a orthogonal suppressor tRNA,  
are introduced into a cell, which is grown in the presence of a selection agent, e.g.,  
10 antibiotic media, such as ampicillin. Only if the synthetase is capable of aminoacylating  
(charging) the suppressor tRNA with some amino acid does the selector codon get  
decoded allowing survival of the cell on antibiotic media.

[0114] Applying this selection in the presence of the unnatural amino acid, the  
synthetase genes that encode synthetases that have some ability to aminoacylate are  
15 selected away from those synthetases that have no activity. The resulting pool of  
synthetases can be charging any of the 20 naturally occurring amino acids or the unnatural  
amino acid. To further select for those synthetases that exclusively charge the unnatural  
amino acid, a second selection, e.g., a negative selection, is applied. In this case, an  
expression vector containing a negative selection marker and an O-tRNA is used, along  
20 with an expression vector containing a member of the mutated RS library. This negative  
selection marker contains at least one selector codon, e.g., TAG. These expression vectors  
are introduced into another cell and grown without unnatural amino acids and, optionally,  
a selection agent, e.g., tetracycline. In the negative selection, those synthetases with  
specificities for natural amino acids charge the orthogonal tRNA, resulting in suppression  
25 of a selector codon in the negative marker and cell death. Since no unnatural amino acid  
is added, synthetases with specificities for the unnatural amino acid survive. For example,  
a selector codon, e.g., a stop codon, is introduced into the reporter gene, e.g., a gene that  
encodes a toxic protein, such as barnase. If the synthetase is able to charge the suppressor  
tRNA in the absence of unnatural amino acid, the cell will be killed by translating the  
30 toxic gene product. Survivors passing both selection/screens encode synthetases  
specifically charging the orthogonal tRNA with an unnatural amino acid.

[0115] In one embodiment, methods for producing at least one recombinant orthogonal aminoacyl-tRNA synthetase (O-RS) include: (a) generating a library of mutant RSs derived from at least one aminoacyl-tRNA synthetase (RS) from a first organism; (b) selecting the library of mutant RSs for members that aminoacylate an orthogonal tRNA (O-tRNA) in the presence of an unnatural amino acid and a natural amino acid, thereby providing a pool of active mutant RSs; and, (c) negatively selecting the pool for active mutant RSs that preferentially aminoacylate the O-tRNA in the absence of the unnatural amino acid, thereby providing the at least one recombinant O-RS; wherein the at least one recombinant O-RS preferentially aminoacylates the O-tRNA with the unnatural amino acid. Optionally, more mutations are introduced by mutagenesis, e.g., random mutagenesis, recombination or the like, into the selected synthetase genes to generate a second-generation synthetase library, which is used for further rounds of selection until a mutant synthetase with desired activity is evolved. Recombinant O-RSs produced by the methods are included in the present invention. As explained below, orthogonal tRNA/synthetase pairs or the invention are also optionally generated by importing such from a first organism into a second organism.

[0116] In one embodiment, the RS is an inactive RS. The inactive RS can be generated by mutating an active RS. For example, the inactive RS can be generated by mutating at least about 5 amino acids to different amino acids, e.g., alanine.

[0117] The library of mutant RSs can be generated using various mutagenesis techniques known in the art. For example, the mutant RSs can be generated by site-specific mutations, random point mutations, in vitro homologous recombinant, chimeric constructs or the like. In one embodiment, mutations are introduced into the editing site of the synthetase to hamper the editing mechanism and/or to alter substrate specificity. *See, e.g., Figure 3 and Figure 4. Figure 3 illustrates site-specific mutations to generate directed libraries for tyrosine analogues. Figure 4 illustrates a consensus sequence for pentafluorophenylalanine selection to generate directed libraries for these analogues. Libraries of mutant RSs also include chimeric synthetase libraries, e.g., libraries of chimeric *Methanococcus jannaschii*/*Escherichia coli* synthetases. The domain of one synthetase can be added or exchanged with a domain from another synthetase. Figure 5 schematically illustrates the transplantation of one domain, e.g., the CPI domain, from one organism, e.g., *Escherichia coli*, to the synthetase of other organism, e.g., *Methanococcus**

*jannaschii* TyrRS. CPI can be transplanted from *Escherichia coli* TyrRS to *H. sapiens* TyrRS. See, e.g., Wakasugi, K., et al., EMBO J. 17:297-305 (1998). Figure 6 schematically illustrates the construction of chimeric *Methanococcus jannaschii*/*Escherichia coli* synthetases and Figure 7 schematically illustrates the generation of a library of chimeric synthetases, e.g., *Methanococcus jannaschii*/*Escherichia coli* synthetases. See, e.g., Sieber, et al., Nature Biotechnology, 19:456-460 (2001). The chimeric library is screened for a variety of properties, e.g., for members that are expressed and in frame, for members that lack activity with a desired synthetase, and/or for members that show activity with a desired synthetase.

10 [0118] In one embodiment, the positive selection step includes: introducing a positive selection marker, e.g., an antibiotic resistance gene, or the like, and the library of mutant RSs into a plurality of cells, wherein the positive selection marker comprises at least one selector codon, e.g., an amber codon; growing the plurality of cells in the presence of a selection agent; selecting cells that survive in the presence of the selection agent by suppressing the at least one selector codon in the positive selection marker, thereby providing a subset of positively selected cells that contains the pool of active mutant RSs. Optionally, the selection agent concentration can be varied.

15 [0119] In one embodiment, negative selection includes: introducing a negative selection marker with the pool of active mutant RSs from the positive selection into a plurality of cells of a second organism, wherein the negative selection marker is an antibiotic resistance gene, e.g., a chloramphenicol acetyltransferase (CAT) gene, comprising at least one selector codon; and, selecting cells that survive in a 1st media supplemented with the unnatural amino acid and a selection agent, but fail to survive in a 2nd media not supplemented with the unnatural amino acid and the selection agent, thereby providing surviving cells with the at least one recombinant O-RS. Optionally, the concentration of the selection agent is varied.

20 [0120] The 1<sup>st</sup> and 2<sup>nd</sup> media described above can include, e.g., a direct replica plate method. For example, after passing the positive selection, cells are grown in the presence of either ampicillin or chloramphenicol and the absence of the unnatural amino acid. Those cells that do not survive are isolated from a replica plate supplemented with the unnatural amino acid. No transformation into a second negative selection strain is needed, and the phenotype is known. Compared to other potential selection markers, a

25 30

positive selection based on antibiotic resistance offers the ability to tune selection stringency by varying the concentration of the antibiotic, and to compare the suppression efficiency by monitoring the highest antibiotic concentration cells can survive. In addition, the growth process is also an enrichment procedure. This can lead to a quick  
5 accumulation of the desired phenotype.

[0121] In another embodiment, negatively selecting the pool for active mutant RSs includes: isolating the pool of active mutant RSs from the positive selection step (b); introducing a negative selection marker, wherein the negative selection marker is a toxic marker gene, e.g., a ribonuclease barnase gene, comprising at least one selector codon, and  
10 the pool of active mutant RSs into a plurality of cells of a second organism; and selecting cells that survive in a 1st media not supplemented with the unnatural amino acid, but fail to survive in a 2nd media supplemented with the unnatural amino acid, thereby providing surviving cells with the at least one recombinant O-RS, wherein the at least one recombinant O-RS is specific for the unnatural amino acid. Optionally, the negative  
15 selection marker comprises two or more selector codons.

[0122] In one aspect, positive selection is based on suppression of a selector codon in a positive selection marker, e.g., a chloramphenicol acetyltransferase (CAT) gene comprising a selector codon, e.g., an amber stop codon, in the CAT gene, so that chloramphenicol can be applied as the positive selection pressure. In addition, the CAT  
20 gene can be used as both a positive marker and negative marker as describe herein in the presence and absence of unnatural amino acid. Optionally, the CAT gene comprising a selector codon is used for the positive selection and a negative selection marker, e.g., a toxic marker, such as a barnase gene comprising at least one or more selector codons, is used for the negative selection.

25 [0123] In another aspect, positive selection is based on suppression of a selector codon at nonessential position in the  $\beta$ -lactamase gene, rendering cells ampicillin resistant; and a negative selection using the ribonuclease barnase as the negative marker is used. In contrast to  $\beta$ -lactamase, which is secreted into the periplasm, CAT localizes in the cytoplasm; moreover, ampicillin is bacteriocidal, while chloramphenicol is bacteriostatic.

30 [0124] The recombinant O-RS can be further mutated and selected. In one embodiment, the methods for producing at least one recombinant orthogonal aminoacyl-tRNA synthetase (O-RS) can further comprise: (d) isolating the at least one recombinant

O-RS; (e) generating a second set of mutated O-RS derived from the at least one recombinant O-RS; and, (f) repeating steps (b) and (c) until a mutated O-RS is obtained that comprises an ability to preferentially aminoacylate the O-tRNA. Optionally, steps (d)-(f) are repeated, e.g., at least about two times. In one aspect, the second set of mutated  
5 O-RS can be generated by mutagenesis, e.g., random mutagenesis, site-specific mutagenesis, recombination or a combination thereof.

[0125] The stringency of the selection steps, e.g., the positive selection step (b), the negative selection step (c) or both the positive and negative selection steps (b) and (c), in the above described-methods, optionally include varying the selection stringency. For  
10 example, because barnase is an extremely toxic protein, the stringency of the negative selection can be controlled by introducing different numbers of selector codons into the barnase gene. In one aspect of the present invention, the stringency is varied because the desired activity can be low during early rounds. Thus, less stringent selection criteria are applied in early rounds and more stringent criteria are applied in later rounds of selection.

[0126] Other types of selections can be used in the present invention for, e.g., O-RS, O-tRNA, and O-tRNA/O-RS pair. For example, the positive selection step (b), the negative selection step (c) or both the positive and negative selection steps (b) and (c) can include using a reporter, wherein the reporter is detected by fluorescence-activated cell sorting (FACS). For example, a positive selection can be done first with a positive  
20 selection marker, e.g., chloramphenicol acetyltransferase (CAT) gene, where the CAT gene comprises a selector codon, e.g., an amber stop codon, in the CAT gene, which followed by a negative selection screen, that is based on the inability to suppress a selector codon(s), e.g., two or more, at positions within a negative marker, e.g., T7 RNA polymerase gene. In one embodiment, the positive selection marker and the negative  
25 selection marker can be found on the same vector, e.g., plasmid. Expression of the negative marker drives expression of the reporter, e.g., green fluorescent protein (GFP). The stringency of the selection and screen can be varied, e.g., the intensity of the light need to fluorescence the reporter can be varied. In another embodiment, a positive selection can be done with a reporter as a positive selection marker, which is screened by  
30 FACs, followed by a negative selection screen, that is based on the inability to suppress a selector codon(s), e.g., two or more, at positions within a negative marker, e.g., barnase gene.

[0127] Optionally, the reporter is displayed on a cell surface, e.g., on a phage display or the like. Cell-surface display, e.g., the OmpA-based cell-surface display system, relies on the expression of a particular epitope, e.g., a poliovirus C3 peptide fused to an outer membrane porin OmpA, on the surface of the *Escherichia coli* cell. The epitope is displayed on the cell surface only when a selector codon in the protein message is suppressed during translation. The displayed peptide then contains the amino acid recognized by one of the mutant aminoacyl-tRNA synthetases in the library, and the cell containing the corresponding synthetase gene can be isolated with antibodies raised against peptides containing specific unnatural amino acids. The OmpA-based cell-surface display system was developed and optimized by Georgiou et al. as an alternative to phage display. See, Francisco, J. A., Campbell, R., Iverson, B. L. & Georgiou, G. *Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface*. Proc. Natl. Acad. Sci. U S A 90:10444-8 (1993).

[0128] Other embodiments of the present invention include carrying one or more of the selection steps in vitro. The selected component, e.g., synthetase and/or tRNA, can then be introduced into a cell for use in in vivo incorporation of an unnatural amino acid.

[0129] Orthogonal tRNA

[0130] Compositions of an orthogonal tRNA (O-tRNA) are also a feature of the invention, e.g., where the O-tRNA recognizes a selector codon and the O-tRNA is preferentially aminoacylated with an unnatural amino acid by an orthogonal aminoacyl-tRNA synthetase. In one embodiment, the O-tRNA comprises a nucleic acid comprising a polynucleotide sequence selected from the group consisting of: SEQ ID NO: 4-34 (see, Table 5) and a complementary polynucleotide sequence thereof.

[0131] Methods for producing a recombinant orthogonal tRNA (O-tRNA) are provided herein. For example, to improve the orthogonality of a tRNA while preserving its affinity toward a desired RS, the methods include a combination of negative and positive selections with a mutant suppressor tRNA library in the absence and presence of the cognate synthetase, respectively. See, Figure 8. In the negative selection, a selector codon(s) is introduced in a marker gene, e.g., a toxic gene, such as barnase, at a nonessential position. When a member of the mutated tRNA library, e.g., derived from *Methanococcus jannaschii*, is aminoacylated by endogenous host, e.g., *Escherichia coli* synthetases (i.e., it is not orthogonal to the host, e.g., *Escherichia coli* synthetases), the



selector codon, e.g., an amber codon, is suppressed and the toxic gene product produced leads to cell death. Cells harboring orthogonal tRNAs or non-functional tRNAs survive. Survivors are then subjected to a positive selection in which a selector codon, e.g., an amber codon, is placed in a positive marker gene, e.g., a drug resistance gene, such as a  $\beta$ -lactamase gene. These cells also contain an expression vector with a cognate RS. These cells are grown in the presence of a selection agent, e.g., ampicillin. tRNAs are then selected for their ability to be aminoacylated by the coexpressed cognate synthetase and to insert an amino acid in response to this selector codon. Cells harboring non-functional tRNAs, or tRNAs that cannot be recognized by the synthetase of interest are sensitive to the antibiotic. Therefore, tRNAs that: (i) are not substrates for endogenous host, e.g., *Escherichia coli*, synthetases; (ii) can be aminoacylated by the synthetase of interest; and (iii) are functional in translation survive both selections.

[0132] Methods of producing a recombinant O-tRNA include: (a) generating a library of mutant tRNAs derived from at least one tRNA, e.g., a suppressor tRNA, from a first organism; (b) negatively selecting the library for mutant tRNAs that are aminoacylated by an aminoacyl-tRNA synthetase (RS) from a second organism in the absence of a RS from the first organism, thereby providing a pool of mutant tRNAs; and, (c) selecting the pool of mutant tRNAs for members that are aminoacylated by an introduced orthogonal RS (O-RS), thereby providing at least one recombinant O-tRNA; wherein the at least one recombinant O-tRNA recognizes a selector codon and is not efficiency recognized by the RS from the second organism and is preferentially aminoacylated by the O-RS. In one embodiment, the recombinant O-tRNA possesses an improvement of orthogonality.

[0133] Libraries of mutated tRNA are constructed. See, for example, Figure 9. Mutations can be introduced at a specific position(s), e.g., at a nonconservative position(s), or at a conservative position, at a randomized position(s), or a combination of both in a desired loop of a tRNA, e.g., an anticodon loop, (D arm, V loop, T $\psi$ C arm) or a combination of loops or all loops. Chimeric libraries of tRNA are also included in the present invention. It should be noted that libraries of tRNA synthetases from various organism (e.g., microorganisms such as eubacteria or archaeobacteria) such as libraries comprising natural diversity (such as libraries that comprise natural diversity (see, e.g.,

U.S. Patent No. 6,238,884 to Short et al. and references therein, U.S. Patent No. 5,756,316 to Schallenberger et al; U.S. Patent No. 5,783,431 to Petersen et al; U.S. Patent No. 5,824,485 to Thompson et al; and U.S. Patent No. 5,958,672 to Short et al), are optionally constructed and screened for orthogonal pairs.

- 5 [0134] In one embodiment, negatively selecting the library for mutant tRNAs that are aminoacylated by an aminoacyl-tRNA synthetase (step (b) above) includes: introducing a toxic marker gene, wherein the toxic marker gene comprises at least one of the selector codons and the library of mutant tRNAs into a plurality of cells from the second organism; and, selecting surviving cells, wherein the surviving cells contain the
- 10 pool of mutant tRNAs comprising at least one orthogonal tRNA or nonfunctional tRNA. For example, the toxic marker gene is optionally a ribonuclease barnase gene, wherein the ribonuclease barnase gene comprises at least one amber codon. Optionally, the ribonuclease barnase gene can include two or more amber codons. The surviving cells can be selected, e.g., by using a comparison ratio cell density assay.
- 15 [0135] In one embodiment, selecting the pool of mutant tRNAs for members that are aminoacylated by an introduced orthogonal RS (O-RS) can include: introducing a positive selection marker gene, wherein the positive selection marker gene comprises a drug resistance gene, e.g., a  $\beta$ -lactamase gene, comprising at least one of the selector codons, e.g., a  $\beta$ -lactamase gene comprising at least one amber stop codon, the O-RS, and
- 20 the pool of mutant tRNAs into a plurality of cells from the second organism; and, selecting surviving cells grown in the presence of a selection agent, e.g., an antibiotic, thereby providing a pool of cells possessing the at least one recombinant tRNA, wherein the recombinant tRNA is aminoacylated by the O-RS and inserts an amino acid into a translation product encoded by the positive marker gene, in response to the at least one
- 25 selector codons. In another embodiment, the concentration of the selection agent is varied. Recombinant O-tRNAs produced by the methods are included in the present invention.

[0136] As described above for generating O-RS, the stringency of the selection steps can be varied. In addition, other selection/screening procedures, which are described herein, such as FACs, cell and phage display can also be used.

- 30 [0137] Selector Codons

[0138] Selector codons of the present invention expand the genetic codon framework of protein biosynthetic machinery. For example, a selector codon includes, e.g., a unique three base codon, a nonsense codon, such as a stop codon, e.g., an amber codon, or an opal codon, an unnatural codon, a four (or more) base codon or the like. A number of selector codons can be introduced into a desired gene, e.g., one or more, two or more, more than three, etc. Additionally, it will be appreciated that multiple different (or similar or identical) unnatural amino acids can thus be incorporated precisely into amino acids (i.e., through use of the multiple selector codons).

[0139] The 64 genetic codons code for 20 amino acids and 3 stop codons. Because only one stop codon is needed for translational termination, the other two can in principle be used to encode nonproteinogenic amino acids. The amber stop codon, UAG, has been successfully used in in vitro biosynthetic system and in *Xenopus* oocytes to direct the incorporation of unnatural amino acids. Among the 3 stop codons, UAG is the least used stop codon in *Escherichia coli*. Some *Escherichia coli* strains contain natural suppressor tRNAs, which recognize UAG and insert a natural amino acid in response to UAG. In addition, these amber suppressor tRNAs have been widely used in conventional protein mutagenesis. Different species preferentially use different codons for their natural amino acids, such preferentiality is optionally utilized in designing/choosing the selector codons herein.

[0140] Although discussed with reference to unnatural amino acids herein, it will be appreciated that a similar strategy can be used incorporate a natural amino acid in response to a particular selector codon. That is, a synthetase can be modified to load a natural amino acid onto an orthogonal tRNA that recognizes a selector codon in a manner similar to the loading of an unnatural amino acid as described throughout.

[0141] In one embodiment, the methods involve the use of a selector codon that is a stop codon for the incorporation of unnatural amino acids in vivo. For example, an O-tRNA is generated that recognizes the stop codon, e.g., UAG, and is aminoacylated by an O-RS with a desired unnatural amino acid. This O-tRNA is not recognized by the naturally occurring aminoacyl-tRNA synthetases. Conventional site-directed mutagenesis can be used to introduce the stop codon, e.g., TAG, at the site of interest in the protein gene. See, e.g., Sayers, J. R., Schmidt, W. Eckstein, F. 5', 3' *Exonuclease in phosphorothioate-based oligonucleotide-directed mutagenesis*. Nucleic Acids Res, 791-

802 (1988). When the O-RS, O-tRNA and the mutant gene are combined in vivo, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing the unnatural amino acid at the specified position.

[0142] The incorporation of unnatural amino acids in vivo can be done without significant perturbation of the host, e.g., *Escherichia coli*. For example, because the suppression efficiency for the UAG codon depends upon the competition between the O-tRNA, e.g., the amber suppressor tRNA, and the release factor 1 (RF1) (which binds to the UAG codon and initiates release of the growing peptide from the ribosome), the suppression efficiency can be modulated by, e.g., either increasing the expression level of O-tRNA, e.g., the suppressor tRNA, or using an RF1 deficient strain. Additionally, suppression efficiency and unnatural amino acid uptake by carrying out random mutagenesis on an organism or on a portion of an organism's genome and performing proper selection using, e.g., one of the reporter systems described herein.

[0143] Unnatural amino acids can also be encoded with rare codons. For example, when the arginine concentration in an in vitro protein synthesis reaction is reduced, the rare arginine codon, AGG, has proven to be efficient for insertion of Ala by a synthetic tRNA acylated with alanine. See, e.g., C. H. Ma, W. Kudlicki, O. W. Odom, G. Kramer and B. Hardesty, Biochemistry, 32:7939 (1993). In this case, the synthetic tRNA competes with the naturally occurring tRNA<sup>Arg</sup>, which exists as a minor species in *Escherichia coli*. Some organisms do not use all triplet codons. An unassigned codon AGA in *Micrococcus luteus* has been utilized for insertion of amino acids in an in vitro transcription/translation extract. See, e.g., A. K. Kowal and J. S. Oliver, Nucl. Acid. Res., 25:4685 (1997). Components of the present invention can be generated to use these rare codons in vivo.

[0144] Selector codons also comprise four or more base codons, such as, four, five six or more. Examples of four base codons include, e.g., AGGA, CUAG, UAGA, CCCU and the like. Examples of five base codons include, e.g., AGGAC, CCCCUC, CCCUC, CUAGA, CUACU, UAGGC and the like. For example, in the presence of mutated O-tRNAs, e.g., a special frameshift suppressor tRNAs, with anticodon loops, e.g., with at least 8-10 nt anticodon loops, the four or more base codon is read as single amino acid. In other embodiments, the anticodon loops can decode, e.g., at least a four-base codon, at least a five-base codon, or at least a six-base codon or more. Since there are 256 possible

four-base codons, multiple unnatural amino acids can be encoded in the same cell using the four or more base codon. *See also*, J. Christopher Anderson et al., *Exploring the Limits of Codon and Anticodon Size*, Chemistry and Biology, Vol. 9, 237-244 (2002); Thomas J. Magliery, *Expanding the Genetic Code: Selection of Efficient Suppressors of*  
5 *Four-base Codons and Identification of "Shifty" Four-base Codons with a Library Approach in Escherichia coli*, J. Mol. Biol. 307: 755-769 (2001).

[0145] Methods of the present invention include using extended codons based on frameshift suppression. Four or more base codons can insert, e.g., one or multiple unnatural amino acids into the same protein. For example, four-base codons have been  
10 used to incorporate unnatural amino acids into proteins using in vitro biosynthetic methods. *See, e.g.*, C. H. Ma, W. Kudlicki, O. W. Odom, G. Kramer and B. Hardesty, Biochemistry, 1993, 32, 7939 (1993); and, T. Hohsaka, D. Kajihara, Y. Ashizuka, H. Murakami and M. Sisido, J. Am. Chem. Soc., 121:34 (1999). CGGG and AGGU were used to simultaneously incorporate 2-naphthylalanine and an NBD derivative of lysine  
15 into streptavidin in vitro with two chemically acylated frameshift suppressor tRNAs. *See, e.g.*, T. Hohsaka, Y. Ashizuka, H. Sasaki, H. Murakami and M. Sisido, J. Am. Chem. Soc., 121:12194 (1999). In an in vivo study, Moore et al. examined the ability of tRNA<sup>Leu</sup> derivatives with NCUA anticodons to suppress UAGN codons (N can be U, A, G, or C), and found that the quadruplet UAGA can be decoded by a tRNA<sup>Leu</sup> with a UCUA  
20 anticodon with an efficiency of 13 to 26% with little decoding in the 0 or -1 frame. *See*, B. Moore, B. C. Persson, C. C. Nelson, R. F. Gesteland and J. F. Atkins, J. Mol. Biol., 298:195 (2000). In one embodiment, extended codons based on rare codons or nonsense codons can be used in present invention, which can reduce missense readthrough and frameshift suppression at unwanted sites.

25 [0146] A translational bypassing system can also be used to incorporate an unnatural amino acid in a desired polypeptide. In a translational bypassing system, a large sequence is inserted into a gene but is not translated into protein. The sequence contains a structure that serves as a cue to induce the ribosome to hop over the sequence and resume translation downstream of the insertion.

30 [0147] Alternatively, or in combination with others methods described above to incorporate an unnatural amino acid in a polypeptide, a trans-translation system can be used. This system involves a molecule called tmRNA present in *Escherichia coli*. This

RNA molecule is structurally related to an alanyl tRNA and is aminoacylated by the alanyl synthetase. The difference between tmRNA and tRNA is that the anticodon loop is replaced with a special large sequence. This sequence allows the ribosome to resume translation on sequences that have stalled using an open reading frame encoded within the tmRNA as template. In the present invention, an orthogonal tmRNA can be generated that is preferentially aminoacylated with an orthogonal synthetase and loaded with an unnatural amino acid. By transcribing a gene by the system, the ribosome stalls at a specific site; the unnatural amino acid is introduced at that site, and translation resumes using the sequence encoded within the orthogonal tmRNA.

10 [0148] Selector codons also optionally include unnatural base pairs. These unnatural base pairs further expand the existing genetic alphabet. One extra base pair increases the number of triplet codons from 64 to 125. Properties of third base pairs include stable and selective base pairing, efficient enzymatic incorporation into DNA with high fidelity by a polymerase, and the efficient continued primer extension after synthesis of the nascent unnatural base pair. Descriptions of unnatural base pairs which can be adapted for methods and compositions include, e.g., Hirao, et al., *An unnatural base pair for incorporating amino acid analogues into protein*, Nature Biotechnology, 20:177-182 (2002). Other publications are listed below.

[0149] For in vivo usage, the unnatural nucleoside is membrane permeable and is phosphorylated to form the corresponding triphosphate. In addition, the increased genetic information is stable and not destroyed by cellular enzymes. Previous efforts by Benner and others took advantage of hydrogen bonding patterns that are different from those in canonical Watson-Crick pairs, the most noteworthy example of which is the iso-C:iso-G pair. See, e.g., C. Switzer, S. E. Moroney and S. A. Benner, J. Am. Chem. Soc., 111:8322 (1989); and, J. A. Piccirilli, T. Krauch, S. E. Moroney and S. A. Benner, Nature, 1990, 343:33 (1990); and E. T. Kool, Curr. Opin. Chem. Biol., 4:602 (2000). These bases in general mispair to some degree with natural bases and cannot be enzymatically replicated. Kool and co-workers demonstrated that hydrophobic packing interactions between bases can replace hydrogen bonding to drive the formation of base pair. See, E. T. Kool, Curr. Opin. Chem. Biol., 4:602 (2000); and, K. M. Guckian and E. T. Kool, Angew. Chem. Int. Ed. Engl., 36, 2825 (1998). In an effort to develop an unnatural base pair satisfying all the above requirements, Schultz, Romesberg and co-workers have systematically synthesized

- and studied a series of unnatural hydrophobic bases. The PICS:PICS self-pair, which is shown in **Figure 10**, is found to be more stable than natural base pairs, and can be efficiently incorporated into DNA by the Klenow fragment of *Escherichia coli* DNA polymerase I (KF). *See, e.g.*, D. L. McMinn, A. K. Ogawa, Y. Q. Wu, J. Q. Liu, P. G. Schultz and F. E. Romesberg, J. Am. Chem. Soc., 121:11586 (1999); and, A. K. Ogawa, Y. Q. Wu, D. L. McMinn, J. Q. Liu, P. G. Schultz and F. E. Romesberg, J. Am. Chem. Soc., 122:3274 (2000). A 3MN:3MN self-pair can be synthesized by KF with efficiency and selectivity sufficient for biological function. *See, e.g.*, A. K. Ogawa, Y. Q. Wu, M. Berger, P. G. Schultz and F. E. Romesberg, J. Am. Chem. Soc., 122:8803 (2000).
- However, both bases act as a chain terminator for further replication. A mutant DNA polymerase has been recently evolved that can be used to replicate the PICS self pair. In addition, a 7AI self pair can be replicated using a combination of KF and pol  $\beta$  polymerase. *See, e.g.*, E. J. L. Tae, Y. Q. Wu, G. Xia, P. G. Schultz and F. E. Romesberg, J. Am. Chem. Soc., 123:7439 (2001). A novel metallobase pair, Dipic:Py, has also been developed, which forms a stable pair upon binding Cu(II). *See*, E. Meggers, P. L. Holland, W. B. Tolman, F. E. Romesberg and P. G. Schultz, J. Am. Chem. Soc., 122:10714 (2000). Because extended codons and unnatural codons are intrinsically orthogonal to natural codons, the methods of the present invention can take advantage of this property to generate orthogonal tRNAs for them.
- 20   **[0150]           Orthogonal tRNA and Orthogonal aminoacyl-tRNA synthetase pairs**
- [0151]**           An orthogonal pair is composed of an O-tRNA, e.g., a suppressor tRNA, a frameshift tRNA, or the like, and an O-RS. The O-tRNA is not acylated by endogenous synthetases and is capable of decoding a selector codon, as described above. The O-RS recognizes the O-tRNA, e.g., with an extended anticodon loop, and preferentially
- 25   aminoacylates the O-tRNA with an unnatural amino acid. Methods for generating orthogonal pairs along with compositions of orthogonal pairs are included in the present invention. The development of multiple orthogonal tRNA/synthetase pairs can allow the simultaneous incorporation of multiple unnatural amino acids using different codons into the same polypeptide/protein.
- 30   **[0152]**           In the present invention, methods and related compositions relate to the generation of orthogonal pairs (O-tRNA/O-RS) that can incorporate an unnatural amino acid into a protein in vivo. For example, compositions of O-tRNAs of the present

invention can comprise an orthogonal aminoacyl-tRNA synthetase (O-RS). In one embodiment, the O-tRNA and the O-RS can be complementary, e.g., an orthogonal O-tRNA/O-RS pair. Examples of pairs include a mutRNATyr-mutTyrRS pair, such as a mutRNATyr-SS12TyrRS pair, a mutRNALeu-mutLeuRS pair, a mutRNAThr-mutThrRS pair, a mutRNAGlu-mutGluRS pair, or the like. In one embodiment, an orthogonal pair of the present invention comprises the desired properties of the orthogonal tRNA-aminoacyl-tRNA synthetase pair and is other than a mutRNAGln-mutGlnRS derived from *Escherichia coli*, a mutRNAAsp-mutAspRS derived from yeast or a mutRNAPheCUA-mutphenylalanineRS from yeast, where these pairs do not possess the properties of the pairs of the present invention.

[0153] The O-tRNA and the O-RS can be derived by mutation of a naturally occurring tRNA and/or RS from a variety of organisms, which are described under sources and hosts. In one embodiment, the O-tRNA and O-RS are derived from at least one organism. In another embodiment, the O-tRNA is derived by mutation of a naturally occurring or mutated naturally occurring tRNA from a first organism and the O-RS is derived by mutation of a naturally occurring or mutated naturally occurring RS from a second organism.

[0154] Methods for generating specific O-tRNA/O-RS pairs are also provided in the present invention. These methods solve the problems discussed below for the other strategies that were attempted to generate orthogonal tRNA/RS pairs. Specifically, methods of the present invention include: (a) generating a library of mutant tRNAs derived from at least one tRNA from a first organism; (b) negatively selecting the library for mutant tRNAs that are aminoacylated by an aminoacyl-tRNA synthetase (RS) from a second organism in the absence of a RS from the first organism, thereby providing a pool of mutant tRNAs; (c) selecting the pool of mutant tRNAs for members that are aminoacylated by an introduced orthogonal RS (O-RS), thereby providing at least one recombinant O-tRNA. The at least one recombinant O-tRNA recognizes a selector codon and is not efficiently recognized by the RS from the second organism and is preferentially aminoacylated by the O-RS. The method also includes: (d) generating a library of mutant RSs derived from at least one aminoacyl-tRNA synthetase (RS) from a third organism; (e) selecting the library of mutant RSs for members that preferentially aminoacylate the at least one recombinant O-tRNA in the presence of an unnatural amino acid and a natural



amino acid, thereby providing a pool of active mutant RSs; and, (f) negatively selecting the pool for active mutant RSs that preferentially aminoacylate the at least one recombinant O-tRNA in the absence of the unnatural amino acid, thereby providing the at least one specific O-tRNA/O-RS pair, where the at least one specific O-tRNA/O-RS pair  
5 comprises at least one recombinant O-RS that is specific for the unnatural amino acid and the at least one recombinant O-tRNA. Pairs produced by the methods of the present invention are also included.

[0155] Previously, generation of an orthogonal tRNA/synthetase pair from an existing *Escherichia coli* tRNA/synthetase pair was attempted. The method involves  
10 eliminating the tRNA's affinity toward its cognate synthetase by mutating nucleotides at the tRNA-synthetase interface while preserving its orthogonality to other synthetases and its ability to function in translation. Using the cognate wild-type synthetase as the starting template, a mutant synthetase is then evolved that uniquely recognizes the engineered orthogonal tRNA. Based on an analysis of the X-ray crystal structure of *Escherichia coli*  
15 glutamyl-tRNA synthetase (GlnRS) complexed with tRNAGln2, three sites ("knobs") in tRNAGln2 were identified which make specific contacts with GlnRS. See, e.g., D. R. Liu, T. J. Magliery and P. G. Schultz, Chem. Biol., 4:685 (1997); and, D. R. Liu, T. J. Magliery, M. Pastnak and P. G. Schultz, Proc. Natl. Acad. Sci. U S A, 94:10092 (1997). These sites were mutated in the tRNA, and mutant suppressor tRNAs containing all  
20 possible combinations of knobs 1, 2, and 3 were generated and tested individually by in vitro aminoacylation with GlnRS and in vitro suppression of amber mutants of chorismate mutase. A mutant tRNA (O-tRNA) bearing all three-knob mutations was shown to be orthogonal to all endogenous *Escherichia coli* synthetases and competent in translation. Next, multiple rounds of DNA shuffling together with oligonucleotide-directed  
25 mutagenesis were used to generate libraries of mutant GlnRS's. These mutant enzymes were selected for their ability to acylate the O-tRNA in vivo using *Escherichia coli* strain BT235. Only if a mutant GlnRS charges the O-tRNA with glutamine can the genomic amber codon in lacZ be suppressed, enabling BT235 cells to grow on lactose minimal media. Several mutant synthetases surviving each round of selection were purified and  
30 assayed in vitro. The ratio of wild-type (wt) tRNAGln acylation to O-tRNA acylation by mutant synthetase decreased significantly upon multiple rounds of selection. However, no mutant *Escherichia coli* GlnRS's have been evolved that charge the O-tRNA more efficiently than wild-type *Escherichia coli* tRNAGln2. The best mutant evolved after

seven rounds of DNA shuffling and selection acylates the O-tRNA at only one-ninth the rate of wt tRNA<sup>Gln</sup>. However, these experiments failed to produce a synthetase candidate with the desired properties, e.g., a synthetase that does not acylate any wt tRNA, since misacylation of a wt tRNA with an unnatural amino acid could result in a lethal

5 phenotype. In addition, the mutations within the tRNA interact in complicated, non-additive ways with respect to both aminoacylation and translation. See, D. R. Liu, T. J. Magliery and P. G. Schultz, Chem. Biol., 14:685 (1997). Thus, alternative methods are typically used to provide a functional pair with the desired properties.

[0156] A second strategy for generating an orthogonal tRNA/synthetase pair  
10 involves importing a tRNA/synthetase pair from another organism into *Escherichia coli*. The properties of the heterologous synthetase candidate include, e.g., that it does not charge any *Escherichia coli* tRNA, and the properties of the heterologous tRNA candidate include, e.g., that it is not acylated by any *Escherichia coli* synthetase. In addition, the suppressor tRNA derived from the heterologous tRNA is orthogonal to all *Escherichia*  
15 *coli* synthetases. Schimmel et al. reported that *Escherichia coli* GlnRS (EcGlnRS) does not acylate *Saccharomyces cerevisiae* tRNA<sup>Gln</sup> (EcGlnRS lacks an N-terminal RNA-binding domain possessed by *Saccharomyces cerevisiae* GlnRS (ScGlnRS)). See, E. F. Whelihan and P. Schimmel, EMBO J., 16:2968 (1997). The *Saccharomyces cerevisiae* amber suppressor tRNA<sup>Gln</sup> (SctRNA<sup>Gln</sup>CUA) was then analyzed to determine whether it  
20 is also not a substrate for EcGlnRS. In vitro aminoacylation assays showed this to be the case; and in vitro suppression studies show that the SctRNA<sup>Gln</sup>CUA is competent in translation. See, e.g., D. R. Liu and P. G. Schultz, Proc. Natl. Acad. Sci. U S A, 96:4780 (1999). It was further shown that ScGlnRS does not acylate any *Escherichia coli* tRNA, only the SctRNA<sup>Gln</sup>CUA in vitro. The degree to which ScGlnRS is able to aminoacylate  
25 the SctRNA<sup>Gln</sup>CUA in *Escherichia coli* was also evaluated using an in vivo complementation assay. An amber nonsense mutation was introduced at a permissive site in the  $\beta$ -lactamase gene. Suppression of the mutation by an amber suppressor tRNA should produce full-length  $\beta$ -lactamase and confer ampicillin resistance to the cell. When only SctRNA<sup>Gln</sup>CUA is expressed, cells exhibit an IC<sub>50</sub> of 20  $\mu$ g/mL ampicillin,  
30 indicating virtually no acylation by endogenous *Escherichia coli* synthetases; when SctRNA<sup>Gln</sup>CUA is coexpressed with ScGlnRS, cells acquire an IC<sub>50</sub> of about 500  $\mu$ g/mL ampicillin, demonstrating that ScGlnRS acylates SctRNA<sup>Gln</sup>CUA efficiently in

*Escherichia coli*. See, D. R. Liu and P. G. Schultz, Proc. Natl. Acad. Sci. U S A, 96:4780 (1999). The *Saccharomyces cerevisiae* tRNA<sup>Gln</sup>CUA/GlnRS is orthogonal to *Escherichia coli*.

[0157] This strategy was later applied to a tRNA<sup>Asp</sup>/AspRS system.

- 5 *Saccharomyces cerevisiae* tRNA<sup>Asp</sup> is known to be orthogonal to *Escherichia coli* synthetases. See, e.g., B. P. Doctor and J. A. Mudd, J. Biol. Chem., 238:3677 (1963); and, Y. Kwok and J. T. Wong, Can. J. Biochem., 58:213 (1980). It was demonstrated that an amber suppressor tRNA derived from it (SctRNA<sup>Asp</sup>CUA) is also orthogonal in *Escherichia coli* using the in vivo  $\beta$ -lactamase assay described above. However, the
- 10 anticodon of tRNA<sup>Asp</sup> is a critical recognition element of AspRS, see, e.g., R. Giege, C. Florentz, D. Kern, J. Gangloff, G. Eriani and D. Moras, Biochimie, 78:605 (1996), and mutation of the anticodon to CUA results in a loss of affinity of the suppressor for AspRS. An *Escherichia coli* AspRS E93K mutant has been shown to recognize *Escherichia coli* amber suppressor tRNA<sup>Asp</sup>CUA about an order of magnitude better than wt AspRS. See,
- 15 e.g., F. Martin, 'Thesis', Universite Louis Pasteur, Strasbourg, France, 1995. It was speculated that introduction of the related mutation in *Saccharomyces cerevisiae* AspRS (E188K) might restore its affinity for SctRNA<sup>Asp</sup>CUA. It was determined that the *Saccharomyces cerevisiae* AspRS(E188K) mutant does not acylate *Escherichia coli* tRNAs, but charges SctRNA<sup>Asp</sup>CUA with moderate efficiency as shown by in vitro
- 20 aminoacylation experiments. See, e.g., M. Pastnak, T. J. Magliery and P. G. Schultz, Helv. Chim. Acta, 83:2277 (2000). Although the SctRNA<sup>Asp</sup>CUA/ ScAspRS(E188K) can serve as another orthogonal pair in *Escherichia coli*, it possesses weak activity.

- [0158] A similar approach involves the use of a heterologous synthetase as the orthogonal synthetase but a mutant initiator tRNA of the same organism or a related
- 25 organism as the orthogonal tRNA. RajBhandary and coworkers found that an amber mutant of human initiator tRNA<sup>fMet</sup> is acylated by *Escherichia coli* GlnRS and acts as an amber suppressor in yeast cells only when EcGlnRS is coexpressed. See, A. K. Kowal, C. Kohrer and U. L. RajBhandary, Proc. Natl. Acad. Sci. U S A, 98:2268 (2001). This pair thus represents an orthogonal pair for use in yeast. Also, an *Escherichia coli* initiator
- 30 tRNA<sup>fMet</sup> amber mutant was found that is inactive toward any *Escherichia coli* synthetases. A mutant yeast TyrRS was selected that charges this mutant tRNA, resulting in an orthogonal pair in *Escherichia coli*. See, A. K. Kowal, et al, (2001), *supra*.

[0159] The prokaryotic and eukaryotic tRNA<sup>Tyr</sup>/TyrRS pairs have significant differences: the identity elements of prokaryotic tRNA<sup>Tyr</sup> include a long variable arm in contrast to the short arm of eukaryotic tRNA<sup>Tyr</sup>. In addition, eukaryotic tRNA<sup>Tyr</sup> contains a C1:G72 positive recognition element whereas prokaryotic tRNA<sup>Tyr</sup> has no such consensus base pair. In vitro studies have also shown that tRNA<sup>Tyr</sup> of *Saccharomyces cerevisiae* and *H. sapiens* cannot be aminoacylated by bacterial synthetases, nor do their TyrRS aminoacylate bacterial tRNA. See, e.g., K. Wakasugi, C. L. Quinn, N. Tao and P. Schimmel, EMBO J., 17:297 (1998); and, T. A. Kleeman, D. Wei, K. L. Simpson and E. A. First, J. Biol. Chem., 272:14420 (1997). But, in spite of all these promising features for orthogonality, in vivo  $\beta$ -lactamase complementation assays showed that the amber suppressor tRNA<sup>Tyr</sup>CUA derived from both *Saccharomyces cerevisiae* and *H. sapiens* are not orthogonal in *Escherichia coli*. See, e.g., L. Wang, T. J. Magliery, D. R. Liu and P. G. Schultz, J. Am. Chem. Soc., 122:5010 (2000). The susceptibility of the suppressor tRNA to acylation by *Escherichia coli* synthetases is due to the change of one single nucleotide in the anticodon (G34 to C34).

[0160] Using the methods of the present invention, the pairs and components of pairs desired above are evolved to generate orthogonal tRNA/synthetase pairs that possess desired characteristic, e.g., that can preferentially aminoacylate an O-tRNA with an unnatural amino acid.

20 [0161] **Source and Host Organisms**

[0162] The orthogonal tRNA-RS pair, e.g., derived from at least a first organism or at least two organisms, which can be the same or different, can be used in a variety of organisms, e.g., a second organism. The first and the second organisms of the methods of the present invention can be the same or different. In one embodiment, the first organism is a prokaryotic organism, e.g., *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Halobacterium*, *Escherichia coli*, *A. fulgidus*, *Halobacterium*, *P. furiosus*, *P. horikoshii*, *A. pernix*, *T. thermophilus*, or the like. Alternatively, the first organism is a eukaryotic organism, e.g., plants (e.g., complex plants such as monocots, or dicots), algae, protists, fungi (e.g., yeast, etc), animals (e.g., mammals, insects, arthropods, etc.), or the like. In another embodiment, the second organism is a prokaryotic organism, *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, *Halobacterium*, *Escherichia coli*, *A. fulgidus*, *Halobacterium*, *P. furiosus*, *P. horikoshii*, *A. pernix*, *T.*

*thermophilus*, or the like. Alternatively, the second organism can be a eukaryotic organism, e.g., plants, fungi, animals, or the like.

- [0163] As described above, the individual components of a pair can be derived from the same organism or different organisms. For example, tRNA can be derived from a prokaryotic organism, e.g., an archaeobacterium, such as *Methanococcus jannaschii* and *Halobacterium NRC-1* or a eubacterium, such as *Escherichia coli*, while the synthetase can be derived from same or another prokaryotic organism, such as, *Methanococcus jannaschii*, *Archaeoglobus fulgidus*, *Methanobacterium thermoautotrophicum*, *P. furiosus*, *P. horikoshii*, *A. pernix*, *T. thermophilus*, *Halobacterium*, *Escherichia coli* or the like.
- 10 Eukaryotic sources can also be used, e.g., plants (e.g., complex plants such as monocots, or dicots), algae, protists, fungi (e.g., yeast, etc.), animals (e.g., mammals, insects, arthropods, etc.), or the like.

- [0164] Methods for selecting an orthogonal tRNA-tRNA synthetase pair for use in an in vivo translation system of a second organism are also included in the present invention. The methods include: introducing a marker gene, a tRNA and an aminoacyl-tRNA synthetase (RS) isolated or derived from a first organism into a first set of cells from the second organism; introducing the marker gene and the tRNA into a duplicate cell set from the second organism; and, selecting for surviving cells in the first set that fail to survive in the duplicate cell set, where the first set and the duplicate cell set are grown in the presence of a selection agent, and where the surviving cells comprise the orthogonal tRNA-tRNA synthetase pair for use in the in vivo translation system of the second organism. In one embodiment, comparing and selecting includes an in vivo complementation assay. In another embodiment, the concentration of the selection agent is varied.
- 20

- 25 [0165] For example, a tRNA/synthetase pair can be chosen based on where the identity elements, which are recognition sites of the tRNA for the synthetase, are found. For example, a tRNA/synthetase pair is chosen when the identity elements are outside of the anticodon, e.g., the tRNA<sup>Tyr</sup>/TyrRS pair from the archaeobacterial *Methanococcus jannaschii*. This TyrRS is missing most of the non-conserved domain binding for the anticodon loop of its tRNA<sup>Tyr</sup>, but can discriminate tRNA with C1:G72 from that with G1:C72. Furthermore, the *Methanococcus jannaschii* TyrRS (MjTyrRS) aminoacylates *Saccharomyces cerevisiae* but not *Escherichia coli* crude tRNA. See, e.g., B. A. Steer and
- 30


P. Schimmel, *J. Biol. Chem.*, 274:35601 (1999). Using an in vivo complementation assay with an expression vector containing a reporter gene, e.g.,  $\beta$ -lactamase gene, with at least one selector codon, cells expressing the *Methanococcus jannaschii* tRNA<sup>TyrCUA</sup> (*Mj* tRNA<sup>TyrCUA</sup>) alone survive to an IC<sub>50</sub> of 55  $\mu$ g/mL ampicillin; cells coexpressing *Mj* tRNA<sup>TyrCUA</sup> with its TyrRS survive to an IC<sub>50</sub> of 1220  $\mu$ g/mL ampicillin. Although *Mj* tRNA<sup>TyrCUA</sup> is less orthogonal in *Escherichia coli* than the SctRNA<sup>GlnCUA</sup> (IC<sub>50</sub> 20  $\mu$ g/mL), the *Mj*TyrRS has higher aminoacylation activity toward its cognate amber suppressor tRNA. See, e.g., L. Wang, T. J. Magliery, D. R. Liu and P. G. Schultz, *J. Am. Chem. Soc.*, 122:5010 (2000). As a result, *Methanococcus jannaschii* /TyrRS is identified as an orthogonal pair in *Escherichia coli* and can be selected for use in an in vivo translation system.

#### [0166] Unnatural Amino Acids

[0167] A wide variety of unnatural amino acids can be used in the methods of the invention. The unnatural amino acid can be chosen based on desired characteristics of the unnatural amino acid, e.g., function of the unnatural amino acid, such as modifying protein biological properties such as toxicity, biodistribution, or half life, structural properties, spectroscopic properties, chemical and/or photochemical properties, catalytic properties, ability to react with other molecules (either covalently or noncovalently), or the like.

[0168] As used herein an "unnatural amino acid" refers to any amino acid, modified amino acid, or amino acid analogue other than selenocysteine and the following twenty genetically encoded alpha-amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine. The generic structure of an alpha-amino acid is illustrated by Formula I:

I




An unnatural amino acid is typically any structure having Formula I wherein the R group is any substituent other than one used in the twenty natural amino acids. See, e.g., any biochemistry text such as *Biochemistry* by L. Stryer, 3<sup>rd</sup> ed. 1988, Freeman and Company, New York, for structures of the twenty natural amino acids. Note that, the unnatural


amino acids of the present invention may be naturally occurring compounds other than the twenty alpha-amino acids above. Because the unnatural amino acids of the invention typically differ from the natural amino acids in side chain only, the unnatural amino acids form amide bonds with other amino acids, e.g., natural or unnatural, in the same manner in which they are formed in naturally occurring proteins. However, the unnatural amino acids have side chain groups that distinguish them from the natural amino acids. For example, R in Formula I optionally comprises an alkyl-, aryl-, acyl-, keto-, azido-, hydroxyl-, hydrazine, cyano-, halo-, hydrazide, alkenyl, alkynyl, ether, thiol, seleno-, sulfonyl-, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, ester, thioacid, hydroxylamine, amino group, or the like or any combination thereof. Other unnatural amino acids of interest include, but are not limited to, amino acids comprising a photoactivatable cross-linker, spin-labeled amino acids, fluorescent amino acids, metal binding amino acids, metal-containing amino acids, radioactive amino acids, amino acids with novel functional groups, amino acids that covalently or noncovalently interact with other molecules, photocaged and/or photoisomerizable amino acids, amino acids comprising biotin or a biotin analogue, glycosylated amino acids such as a sugar substituted serine, other carbohydrate modified amino acids, keto containing amino acids, amino acids comprising polyethylene glycol or polyether, heavy atom substituted amino acids, chemically cleavable and/or photocleavable amino acids, amino acids with an elongated side chains as compared to natural amino acids, e.g., polyethers or long chain hydrocarbons, e.g., greater than about 5 or greater than about 10 carbons, carbon-linked sugar-containing amino acids, redox-active amino acids, amino thioacid containing amino acids, and amino acids comprising one or more toxic moiety.

[0169] In addition to unnatural amino acids that contain novel side chains, unnatural amino acids also optionally comprise modified backbone structures, e.g., as illustrated by the structures of Formula II and III:

II



### III



wherein Z typically comprises OH, NH<sub>2</sub>, SH, NH-R', or S-R'; X and Y, which may be the same or different, typically comprise S or O, and R and R', which are optionally the same or different, are typically selected from the same list of constituents for the R group described above for the unnatural amino acids having Formula I as well as hydrogen. For example, unnatural amino acids of the invention optionally comprise substitutions in the amino or carboxyl group as illustrated by Formulas II and III. Unnatural amino acids of this type include, but are not limited to, α-hydroxy acids, α-thioacids α-aminothiocarboxylates, e.g., with side chains corresponding to the common twenty natural amino acids or unnatural side chains. In addition, substitutions at the α-carbon optionally include L, D, or α-α-disubstituted amino acids such as D-glutamate, D-alanine, D-methyl-O-tyrosine, aminobutyric acid, and the like. Other structural alternatives include cyclic amino acids, such as proline analogues as well as 3, 4, 6, 7, 8, and 9 membered ring proline analogues, β and γ amino acids such as substituted β-alanine and γ-amino butyric acid.

[0170] For example, many unnatural amino acids are based on natural amino acids, such as tyrosine, glutamine, phenylalanine, and the like. Tyrosine analogs include para-substituted tyrosines, ortho-substituted tyrosines, and meta substituted tyrosines, wherein the substituted tyrosine comprises an acetyl group, a benzoyl group, an amino group, a hydrazine, an hydroxyamine, a thiol group, a carboxy group, an isopropyl group, a methyl group, a C<sub>6</sub> - C<sub>20</sub> straight chain or branched hydrocarbon, a saturated or unsaturated hydrocarbon, an O-methyl group, a polyether group, a nitro group, or the like. In addition, multiply substituted aryl rings are also contemplated. Glutamine analogs of the invention include, but are not limited to, α-hydroxy derivatives, γ-substituted derivatives, cyclic derivatives, and amide substituted glutamine derivatives. Example phenylalanine analogs include, but are not limited to, meta-substituted phenylalanines, wherein the substituent comprises a hydroxy group, a methoxy group, a methyl group, an allyl group, an acetyl group, or the like. Specific examples of unnatural amino acids include, but are not limited



to, O-methyl-L-tyrosine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAc $\beta$ -serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a *p*-azido-L-phenylalanine, a *p*-acyl-L-phenylalanine, a *p*-benzoyl-L-phenylalanine, an L-phosphoserine, a  
5 phosphoserine, a phosphonotyrosine, a *p*-iodo-phenylalanine, a *p*-bromophenylalanine, a *p*-amino-L-phenylalanine, and an isopropyl-L-phenylalanine, and the like. The structures of a variety of non-limiting unnatural amino acids are provided in the figures, e.g., Figures 29, 30, and 31.

[0171] Typically, the unnatural amino acids of the invention are selected or  
10 designed to provide additional characteristics unavailable in the twenty natural amino acids. For example, unnatural amino acid are optionally designed or selected to modify the biological properties of a protein, e.g., into which they are incorporated. For example, the following properties are optionally modified by inclusion of an unnatural amino acid into a protein: toxicity, biodistribution, solubility, stability, e.g., thermal, hydrolytic,  
15 oxidative, resistance to enzymatic degradation, and the like, facility of purification and processing, structural properties, spectroscopic properties, chemical and/or photochemical properties, catalytic activity, redox potential, half-life, ability to react with other molecules, e.g., covalently or noncovalently, and the like.

[0172] Further details regarding unnatural amino acids are described in  
20 corresponding application, "In vivo Incorporation of Unnatural Amino Acids", attorney docket number 54-000120PC/US, filed April 19, 2002, which is incorporated herein by reference.

[0173] Use of mutant tRNA and O-RS and O-tRNA/O-RS pairs

[0174] The compositions of the present invention and compositions made by the  
25 methods of the present invention optionally are in a cell. The O-tRNA/O-RS pairs or individual components of the present invention can then be used in a host system's translation machinery, which results in an unnatural amino acid being incorporated into a protein. The corresponding patent application "In vivo Incorporation of Unnatural Amino Acids", attorney docket number 54-000120PC/US by Schultz, et al. describes this process  
30 and is incorporated herein by reference. For example, when an O-tRNA/O-RS pair is introduced into a host, e.g., *Escherichia coli*, the pair leads to the in vivo incorporation of an unnatural amino acid, e.g., a synthetic amino acid, such as O-methyl-L-tyrosine, which

can be exogenously added to the growth medium, into a protein, e.g., dihydrofolate reductase or a therapeutic protein such as EPO, in response to a selector codon, e.g., an amber nonsense codon. Optionally, the compositions of the present invention can be in an in vitro translation system, or in an in vivo system(s).

5   **[0175]       Nucleic acid and polypeptide sequence variants**

**[0176]**       As described above and below, the invention provides for nucleic acid polynucleotide sequences and polypeptide amino acid sequences, e.g., O-tRNAs and O-RSs, and, e.g., compositions and methods comprising said sequences. Examples of said sequences, e.g., O-tRNAs and O-RSs are disclosed herein. However, one of skill in the art  
10   will appreciate that the invention is not limited to those sequences disclosed herein. One of skill will appreciate that the present invention also provides many related and unrelated sequences with the functions described herein, e.g., encoding an O-tRNA or an O-RS.

**[0177]**       One of skill will also appreciate that many variants of the disclosed sequences are included in the invention. For example, conservative variations of the  
15   disclosed sequences that yield a functionally identical sequence are included in the invention. Variants of the nucleic acid polynucleotide sequences, wherein the variants hybridize to at least one disclosed sequence, are considered to be included in the invention. Unique subsequences of the sequences disclosed herein, as determined by, e.g., standard sequence comparison techniques, are also included in the invention.

20   **[0178]       Conservative variations**

**[0179]**       Owing to the degeneracy of the genetic code, "silent substitutions" (*i.e.*, substitutions in a nucleic acid sequence which do not result in an alteration in an encoded polypeptide) are an implied feature of *every* nucleic acid sequence which encodes an amino acid. Similarly, "conservative amino acid substitutions," in one or a few amino  
25   acids in an amino acid sequence are substituted with different amino acids with highly similar properties, are also readily identified as being highly similar to a disclosed construct. Such conservative variations of each disclosed sequence are a feature of the present invention.

**[0180]**       "Conservative variations" of a particular nucleic acid sequence refers to  
30   those nucleic acids which encode identical or essentially identical amino acid sequences, or, where the nucleic acid does not encode an amino acid sequence, to essentially identical

sequences, *see*, Table 1 below. One of skill will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 5%, more typically less than 4%, 2% or 1%) in an encoded sequence are "conservatively modified variations" where the alterations result in the deletion of an amino acid, addition of an amino acid, or substitution of an amino acid with a chemically similar amino acid. Thus, "conservative variations" of a listed polypeptide sequence of the present invention include substitutions of a small percentage, typically less than 5%, more typically less than 2% or 1%, of the amino acids of the polypeptide sequence, with a conservatively selected amino acid of the same conservative substitution group. Finally, the addition of sequences which do not alter the encoded activity of a nucleic acid molecule, such as the addition of a non-functional sequence, is a conservative variation of the basic nucleic acid.

[0181] Table 1 -- Conservative Substitution Groups

1	Alanine (A)	Serine (S)	Threonine (T)	
2	Aspartic acid (D)	Glutamic acid (E)		
3	Asparagine (N)	Glutamine (Q)		
4	Arginine (R)	Lysine (K)		
5	Isoleucine (I)	Leucine (L)	Methionine (M)	Valine (V)
6	Phenylalanine (F)	Tyrosine (Y)	Tryptophan (W)	

15 [0182] **Nucleic Acid Hybridization**

[0183] Comparative hybridization can be used to identify nucleic acids of the invention, including conservative variations of nucleic acids of the invention, and this comparative hybridization method is a preferred method of distinguishing nucleic acids of the invention. In addition, target nucleic acids which hybridize to the nucleic acids represented by SEQ ID NO:1-3 or SEQ ID NO:4-34 (*see*, Table 5) under high, ultra-high and ultra-ultra high stringency conditions are a feature of the invention. Examples of such nucleic acids include those with one or a few silent or conservative nucleic acid substitutions as compared to a given nucleic acid sequence.

[0184] A test nucleic acid is said to specifically hybridize to a probe nucleic acid when it hybridizes at least  $\frac{1}{2}$  as well to the probe as to the perfectly matched complementary target, i.e., with a signal to noise ratio at least  $\frac{1}{2}$  as high as hybridization of the probe to the target under conditions in which the perfectly matched probe binds to the perfectly matched complementary target with a signal to noise ratio that is at least about 5x-10x as high as that observed for hybridization to any of the unmatched target nucleic acids.

[0185] Nucleic acids "hybridize" when they associate, typically in solution. Nucleic acids hybridize due to a variety of well characterized physico-chemical forces, such as hydrogen bonding, solvent exclusion, base stacking and the like. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes* part I chapter 2, "Overview of principles of hybridization and the strategy of nucleic acid probe assays," (Elsevier, New York), as well as in Ausubel, *infra*. Hames and Higgins (1995) Gene Probes 1 IRL Press at Oxford University Press, Oxford, England, (Hames and Higgins 1) and Hames and Higgins (1995) Gene Probes 2 IRL Press at Oxford University Press, Oxford, England (Hames and Higgins 2) provide details on the synthesis, labeling, detection and quantification of DNA and RNA, including oligonucleotides.

[0186] An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42°C, with the hybridization being carried out overnight. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see*, Sambrook, *infra* for a description of SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove background probe signal. An example low stringency wash is 2x SSC at 40°C for 15 minutes. In general, a signal to noise ratio of 5x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

[0187] "Stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments such as Southern and northern hybridizations are sequence dependent, and are different under different environmental parameters. An extensive

guide to the hybridization of nucleic acids is found in Tijssen (1993), *supra*. and in Hames and Higgins, 1 and 2. Stringent hybridization and wash conditions can easily be determined empirically for any test nucleic acid. For example, in determining highly stringent hybridization and wash conditions, the hybridization and wash conditions are gradually increased (e.g., by increasing temperature, decreasing salt concentration, increasing detergent concentration and/or increasing the concentration of organic solvents such as formalin in the hybridization or wash), until a selected set of criteria are met. For example, the hybridization and wash conditions are gradually increased until a probe binds to a perfectly matched complementary target with a signal to noise ratio that is at least 5x as high as that observed for hybridization of the probe to an unmatched target.

[0188] "Very stringent" conditions are selected to be equal to the thermal melting point ( $T_m$ ) for a particular probe. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the test sequence hybridizes to a perfectly matched probe. For the purposes of the present invention, generally, "highly stringent" hybridization and wash conditions are selected to be about 5° C lower than the  $T_m$  for the specific sequence at a defined ionic strength and pH.

[0189] "Ultra high-stringency" hybridization and wash conditions are those in which the stringency of hybridization and wash conditions are increased until the signal to noise ratio for binding of the probe to the perfectly matched complementary target nucleic acid is at least 10x as high as that observed for hybridization to any of the unmatched target nucleic acids. A target nucleic acid which hybridizes to a probe under such conditions, with a signal to noise ratio of at least ½ that of the perfectly matched complementary target nucleic acid is said to bind to the probe under ultra-high stringency conditions.

[0190] Similarly, even higher levels of stringency can be determined by gradually increasing the hybridization and/or wash conditions of the relevant hybridization assay. For example, those in which the stringency of hybridization and wash conditions are increased until the signal to noise ratio for binding of the probe to the perfectly matched complementary target nucleic acid is at least 10X, 20X, 50X, 100X, or 500X or more as high as that observed for hybridization to any of the unmatched target nucleic acids. A target nucleic acid which hybridizes to a probe under such conditions, with a signal to

noise ratio of at least  $\frac{1}{2}$  that of the perfectly matched complementary target nucleic acid is said to bind to the probe under ultra-ultra-high stringency conditions.

[0191] Nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

[0192] Unique subsequences

[0193] In one aspect, the invention provides a nucleic acid which comprises a unique subsequence in a nucleic acid selected from the sequences of O-tRNAs and O-RSs disclosed herein, *e.g.*, SEQ ID NO:1-3 or SEQ ID NO:4-34 (*see*, Table 5). The unique subsequence is unique as compared to a nucleic acid corresponding to any previously known O-tRNA or O-RS nucleic acid sequence, *e.g.*, as found in Genbank. Alignment can be performed using, *e.g.*, BLAST set to default parameters. Any unique subsequence is useful, *e.g.*, as a probe to identify the nucleic acids of the invention.

[0194] Similarly, the invention includes a polypeptide which comprises a unique subsequence in a polypeptide selected from the sequences of O-RSs disclosed herein, *e.g.*, SEQ ID NO:35-66 (*see*, Table 5). Here, the unique subsequence is unique as compared to a polypeptide corresponding to any of known polypeptide sequence.

[0195] The invention also provides for target nucleic acids which hybridizes under stringent conditions to a unique coding oligonucleotide which encodes a unique subsequence in a polypeptide selected from the sequences of O-RSs wherein the unique subsequence is unique as compared to a polypeptide corresponding to any of the control polypeptides. Unique sequences are determined as noted above.

[0196] Sequence comparison, identity, and homology

[0197] The terms "identical" or percent "identity," in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (or other algorithms available to persons of skill) or by visual inspection.

[0198] The phrase "substantially identical," in the context of two nucleic acids or polypeptides (*e.g.*, DNAs encoding an O-tRNA or O-RS, or the amino acid sequence of an O-RS) refers to two or more sequences or subsequences that have at least about 60%, preferably 80%, most preferably 90-95% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. Such "substantially identical" sequences are typically considered to be "homologous," without reference to actual ancestry. Preferably, "substantial identity" exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues, or over the full length of the two sequences to be compared.

[0199] For sequence comparison and homology determination, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0200] Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (*see generally*, Ausubel et al., *infra*).

[0201] One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information ([www.ncbi.nlm.nih.gov/](http://www.ncbi.nlm.nih.gov/)). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either

match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended  
5 in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are  
10 halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a  
15 wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (*see*, Henikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).

[0202] In addition to calculating percent sequence identity, the BLAST algorithm  
20 also performs a statistical analysis of the similarity between two sequences (*see, e.g.,* Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered  
25 similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0203] **Defining Polypeptides by Immunoreactivity**

[0204] Because the polypeptides of the invention provide a variety of new  
30 polypeptide sequences (e.g., comprising unnatural amino acids in the case of proteins synthesized in the translation systems herein, or, e.g., in the case of the novel synthetases herein, novel sequences of standard amino acids), the polypeptides also provide new



structural features which can be recognized, e.g., in immunological assays. The generation of antisera which specifically bind the polypeptides of the invention, as well as the polypeptides which are bound by such antisera, are a feature of the invention.

[0205] For example, the invention includes synthetase proteins that specifically  
5 bind to or that are specifically immunoreactive with an antibody or antisera generated against an immunogen comprising an amino acid sequence selected from one or more SEQ ID NO:35-66 (*see*, Table 5). To eliminate cross-reactivity with other homologues, the antibody or antisera is subtracted with available synthetases, such as the wild-type *Methanococcus jannaschii* (*M. jannaschii*) tyrosyl synthetase (TyrRS), e.g., the "control"  
10 polypeptides. Where the the wild-type *Methanococcus jannaschii* (*M. jannaschii*) tyrosyl synthetase (TyrRS) corresponds to a nucleic acid, a polypeptide encoded by the nucleic acid is generated and used for antibody/antisera subtraction purposes.

[0206] In one typical format, the immunoassay uses a polyclonal antiserum which was raised against one or more polypeptide comprising one or more of the sequences  
15 corresponding to one or more of SEQ ID NO:35-66 (*see*, Table 5) or a substantial subsequence thereof (i.e., at least about 30% of the full length sequence provided). The set of potential polypeptide immunogens derived from SEQ ID NO:35-66 (*see*, Table 5) are collectively referred to below as "the immunogenic polypeptides." The resulting antisera is optionally selected to have low cross-reactivity against the control synthetase  
20 homologues and any such cross-reactivity is removed, e.g., by immunoabsorbtion, with one or more of the control synthetase homologues, prior to use of the polyclonal antiserum in the immunoassay.

[0207] In order to produce antisera for use in an immunoassay, one or more of the immunogenic polypeptides is produced and purified as described herein. For example,  
25 recombinant protein can be produced in a recombinant cell. An inbred strain of mice (used in this assay because results are more reproducible due to the virtual genetic identity of the mice) is immunized with the immunogenic protein(s) in combination with a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (*see*, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor  
30 Publications, New York, for a standard description of antibody generation, immunoassay formats and conditions that can be used to determine specific immunoreactivity. Additional references and discussion of antibodies is also found herein and can be applied

here to defining polypeptides by immunoreactivity). Alternatively, one or more synthetic or recombinant polypeptide derived from the sequences disclosed herein is conjugated to a carrier protein and used as an immunogen.

5 [0208] Polyclonal sera are collected and titered against the immunogenic polypeptide in an immunoassay, for example, a solid phase immunoassay with one or more of the immunogenic proteins immobilized on a solid support. Polyclonal antisera with a titer of  $10^6$  or greater are selected, pooled and subtracted with the control synthetase polypeptides to produce subtracted pooled titered polyclonal antisera.

10 [0209] The subtracted pooled titered polyclonal antisera are tested for cross reactivity against the control homologues in a comparative immunoassay. In this comparative assay, discriminatory binding conditions are determined for the subtracted titered polyclonal antisera which result in at least about a 5-10 fold higher signal to noise ratio for binding of the titered polyclonal antisera to the immunogenic synthetase as compared to binding to the control synthetase homologues. That is, the stringency of the binding reaction is adjusted by the addition of non-specific competitors such as albumin or non-fat dry milk, and/or by adjusting salt conditions, temperature, and/or the like. These binding conditions are used in subsequent assays for determining whether a test polypeptide (a polypeptide being compared to the immunogenic polypeptides and/or the control polypeptides) is specifically bound by the pooled subtracted polyclonal antisera.

15 20 In particular, test polypeptides which show at least a 2-5x higher signal to noise ratio than the control synthetase homologues under discriminatory binding conditions, and at least about a  $\frac{1}{2}$  signal to noise ratio as compared to the immunogenic polypeptide(s), shares substantial structural similarity with the immunogenic polypeptide as compared to known synthetases, and is, therefore a polypeptide of the invention.

25 [0210] In another example, immunoassays in the competitive binding format are used for detection of a test polypeptide. For example, as noted, cross-reacting antibodies are removed from the pooled antisera mixture by immunoabsorbtion with the control polypeptides. The immunogenic polypeptide(s) are then immobilized to a solid support which is exposed to the subtracted pooled antisera. Test proteins are added to the assay to compete for binding to the pooled subtracted antisera. The ability of the test protein(s) to compete for binding to the pooled subtracted antisera as compared to the immobilized protein(s) is compared to the ability of the immunogenic polypeptide(s) added to the assay

30

to compete for binding (the immunogenic polypeptides compete effectively with the immobilized immunogenic polypeptides for binding to the pooled antisera). The percent cross-reactivity for the test proteins is calculated, using standard calculations.

[0211] In a parallel assay, the ability of the control proteins to compete for binding to the pooled subtracted antisera is optionally determined as compared to the ability of the immunogenic polypeptide(s) to compete for binding to the antisera. Again, the percent cross-reactivity for the control polypeptides is calculated, using standard calculations. Where the percent cross-reactivity is at least 5-10x as high for the test polypeptides as compared to the control polypeptides and or where the binding of the test polypeptides is approximately in the range of the binding of the immunogenic polypeptides, the test polypeptides are said to specifically bind the pooled subtracted antisera.

[0212] In general, the immunoabsorbed and pooled antisera can be used in a competitive binding immunoassay as described herein to compare any test polypeptide to the immunogenic and/or control polypeptide(s). In order to make this comparison, the immunogenic, test and control polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the subtracted antisera to, e.g., an immobilized control, test or immunogenic protein is determined using standard techniques. If the amount of the test polypeptide required for binding in the competitive assay is less than twice the amount of the immunogenic polypeptide that is required, then the test polypeptide is said to specifically bind to an antibody generated to the immunogenic protein, provided the amount is at least about 5-10x as high as for the control polypeptide.

[0213] As an additional determination of specificity, the pooled antisera is optionally fully immunosorbed with the immunogenic polypeptide(s) (rather than the control polypeptides) until little or no binding of the resulting immunogenic polypeptide subtracted pooled antisera to the immunogenic polypeptide(s) used in the immunosorbition is detectable. This fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If little or no reactivity is observed (i.e., no more than 2x the signal to noise ratio observed for binding of the fully immunosorbed antisera to the immunogenic polypeptide), then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

[0214] General Techniques

[0215] General texts which describe molecular biological techniques, which are applicable to the present invention, such as cloning, mutation, cell culture and the like, include Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook et al.,  
5 Molecular Cloning - A Laboratory Manual (3rd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2000 ("Sambrook") and Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2002) ("Ausubel"). These texts describe mutagenesis, the use of vectors, promoters and  
10 many other relevant topics related to, e.g., the generation of orthogonal tRNA, orthogonal synthetases, and pairs thereof.

[0216] Various types of mutagenesis are used in the present invention, e.g., to produce novel synthetases or tRNAs. They include but are not limited to site-directed, random point mutagenesis, homologous recombination (DNA shuffling), mutagenesis  
15 using uracil containing templates, oligonucleotide-directed mutagenesis, phosphorothioate-modified DNA mutagenesis, mutagenesis using gapped duplex DNA or the like. Additional suitable methods include point mismatch repair, mutagenesis using repair-deficient host strains, restriction-selection and restriction-purification, deletion mutagenesis, mutagenesis by total gene synthesis, double-strand break repair, and the like.  
20 Mutagenesis, e.g., involving chimeric constructs, are also included in the present invention. In one embodiment, mutagenesis can be guided by known information of the naturally occurring molecule or altered or mutated naturally occurring molecule, e.g., sequence, sequence comparisons, physical properties, crystal structure or the like.

[0217] The above texts and examples found herein describe these procedures as well as the following publications and references cited within: Sieber, et al., *Nature Biotechnology*, 19:456-460 (2001); Ling et al., *Approaches to DNA mutagenesis: an overview*, Anal Biochem. 254(2): 157-178 (1997); Dale et al., *Oligonucleotide-directed random mutagenesis using the phosphorothioate method*, Methods Mol. Biol. 57:369-374 (1996); I. A. Lorimer, I. Pastan, Nucleic Acids Res. 23, 3067-8 (1995); W. P. C. Stemmer,  
30 Nature 370, 389-91 (1994); Arnold, *Protein engineering for unusual environments*, Current Opinion in Biotechnology 4:450-455 (1993); Bass et al., *Mutant Trp repressors with new DNA-binding specificities*, Science 242:240-245 (1988); Fritz et al.,

- Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro*, Nucl. Acids Res. 16: 6987-6999 (1988); Kramer et al., *Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations*, Nucl. Acids Res. 16: 7207 (1988);
- 5 Sakamar and Khorana, *Total synthesis and expression of a gene for the  $\alpha$ -subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin)*, Nucl. Acids Res. 14: 6361-6372 (1988); Sayers et al., *Y-T Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis*, Nucl. Acids Res. 16:791-802 (1988); Sayers et al., *Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction*
- 10 *endonucleases in the presence of ethidium bromide*, (1988) Nucl. Acids Res. 16: 803-814; Carter, *Improved oligonucleotide-directed mutagenesis using M13 vectors*, Methods in Enzymol. 154: 382-403 (1987); Kramer & Fritz *Oligonucleotide-directed construction of mutations via gapped duplex DNA*, Methods in Enzymol. 154:350-367 (1987); Kunkel, *The efficiency of oligonucleotide directed mutagenesis*, in Nucleic Acids & Molecular
- 15 Biology (Eckstein, F. and Lilley, D.M.J. eds., Springer Verlag, Berlin)) (1987); Kunkel et al., *Rapid and efficient site-specific mutagenesis without phenotypic selection*, Methods in Enzymol. 154, 367-382 (1987); Zoller & Smith, *Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template*, Methods in Enzymol. 154:329-350 (1987); Carter, *Site-directed mutagenesis*, Biochem. J.
- 20 237:1-7 (1986); Eghtedarzadeh & Henikoff, *Use of oligonucleotides to generate large deletions*, Nucl. Acids Res. 14: 5115 (1986); Mandecki, *Oligonucleotide-directed double-strand break repair in plasmids of Escherichia coli: a method for site-specific mutagenesis*, Proc. Natl. Acad. Sci. USA, 83:7177-7181 (1986); Nakamaye & Eckstein, *Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its*
- 25 *application to oligonucleotide-directed mutagenesis*, Nucl. Acids Res. 14: 9679-9698 (1986); Wells et al., *Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin*, Phil. Trans. R. Soc. Lond. A 317: 415-423 (1986); Botstein & Shortle, *Strategies and applications of in vitro mutagenesis*, Science 229:1193-1201(1985); Carter et al., *Improved oligonucleotide site-directed mutagenesis using M13 vectors*, Nucl. Acids
- 30 Res. 13: 4431-4443 (1985); Grundström et al., *Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis*, Nucl. Acids Res. 13: 3305-3316 (1985); Kunkel, *Rapid and efficient site-specific mutagenesis without phenotypic selection*, Proc. Natl. Acad. Sci. USA 82:488-492 (1985); Smith, *In vitro mutagenesis*, Ann. Rev. Genet.

- 19:423-462(1985); Taylor et al., *The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA*, Nucl. Acids Res. 13: 8749-8764 (1985); Taylor et al., *The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA*, Nucl. Acids Res. 13: 8765-8787 (1985); Wells et al.,
- 5 *Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites*, Gene 34:315-323 (1985); Kramer et al., *The gapped duplex DNA approach to oligonucleotide-directed mutation construction*, Nucl. Acids Res. 12: 9441-9456 (1984); Kramer et al., *Point Mismatch Repair*, Cell 38:879-887 (1984); Nambiar et al., *Total synthesis and cloning of a gene coding for the ribonuclease S protein*, Science 223: 1299-
- 10 1301 (1984); Zoller & Smith, *Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors*, Methods in Enzymol. 100:468-500 (1983); and Zoller & Smith, *Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any DNA fragment*, Nucleic Acids Res. 10:6487-6500 (1982). Additional details on many of the above methods can be found in
- 15 Methods in Enzymology Volume 154, which also describes useful controls for troubleshooting problems with various mutagenesis methods.

[0218] Oligonucleotides, e.g., for use in mutagenesis of the present invention, e.g., mutating libraries of synthetases, or altering tRNAs, are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage and

20 Caruthers, Tetrahedron Letts. 22(20):1859-1862, (1981) e.g., using an automated synthesizer, as described in Needham-VanDevanter et al., Nucleic Acids Res., 12:6159-6168 (1984).

[0219] In addition, essentially any nucleic acid can be custom or standard ordered from any of a variety of commercial sources, such as The Midland Certified Reagent

25 Company (mcrc@oligos.com), The Great American Gene Company (www.genco.com), ExpressGen Inc. (www.expressgen.com), Operon Technologies Inc. (Alameda, CA) and many others.

[0220] The present invention also relates to host cells and organisms for the in vivo incorporation of an unnatural amino acid via orthogonal tRNA/RS pairs. Host cells

30 are genetically engineered (e.g., transformed, transduced or transfected) with the vectors of this invention, which can be, for example, a cloning vector or an expression vector. The vector can be, for example, in the form of a plasmid, a bacterium, a virus, a naked

polynucleotide, or a conjugated polynucleotide. The vectors are introduced into cells and/or microorganisms by standard methods including electroporation (From et al., Proc. Natl. Acad. Sci. USA 82, 5824 (1985), infection by viral vectors, high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface (Klein et al., Nature 327, 70-73 (1987)). Berger, Sambrook, and Ausubel provide a variety of appropriate transformation methods.

[0221] The engineered host cells can be cultured in conventional nutrient media modified as appropriate for such activities as, for example, screening steps, activating promoters or selecting transformants. These cells can optionally be cultured into transgenic organisms.

[0222] Other useful references, e.g. for cell isolation and culture (e.g., for subsequent nucleic acid isolation) include Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York and the references cited therein; Payne et al. (1992) Plant Cell and Tissue Culture in Liquid Systems John Wiley & Sons, Inc. New York, NY; Gamborg and Phillips (eds.) (1995) Plant Cell, Tissue and Organ Culture; Fundamental Methods Springer Lab Manual, Springer-Verlag (Berlin Heidelberg New York) and Atlas and Parks (eds.) The Handbook of Microbiological Media (1993) CRC Press, Boca Raton, FL.

[0223] Several well-known methods of introducing target nucleic acids into bacterial cells are available, any of which can be used in the present invention. These include: fusion of the recipient cells with bacterial protoplasts containing the DNA, electroporation, projectile bombardment, and infection with viral vectors, etc. Bacterial cells can be used to amplify the number of plasmids containing DNA constructs of this invention. The bacteria are grown to log phase and the plasmids within the bacteria can be isolated by a variety of methods known in the art (*see*, for instance, Sambrook). In addition, a plethora of kits are commercially available for the purification of plasmids from bacteria, (*see*, e.g., EasyPrep™, FlexiPrep™, both from Pharmacia Biotech; StrataClean™, from Stratagene; and, QIAprep™ from Qiagen). The isolated and purified plasmids are then further manipulated to produce other plasmids, used to transfect cells or incorporated into related vectors to infect organisms. Typical vectors contain transcription and translation terminators, transcription and translation initiation sequences, and promoters useful for regulation of the expression of the particular target nucleic acid. The

vectors optionally comprise generic expression cassettes containing at least one independent terminator sequence, sequences permitting replication of the cassette in eukaryotes, or prokaryotes, or both, (e.g., shuttle vectors) and selection markers for both prokaryotic and eukaryotic systems. Vectors are suitable for replication and integration in prokaryotes, eukaryotes, or preferably both. *See*, Gilman & Smith, Gene 8:81 (1979); Roberts, et al., Nature, 328:731 (1987); Schneider, B., et al., Protein Expr. Purif. 6435:10 (1995); Ausubel, Sambrook, Berger (*all supra*). A catalogue of Bacteria and Bacteriophages useful for cloning is provided, e.g., by the ATCC, e.g., The ATCC Catalogue of Bacteria and Bacteriophage (1992) Gherna et al. (eds.) published by the ATCC. Additional basic procedures for sequencing, cloning and other aspects of molecular biology and underlying theoretical considerations are also found in Watson et al. (1992) Recombinant DNA Second Edition Scientific American Books, NY.

### EXAMPLES

[0224] The following examples are offered to illustrate, but not to limit the claimed invention.

[0225] **Example 1- Improvement of Orthogonality of a tRNA from *Methanococcus jannaschii***

[0226] Because of the complex nature of tRNA-synthetase interactions that are required to achieve a high degree of fidelity in protein translation, the rational design of orthogonal tRNA-synthetase pairs is difficult. This example describes methods that exploit the poor cross recognition of some interspecies tRNA-synthetase pairs, coupled with subsequent in vivo evolution of tRNAs with enhanced orthogonality. *See, also*, L. Wang and P. G. Schultz, Chem. Biol., 8:883 (2001). Specifically, a library of amber suppressor tRNAs derived from *Methanococcus jannaschii* tRNA<sup>Tyr</sup> was generated. tRNA<sup>Tyr</sup>CUAs that are substrates for endogenous *Escherichia coli* aminoacyl-tRNA synthetases were deleted from the pool by negative selection based on suppression of amber nonsense mutations in the barnase gene. The remaining tRNA<sup>Tyr</sup>CUAs were then selected for their ability to suppress amber nonsense codons in the  $\beta$ -lactamase gene in the presence of the cognate *Methanococcus jannaschii* tyrosyl-tRNA synthetase (TyrRS). Four mutant suppressor tRNAs were selected that are poorer substrates for *Escherichia coli* synthetases than *Methanococcus jannaschii* tRNA<sup>Tyr</sup>CUA, but still can be charged



efficiently by *Methanococcus jannaschii* TyrRS. The mutant suppressor tRNA<sup>Tyr</sup>CUA together with the *Methanococcus jannaschii* TyrRS provide a useful orthogonal tRNA-synthetase pair for the in vivo incorporation of unnatural amino acids into proteins.

[0227] The tRNA<sup>Tyr</sup> of *Methanococcus jannaschii*, an archaebacterium, has  
5 different identity elements from those of *Escherichia coli* tRNA<sup>Tyr</sup>. In particular, the *Escherichia coli* tRNA<sup>Tyr</sup> has a G1C72 pair in the acceptor stem while the *Methanococcus jannaschii* tRNA<sup>Tyr</sup> has a C1G72 pair. An amber suppressor tRNA derived from *Methanococcus jannaschii* tRNA<sup>Tyr</sup> was shown not to be efficiently aminoacylated by the *Escherichia coli* synthetases, but functions efficiently in protein  
10 translation in *Escherichia coli*. See, e.g., L. Wang, T.J. Magliery, D. R. Liu, P. G. Schultz, *A new functional suppressor tRNA/aminoacyl-tRNA synthetase pair for the in vivo incorporation of unnatural amino acids into proteins*, J. Am. Chem. Soc. 122:5010-5011 (2000). In addition, the *Methanococcus jannaschii* TyrRS, which has only a minimalist anticodon-loop-binding domain, does not aminoacylate *Escherichia coli* tRNAs, but still  
15 efficiently aminoacylates its own suppressor tRNA<sup>Tyr</sup>CUA. See, e.g., B. A. Steer, P. Schimmel, *Major anticodon-binding region missing from an archaebacterial tRNA synthetase*, J. Biol. Chem. 274 (1999) 35601-35606; and, Wang et al., (2000), *supra*.

[0228] To test the orthogonality of this suppressor tRNA in *Escherichia coli*, an amber codon was introduced at a permissive site (Ala184) in the  $\beta$ -lactamase gene. See,  
20 e.g., D. R. Liu, P. G. Schultz, *Progress toward the evolution of an organism with an expanded genetic code*, Proc. Natl. Acad. Sci. USA 96:4780-4785 (1999). Those tRNAs that can be charged by *Escherichia coli* synthetases will suppress the amber codon and allow cells to live in the presence of ampicillin. The *Methanococcus jannaschii* tRNA<sup>Tyr</sup>CUA suppresses the amber codon in the  $\beta$ -lactamase gene with an IC<sub>50</sub> value of  
25 56  $\mu$ g/ml ampicillin. See Wang et al., (2000), *supra*. In contrast, the orthogonal tRNA<sup>Gln</sup>CUA derived from *Saccharomyces cerevisiae* tRNA<sup>Gln</sup>2 has an IC<sub>50</sub> of 21  $\mu$ g/ml ampicillin when tested in the same assay. See Liu & Schultz, (1999), *supra*. The IC<sub>50</sub> for *Escherichia coli* in the absence of any suppressor tRNA is 10  $\mu$ g/ml ampicillin. This result shows that the *Methanococcus jannaschii* tRNA<sup>Tyr</sup>CUA is a better substrate  
30 for *Escherichia coli* synthetases than the tRNA<sup>Gln</sup>CUA. Consequently, if the *Methanococcus jannaschii* tRNA<sup>Tyr</sup>CUA is used in vivo to deliver unnatural amino acids

into proteins in *Escherichia coli*, it can also be mischarged with natural amino acids by *Escherichia coli* synthetases, leading to heterogeneous amino acid incorporation.

[0229] The improvement of the orthogonality of the *Methanococcus jannaschii* tRNA<sup>TyrCUA</sup> was accomplished by the introduction of 'negative recognition  
5 determinants' to prevent recognition by endogenous *Escherichia coli* synthetases. These mutations should not strongly interfere with the tRNA's interaction with its cognate *Methanococcus jannaschii* TyrRS or the ribosome. Since *Methanococcus jannaschii* TyrRS lacks most of the anticodon-binding domain, *see, e.g.*, B. A. Steer, P. Schimmel, *Major anticodon-binding region missing from an archaeobacterial tRNA synthetase*, J. Biol. Chem. 274:35601-35606 (1999), mutations introduced at the anticodon loop of the  
10 tRNA are expected to have a minimal effect on TyrRS recognition. An anticodon-loop library with four randomized nucleotides was constructed. *See Figure 9*. Given the various combinations and locations of identity elements for various *Escherichia coli* tRNAs, mutations at additional positions can increase the likelihood of finding a mutant  
15 tRNA with the desired properties. Thus, a second library containing mutations at nonconserved positions in all of the tRNA loops (all-loop library) was also constructed. *See Figure 9*. Conserved nucleotides were not randomized so as to maintain the tertiary interactions that stabilize the 'L'-shaped structure of the tRNA. *See, e.g.*, G. Dirheimer, G. Keith, P. Dumas, E. Westhof, *Primary, secondary, and tertiary structures of tRNAs*, in:  
20 D. Söll, U. L. RajBhandary (eds.), *tRNA Structure, Biosynthesis, and Function*, ASM Press, Washington, DC, 1995, pp. 93-126; and, R. Giegé, M. Sissler, C. Florentz, *Universal rules and idiosyncratic features in tRNA identity*, Nucleic Acids Res. 26:5017-5035 (1998). Stem nucleotides were also not mutated since substitution of one such nucleotide requires a compensatory mutation. The 11 nucleotides (C16, C17, U17a, U20,  
25 C32, G37, A38, U45, U47, A59, and U60) were randomized. *See, Figure 9*. The theoretical size of this library is about  $4.19 \times 10^6$ , and a library with a size of about  $1.93 \times 10^8$  colony-forming units was constructed to ensure complete coverage of the mutant library.

[0230] The methods used an *Escherichia coli* strain, *e.g.*, DH10B, which was  
30 obtained from Gibco/BRL. Suppressor tRNA expression plasmids were derived from a plasmid, *e.g.*, pAC123. *See, e.g.*, D. R. Liu, T. J. Magliery, M. Pastnak, P. G. Schultz, *Engineering a tRNA and aminoacyl-tRNA synthetase for the site-specific incorporation of*

*unnatural amino acids into proteins in vivo*, Proc. Natl. Acad. Sci. USA 94:10091-10097 (1997). Plasmids for negative selections were derived from plasmids, e.g., pBATS, pYsupA38B2 and pYsupA38B3 as described below. See, e.g., K. Gabriel, W.H. McClain, *A set of plasmids constitutively producing different RNA levels in Escherichia coli*, J. Mol. Biol. 290 (1999) 385-389; and, Liu & Shultz, (1999), *supra*.

[0231] To select for a member of the *Methanococcus jannaschii* tRNA library with enhanced orthogonality, a combination of negative and positive selections in the absence and presence of the cognate synthetase was used. See Figure 8. In the negative selection, selector codon(s), e.g., amber nonsense, are introduced in a negative marker gene, e.g., a toxic gene, at e.g., a nonessential position. When a member of the mutated, e.g., suppressor, tRNA library is aminoacylated by endogenous (e.g., *Escherichia coli*) synthetases (i.e. it is not orthogonal to the *Escherichia coli* synthetases), the selector codon is suppressed and the toxic gene product produced leads to cell death. Only cells harboring orthogonal tRNAs or nonfunctional tRNAs can survive. All survivors are then subjected to a positive selection in which a selector codon, e.g., an amber codon, is placed in a positive selection marker, e.g., drug resistance gene at, e.g., a nonessential position. tRNAs are then selected for their ability to be aminoacylated by the coexpressed cognate synthetase and to insert an amino acid in response to this amber codon. Cells harboring nonfunctional tRNAs, or tRNAs that cannot be recognized by the synthetase of interest will be sensitive to antibiotic. Therefore, only tRNAs that (1) are not substrates for endogenous *Escherichia coli* synthetases; (2) can be aminoacylated by the synthetase of interest; (3) are functional in translation will survive both selections.

[0232] A negative selection was chosen that takes advantage of the toxicity of barnase when produced in *Escherichia coli* in the absence of its natural inhibitor barstar. See, e.g., R.W. Hartley, Barnase and barstar. *Expression of its cloned inhibitor permits expression of a cloned ribonuclease*, J. Mol. Biol. 202:913-915 (1988). Amber codons were introduced at nonessential positions in the barnase gene based on analysis of the three-dimensional structure of barnase. See, e.g., Liu & Schultz, (1999), *supra*. Because of barnase's extreme autotoxicity, a low copy number pSC101 origin was placed in the plasmid expressing barnase. In addition, different numbers of amber codons were tested to modulate the stringency of the selection. Plasmid pSCB2 was used to express a barnase

mutant with two amber stop codons at Gln2 and Asp44; plasmid pSCB3 contained an additional amber stop codon at Gly65.

[0233] For negative selection, a PCR fragment containing the  $\beta$ -lactamase gene and the pSC101 origin was generated from pBATS using the following oligonucleotides:  
5 LW115, 5'-ATGCATGCTGCATTAATGAATCGGCCAACG-3'; LW116, 5'-TCCCCGCGGAGGTGGCACTTTTCGGGG-3'. DNA encoding barnase containing two (residues Gln2 and Asp44) or three (residues Gln2, Asp44 and Gly65) amber codons were obtained from pYsupA38B2 and pYsupA38B3, respectively, by digestion with SacII and SphI. Ligation of the above fragments afforded plasmids pSCB2 and pSCB3. The  
10 expression of barnase was under arabinose induction. Genes encoding different suppressor tRNAs for in vivo expression were constructed from two overlapping synthetic oligonucleotides (Operon, Alameda, CA, USA) by Klenow extension and inserted between the EcoRI and PstI sites of pAC123 to generate pAC-YYG1 and pAC-JY, respectively, placing transcription under control of the *lpp* promoter and the *rmC*  
15 terminator. pAC-Cm is the control plasmid without any tRNA. To optimize the negative selection conditions, competent DH10B cells harboring pSCB2 or pSCB3 were transformed by electroporation with pAC-Cm, pAC-YYG1, and pAC-JY, separately. Single colonies were picked and grown in 2xYT with chloramphenicol (Cm, 34  $\mu$ g/ml) and ampicillin (Amp, 100  $\mu$ g/ml). Cell cultures grown overnight were washed twice with  
20 minimal media containing 1% glycerol and 0.3 mM leucine (GMML), and resuspended in GMML with Cm and Amp to an OD600 of 0.1. After recovering at 30°C for 10 min, into one culture (set 1) was added 20 mM of arabinose to induce the expression of barnase; no arabinose was added to the second culture (set 2). At different time points, a small amount of cell culture was diluted and plated on 2xYT agar with Cm and Amp to measure cell  
25 density. For negative selections of the suppressor tRNA libraries, the pAC plasmids containing the library were transformed into DH10B cells harboring pSCB2. Cells were quenched by addition of SOC medium and recovered at 30°C for 1 hour, then were washed with phosphate buffer and GMML, and cultured in 1 l GMML. After recovering at 30°C for 30 min, Cm, Amp, and 20 mM arabinose were added. After 36 hours, cells  
30 were pelleted and pAC plasmids were isolated and purified by agarose gel electrophoresis.

[0234] To optimize the selection conditions, two suppressor tRNAs were used that are known to be poorly recognized by the *Escherichia coli* synthetases. A mutant

suppressor tRNA<sup>Tyr</sup> derived from *Saccharomyces cerevisiae* (sc-tRNA<sup>Tyr</sup>CUA, expressed in pAC-YYG1) suppresses the amber codon (Ala184TAG) in the  $\beta$ -lactamase gene, affording an IC<sub>50</sub> value of 12  $\mu$ g/ml ampicillin for *Escherichia coli* cells; and the suppressor tRNA<sup>Tyr</sup> derived from *Methanococcus jannaschii* (mj-tRNA<sup>Tyr</sup>CUA, expressed in pAC-JY) affords an IC<sub>50</sub> of 56  $\mu$ g/ml ampicillin for host cells. *See, e.g.,* Wang et al, (2000), *supra*. For comparison, the suppressor tRNA<sup>Gln</sup>CUA derived from *Saccharomyces cerevisiae* tRNA<sup>Gln</sup>2 has an IC<sub>50</sub> of 21  $\mu$ g/ml ampicillin when tested in the same assay, and has been demonstrated to be orthogonal to *Escherichia coli* synthetases in vitro and in vivo. *See, e.g.,* Liu & Schultz, (1999), *supra*. Therefore, a negative selection that eliminates cells expressing mj-tRNA<sup>Tyr</sup>CUA, but allows the growth of cells expressing sc-tRNA<sup>Tyr</sup>CUA deletes non-orthogonal suppressor tRNAs. Cells were grown in liquid minimal media containing 1% glycerol and 0.3 mM leucine (GMMML) with appropriate antibiotics to maintain plasmid pSCB2 and the pAC plasmid. Arabinose was added to one set of cells (set 1) to induce the expression of the barnase, while in set 2 no arabinose was added. The fraction of cells surviving the selection was determined by the ratio of cell densities in set 1 relative to set 2. *See Figure 11:* cells harboring the control plasmid pAC-Cm (without suppressor tRNA) and plasmid pAC-YYG1 survived, while cells harboring plasmid pAC-JY largely died. When plasmid pSCB3 was used, cells harboring plasmid pAC-JY started to grow in 24 hours. Therefore, the negative selection was carried out using pSCB2, which encodes the barnase gene containing two amber codons under the above conditions for the library selection.

[0235] For positive selection, a plasmid, e.g., pBLAM-JYRS was constructed by inserting the *Methanococcus jannaschii* TyrRS gene from pBSA50 between NdeI and PstI sites of pBLAM-YQRS using oligonucleotides LW104, 5'-GGAATTCCATTAGGACGAATTTGAAATG-3'; and LW105, 5'-AAACTGCAGTTATAATCTCTTTCTAATTGGCTC-3'. *See, e.g.,* Steer, et al., (1999), *supra*; and, Liu & Schultz, (1999), *supra*. To optimize the positive selection conditions, competent DH10B cells harboring pBLAM-JYRS were transformed with pAC-Cm, pAC-YYG1, and pAC-JY, separately. Single colonies were picked and grown in 2 $\times$ YT with Cm and tetracycline (Tet, 40  $\mu$ g/ml). In liquid selections, overnight cell cultures were diluted into 2 $\times$ YT with Cm and Tet at a starting OD<sub>600</sub> of 0.1. Various concentrations of Amp were added, and cell growth was monitored by OD<sub>600</sub>. In plate selections, approximately 10<sup>3</sup> to 10<sup>5</sup> cells were plated on two sets of 2 $\times$ YT agar plates containing

Cm and Tet, one set of which contained 500  $\mu\text{g/ml}$  Amp. For selections involving the mutant tRNA library, pAC plasmids isolated from the cells from the negative selection were transformed into competent DH10B cells harboring pBLAM-JYRS. Cells were recovered at 37°C for 45 minutes, and approximately 105 cells were plated onto each 2×YT agar plate containing Cm, Tet and 500  $\mu\text{g/ml}$  of Amp. After 24 hours, colonies were picked and re-grown in 6 ml 2×YT containing Cm, Tet and 200  $\mu\text{g/ml}$  of Amp. DNA was isolated and pAC plasmid was purified by agarose gel electrophoresis.

[0236] The positive selection is based on suppression of an amber stop codon introduced at position Ala184 in the TEM-1  $\beta$ -lactamase gene. Plasmid pBLAM-JYRS encodes the gene for the *Methanococcus jannaschii* tyrosyl-tRNA synthetase and a  $\beta$ -lactamase with an amber mutation at Ala184. pAC plasmids isolated from cells surviving the negative selection were cotransformed with pBLAM-JYRS into *Escherichia coli* DH10B cells. Cells harboring nonfunctional tRNAs or tRNAs that are poor substrates for the *Methanococcus jannaschii* synthetase die; those with tRNAs that can be charged by the synthetase survive. To test the feasibility of the positive selection, two model suppressor tRNAs were tested in the presence of *Methanococcus jannaschii* TyrRS. The sc-tRNA<sup>Tyr</sup>CUA has a G1:C72 base pair and is not charged efficiently by *Methanococcus jannaschii* TyrRS. When they were coexpressed in cells with the Ala184amber  $\beta$ -lactamase mutant, cells survived to an IC<sub>50</sub> of 18  $\mu\text{g/ml}$  ampicillin. In contrast, cells containing the *Methanococcus jannaschii* tRNA<sup>Tyr</sup>CUA and the cognate TyrRS survive to an IC<sub>50</sub> of 1220  $\mu\text{g/ml}$  ampicillin. See, e.g., Wang, et al., (2000), *supra*. The model positive selection was first tried in liquid 2×YT medium. The growth of cells harboring pBLAM-JYRS and different pAC plasmids in liquid 2×YT medium with various concentrations of ampicillin are shown in **Figure 12, Panel A**. Cells transformed with the mj-tRNA<sup>Tyr</sup>CUA grew at a faster rate and at higher concentrations of ampicillin. If cells were grown longer than 24 hours, cells transformed with either pAC-Cm or pAC-YYG1 also grew to saturation. Therefore, the positive selection was carried out on plates with initial cell densities between 103 and 105 per plate. See **Figure 12, Panel B**. The survival ratio (number of colonies on plates with ampicillin relative to plates without ampicillin) did not change significantly with different initial cell densities, and was stable over the growth time. The positive selection on ampicillin plates resulted in preferential growth of

cells with mj-tRNA<sup>Tyr</sup>CUA expressed. Therefore, for the library selection the positive selection was carried out on plates instead of in liquid medium.

[0237] The library of mutant tRNAs was generated by using the sequences of the two overlapping oligonucleotides used to construct the anticodon-loop library are (the tRNA sequence underlined): LW125, 5'-GGAATTC-3'; LW126, 5'-AAAACTGCAG-3' (where N is equimolar of A, C, T or G). The sequences of oligonucleotides for the all-loop library are: LW145, 5'-GGAATTC-3' and LW146, 5'-AAAACTGCAG-3'. These genes were inserted into pAC123 similarly as described above to afford the tRNA libraries.

10 [0238] The negative and positive selections were carried out in tandem as described above on both the anticodon-loop and all-loop libraries. The selected suppressor tRNAs were isolated and retransformed into *Escherichia coli* DH10B harboring pBLAM to test the tRNA's orthogonality to *Escherichia coli* synthetases. The tRNAs were then retransformed into *Escherichia coli* harboring pBLAM-JYRS to test how efficiently the tRNA was charged by *Methanococcus jannaschii* TyrRS. Sequencing of the clones resulting from one round of negative and positive selection of anticodon-loop library revealed that three independent tRNAs were isolated. See Figure 13. When cotransformed with pBLAM, all had lower IC<sub>50</sub> values than the parent *Methanococcus jannaschii* tRNA<sup>Tyr</sup>CUA, indicating they are poorer substrates for *Escherichia coli* synthetases.

[0239] Mutant AA2 also had very high affinity for *Methanococcus jannaschii* TyrRS. Although this mutant tRNA could be stably maintained in *Escherichia coli*, it slowed the growth rate of cells for unknown reasons. This effect likely led to the emergence of mutants AA3 and AA4, which both had a mutation outside of the randomization region. Cells harboring AA3 or AA4 grew normally. Nevertheless, AA3 and AA4 were relatively poor substrates for the *Methanococcus jannaschii* TyrRS.

25 [0240] Four independent tRNAs were selected from two rounds of negative and positive selections using the all-loop library. See Figure 13. All were poorer substrates for the *Escherichia coli* synthetase than the parent *Methanococcus jannaschii* tRNA<sup>Tyr</sup>CUA, yet were still efficiently charged by the *Methanococcus jannaschii* TyrRS as shown by the in vivo  $\beta$ -lactamase assay. See Table 2. The IC<sub>50</sub> value for cells expressing the best mutant, J17, was 12  $\mu$ g/ml ampicillin, which is even lower than that of

cells with the orthogonal tRNA<sup>Gln</sup>CUA derived from *Saccharomyces cerevisiae* expressed (21  $\mu$ g/ml ampicillin). When J17 was coexpressed with the *Methanococcus jannaschii* TyrRS, cells survived to an IC<sub>50</sub> value of 436  $\mu$ g/ml ampicillin, providing a selection window (ratio of IC<sub>50</sub> value with TyrRS to IC<sub>50</sub> value without TyrRS) of 35-  
 5 fold. In addition, the expression of all these mutant tRNAs did not affect the growth of *Escherichia coli* cells.

[0241] Table 2. In vivo  $\beta$ -lactamase assay of selected suppressor tRNAs

Suppressor tRNA		IC <sub>50</sub> ( $\mu$ g/ml of ampicillin)	
		Coexpressed with pBLAM	Coexpressed with pBLAM-JYRS
10	mj-tRNA <sup>Tyr</sup> CUA	56	1220
	No tRNA <sup>Tyr</sup> CUA	10	10
	Mutant tRNAs selected from anticodon-loop library		
	AA2	22	1420
	AA3	10	110
15	AA4	12	135
	Mutant tRNAs selected from all-loop library		
	<i>Mutant tRNAs surviving both selections</i>		
	J15	30	845
	J17	12	436
20	J18	20	632
	J22	14	459
	<i>Mutant tRNAs surviving negative selection only</i>		
	N11	11	16
	N12	9	18
25	N13	10	12
	N16	9	9

Plasmid pBLAM was used to express the  $\beta$ -lactamase gene with an amber codon at Ala184; plasmid pBLAM-JYRS expressed the amber mutant and the TyrRS of *Methanococcus jannaschii*. Suppressor tRNAs were encoded on pAC plasmid and  
 30 cotransformed with pBLAM or pBLAM-JYRS in the assay.

[0242] To confirm the properties of the selected suppressor tRNAs, they were tested in another in vivo assay based on the suppression of an amber codon in the chloramphenicol acetyltransferase (CAT) gene. In contrast to  $\beta$ -lactamase which is



secreted into the periplasm, CAT localizes in the cytoplasm. Moreover, ampicillin is bacteriocidal while chloramphenicol is bacteriostatic. As shown in Table 3 below, the selected suppressor tRNAs also were orthogonal in the CAT assay, indicating their suitability for CAT selections.

- 5 [0243] Table 3. In vivo chloramphenicol acetyltransferase assay of selected suppressor tRNAs

	Suppressor tRNA	IC <sub>50</sub> (μg/ml of chloramphenicol)	
		pYC only	pYC+pBK-JYRS
	mj-tRNA <sup>Tyr</sup> CUA	27	308
10	No tRNA <sup>Tyr</sup> CUA	3	3
	J15	11	297
	J17	4	240
	J18	6	284
	J22	5	271

- 15 pYC plasmids encoded the chloramphenicol acetyltransferase gene with an amber codon at Asp112 and different suppressor tRNAs listed in the left column of the table. pBK-JYRS was used to express the TyrRS of *Methanococcus jannaschii*.

- [0244] The in vivo complementation assay which is based on suppression of an amber codon in the β-lactamase gene was carried out as described. See, e.g., Liu & Schultz, (1999), *supra*; and, Wang, et al., (2000), *supra*. In the chloramphenicol acetyltransferase (CAT) assay, an amber codon was substituted for Asp112 in the CAT gene of pACYC184 to afford pACMD112TAG. See, e.g., M. Pastnak, T.J. Magliery, P. G. Schultz, *A new orthogonal suppressor tRNA/aminoacyl-tRNA synthetase pair for evolving an organism with an expanded genetic code*, Helv. Chim. Acta 83:2277-2286
- 20 (2000). The genes encoding the suppressor tRNAs under the control of the lpp promoter and rrnC terminator were excised from pAC plasmids with NcoI and AvaI, and inserted into the pre-digested pACMD112TAG to afford plasmids pYC-JY, pYC-J15, pYC-J17, pYC-J18, and pYC-J22, respectively. Plasmid pBK-JYRS, a derivative of pBR322, was used to express the *Methanococcus jannaschii* TyrRS under the control of the *Escherichia coli* GlnRS promoter and terminator. The survival of *Escherichia coli* DH10B cells transformed with pYC plasmid alone or cotransformed with pYC and pBK-JYRS was
- 25
- 30

titrated against a wide range of chloramphenicol concentrations added to the growth media, and IC<sub>50</sub> values were interpolated from the curves.

[0245] For comparison, four colonies were randomly picked that passed the negative selection only, and tested the tRNAs using the in vivo complementation assay.

- 5 All of them had very low IC<sub>50</sub> values when transformed with pBLAM, indicating the negative selection worked well. See Table 2. The IC<sub>50</sub> values were also low when cotransformed with pBLAM-JYRS, revealing that the positive selection functions to delete tRNAs that cannot be charged by the *Methanococcus jannaschii* TyrRS.

- [0246] Analysis of the DNA sequences of the selected tRNAs yielded a  
10 characteristic pattern of nucleotide substitutions. See Figure 13. tRNAs that passed both negative and positive selections all had C32 and T60 unchanged, while G37 was mutated to A, and T17a was mutated to either A or G. Some semi-conserved changes included mutation of A38 to either C or A; mutation of T45 to either T or A; mutation of T47 to either G or T. Other mutations had no obvious common pattern. Twenty (20) tRNAs that  
15 passed the negative selection only were also sequenced, four of which are shown in Figure 13, and found they all lacked at least one of the common mutations listed above.

- [0247] The preferred nucleotides in the selected mutant suppressor tRNAs can play the following roles: (i) they can function as negative determinants for recognition by the *Escherichia coli* synthetases; (ii) they can be identity elements for aminoacylation by  
20 *Methanococcus jannaschii* TyrRS; or (iii) they can also optimize the tRNA's interaction with *Escherichia coli*'s translational machinery so as to increase the suppression efficiency of the tRNA. It is noteworthy that the G37A mutation was found in tRNAs selected from both the anticodon-loop and all-loop library. This mutation is consistent with previous studies that showing that adenine at position 37 enhances amber suppression efficiency.  
25 See, e.g., M. Yarus, *Translational efficiency of transfer RNA's: Use of an expanded anticodon*, *Science* 218:646-652 (1982); D. Bradley, J.V. Park, L. Soll, *tRNA<sup>2Gln</sup> Su+2 mutants that increase amber suppression*, *J. Bacteriol.* 145:704-712 (1981); and, L. G. Kleina, J. Masson, J. Normanly, J. Abelson, J.H. Miller, *Construction of Escherichia coli amber suppressor tRNA genes. II. Synthesis of additional tRNA genes and improvement of suppressor efficiency*, *J. Mol. Biol.* 213:705-717 (1990). Fechter et al. recently reported  
30 that the complete identity set for *Methanococcus jannaschii* tRNA<sup>Tyr</sup> is six nucleotides (C1G72, A73, and anticodon G34U35A36). See P. Fechter, J. Rudinger-Thirion, M.

- Tukalo, R. Giegé, *Major tyrosine identity determinants in Methanococcus jannaschii and Saccharomyces cerevisiae tRNA<sup>Tyr</sup> are conserved but expressed differently*, Eur. J. Biochem. 268:761-767 (2001). The presence of C32 and T60 in all selected mutant suppressors therefore is not required for recognition by *Methanococcus jannaschii* TyrRS.
- 5 All *Escherichia coli* tRNAs have T at position 60 except four tRNAs which have C. See, M. Sprinzl, C. Horn, M. Brown, A. Loudovitch, S. Steinberg, *Compilation of tRNA sequences and sequences of tRNA genes*, Nucleic Acids Res. 26:148-153 (1998). Based on the crystal structure of yeast tRNA<sup>Phe</sup>, nucleotide 60 does not interact with other nucleotides. See J. L. Sussman, S. R. Holbrook, R. W. Warrant, G. M. Church, S.H. Kim,
- 10 *Crystal structure of yeast phenylalanine transfer RNA. I. Crystallographic refinement*, J. Mol. Biol. 123:607-630 (1978). Thus, T60 may maintain the shape of the TC loop for productive interaction with the *Escherichia coli* translational machinery. The change of the TC loop structure may affect translational fidelity, as the insertion of a nucleotide between T60 and the conserved C61 enables a glycine tRNA to shift reading frame. See,
- 15 D. J. O'Mahony, B.H. Hims, S. Thompson, E.J. Murgola, J.F. Atkins, *Glycine tRNA mutants with normal anticodon loop size cause 1 frameshifting*, Proc. Natl. Acad. Sci. USA 86:7979-7983 (1989). The role of C32 is not obvious - position 32 in *Escherichia coli* tRNAs includes T, C, and A, and two *Escherichia coli* tRNA<sup>Tyr</sup>s do have C32. As for position 17a, only tRNA<sup>Thr</sup> has an A at this position.
- 20 [0248] All of the selected suppressor tRNAs are poorer substrates for *Escherichia coli* synthetases relative to the *Methanococcus jannaschii* tRNA<sup>Tyr</sup>CUA, resulting in less mischarging when introduced into *Escherichia coli*. These tRNAs can also be stably maintained in *Escherichia coli* without adverse effects on the growth of host cells. Moreover, they can still be charged efficiently by *Methanococcus jannaschii* TyrRS. All
- 25 these properties make the mutant suppressor tRNA together with the *Methanococcus jannaschii* TyrRS a robust orthogonal tRNA-synthetase pair for the selective incorporation of unnatural amino acids into proteins in vivo. The J17 mutant suppressor tRNA and an engineered mutant TyrRS has been used to deliver O-methyl-L-tyrosine in response to a TAG codon with a fidelity rivaling that of the common 20 amino acids. See, L. Wang, A.
- 30 Brock, B. Herberich, P. G. Schultz, *Expanding the genetic code of Escherichia coli*, Science, 292:498-500 (2001).

[0249]       **Example 2- Mutating TyrRS so that it charges the mutRNA Tyr/CUA with an unnatural amino acid, O-methyl-L-tyrosine**

[0250]       A unique transfer RNA (tRNA)-aminoacyl tRNA synthetase pair has been generated that expands the number of genetically encoded amino acids in *Escherichia coli*.

- 5   When introduced into *Escherichia coli*, this pair leads to the in vivo incorporation of the synthetic amino acid O-methyl-L-tyrosine, added exogenously to the growth medium, into protein in response to an amber nonsense codon. The fidelity of translation is greater than 99%, as determined by analysis of dihydrofolate reductase containing the unnatural amino acid. This approach provides a general method for increasing the genetic repertoire of
- 10   living cells to include a variety of amino acids with novel structural, chemical and physical properties not found in the common twenty amino acids.

- [0251]       An orthogonal tRNA/synthetase pair in *Escherichia coli* can be generated by importing a pair from a different organism, if cross-species aminoacylation is inefficient, and, optionally, the anticodon loop is not a key determinant of synthetase
- 15   recognition. One such candidate pair is the tyrosyl tRNA/synthetase pair of *Methanococcus jannaschii* (*Methanococcus jannaschii*), an archaeobacterium whose tRNA<sup>Tyr</sup> identity elements differ from those of *Escherichia coli* tRNA<sup>Tyr</sup> (in particular, the first base pair of the acceptor stem is GC in *Escherichia coli* and CG in *Methanococcus jannaschii*), and whose tyrosyl synthetase (TyrRS) has only a minimalist
- 20   anticodon loop binding domain. See, e.g., B. A. Steer, & P. Schimmel, J. Biol. Chem. 274:35601-6 (1999). In addition, the *Methanococcus jannaschii* TyrRS does not have an editing mechanism, see, e.g., Jakubowski & Goldman, Microbiol. Rev., 56:412 (1992), and therefore should not proofread an unnatural amino acid ligated to the tRNA. The *Methanococcus jannaschii* TyrRS efficiently aminoacylates an amber suppressor tRNA
- 25   derived from its cognate tRNA<sup>Tyr</sup>, see, e.g., Wang, et al., (2000 J. Am. Chem. Soc., *supra.*, but does not aminoacylate *Escherichia coli* tRNAs, see, e.g., Steer & Schimmel, (1999), *supra.* Moreover, the *Methanococcus jannaschii* tRNA<sup>Tyr</sup><sub>CUA</sub> is a poor substrate for the *Escherichia coli* synthetases but functions efficiently in protein translation in *Escherichia coli*. See, e.g., Wang, et al., (2000 J. Am. Chem. Soc., *supra.*

- 30   [0252]       To further reduce recognition of the orthogonal tRNA, *Methanococcus jannaschii* tRNA<sup>Tyr</sup><sub>CUA</sub>, by *Escherichia coli* synthetases, eleven nucleotides of the tRNA that do not interact directly with the *Methanococcus jannaschii* TyrRS (C16, C17, U17a, U20,

C32, G37, A38, U45, U47, A59 and U60) were randomly mutated to generate a suppressor tRNA library. This tRNA library was passed through a negative selection (e.g., suppression of amber mutations in a toxic reporter gene, e.g., barnase gene), which removes tRNAs that are aminoacylated by *Escherichia coli* synthetases, and then a  
5 positive selection for tRNAs that are efficiently aminoacylated by *Methanococcus jannaschii* TyrRS (e.g., suppression of amber mutations in a reporter gene, e.g.,  $\beta$ -lactamase gene).

[0253] The orthogonal nature of the resulting suppressor tRNAs was tested by an *in vivo* complementation assay, which is based on suppression of an amber stop codon at a  
10 nonessential position (e.g., Ala184) of a reporter gene on a vector, e.g., the TEM-1  $\beta$ -lactamase gene carried on plasmid pBLAM. Aminoacylation of a transformed suppressor tRNA by any endogenous *Escherichia coli* synthetase results in cell growth in the presence of ampicillin. *Escherichia coli* transformed with *Methanococcus jannaschii* tRNA<sup>Tyr</sup><sub>CUA</sub> and the reporter construct, pBLAM, survive at 55  $\mu$ g/mL ampicillin. When the  
15 best mutant suppressor tRNA (mtRNA<sup>Tyr</sup><sub>CUA</sub>) selected from the library was expressed, cells survived at only 12  $\mu$ g/mL ampicillin; similar values are obtained in the absence of any suppressor tRNA. The mutant suppressor tRNA contained the following nucleotide substitutions: C17A, U17aG, U20C, G37A, and U47G. When the *Methanococcus jannaschii* TyrRS is coexpressed with this mtRNA<sup>Tyr</sup><sub>CUA</sub>, cells survive at 440  $\mu$ g/mL  
20 ampicillin. Thus, the mtRNA<sup>Tyr</sup><sub>CUA</sub> is a poorer substrate for the endogenous synthetases than the *Methanococcus jannaschii* tRNA<sup>Tyr</sup><sub>CUA</sub> but is still aminoacylated efficiently by the *Methanococcus jannaschii* TyrRS.

[0254] To alter the amino acid specificity of the orthogonal TyrRS so that it charges the mtRNA<sup>Tyr</sup><sub>CUA</sub> with a desired unnatural amino acid, a library of TyrRS mutants  
25 was generated and screened. Based on the crystal structure of the homologous TyrRS from *Bacillus stearothermophilus*, see, e.g., P. Brick, T. N. Bhat, D. M. Blow, J. Mol. Biol., 208:83 (1988), five residues (Tyr<sup>32</sup>, Glu<sup>107</sup>, Asp<sup>158</sup>, Ile<sup>159</sup> and Leu<sup>162</sup>) in the active site of *Methanococcus jannaschii* TyrRS which are within 6.5 Å of the para position of the aryl ring of bound tyrosine were mutated. See, Figure 14. These residues were all  
30 initially mutated to alanine, and the resulting inactive Ala<sub>5</sub> TyrRS was used as a template for polymerase chain reaction (PCR) random mutagenesis with doped oligonucleotides.

[0255] For example, the TyrRS gene was expressed under the control of *Escherichia coli* GlnRS promoter and terminator in plasmid pBK-JYRS, a pBR322 derived plasmid with kanamycin resistance. Residues Tyr<sup>32</sup>, Glu<sup>107</sup>, Asp<sup>158</sup>, Ile<sup>159</sup> and Leu<sup>162</sup> were substituted with Ala by site-directed mutagenesis to provide plasmid pBK-JYA5. Eight (8) oligonucleotides with NNK (N=A + T + G + C and K= G + T, and M= C + A), e.g., oligonucleotides LW157 5'-GGAATTCCATATGGACGAATTTGAAATG-3', LW164 5'-GTATTT TACCACTTGGTTCAAAACCTATMNNAGCAGATTTTTCATCTTTTTTTCATCTTT TTTTAAAC-3', LW159 5'-TAGGTTTTGAACCAAGTGGTAAAATAC-3', LW165 5'-CATTCAGTGTATAATCCTTATCAAGCTGGAAMNNACTTCCATAA ACATATTTTGCCTTTAAC-3', LW161 5'-TCCAGCTTGATAAGGATTATACA CTGAATG-3', LW167 5'-CATCCCTCCAAGTCAACATCAACGCCMNNATA ATGMNNMNNATTAACCTGCATTATTGGATAGATAAC-3', LW163 5'-GCGT TGATGTTGCAGTTGGAGGGATG-3', and LW105 5'-AAACTGCAGTTATAAT CTCTTTCTAATTGGCTC-3' (Operon, CA) at the mutation sites were used for PCR amplification of the Ala<sub>5</sub> TyrRS mutant (pBK-JYA5) and ligated back into the NdeI-PstI-digested pBK-JYA5 to afford the TyrRS library. The ligated vectors were transformed into *Escherichia coli* DH10B competent cells to yield a library of 1.6 X 10<sup>9</sup> colony forming unit (cfu). The TyrRS genes from 40 randomly picked colonies were sequenced to confirm that there was no base bias at the randomized NNK positions and no other unexpected mutations. The library was amplified by maxiprep, and supercoiled DNA was used to transform the selection strain pYC-J17.

[0256] A positive selection was then applied to the library of mutated orthogonal TyrRS that is based on suppression of an amber stop codon at a nonessential position (e.g., Asp112) in the chloramphenicol acetyltransferase (CAT) gene. See, e.g., M. Pastnak, T.J. Magliery, P. G. Schultz, Helv. Chim. Acta, 83:2277 (2000). Cells transformed with the mutant TyrRS library and mtRNA<sup>Tyr</sup><sub>CUA</sub> gene were grown in media containing the unnatural amino acid and selected for their survival in the presence of various concentrations of chloramphenicol. If a mutant TyrRS charges the orthogonal mtRNA<sup>Tyr</sup><sub>CUA</sub> with any amino acid, either natural or unnatural, the cell produces CAT and survives. The surviving cells were then grown in the presence of chloramphenicol and in the absence of the unnatural amino acid. Those cells that did not survive, e.g., which encode mutant TyrRS's that

charge the orthogonal  $\text{mtRNA}_{\text{CUA}}^{\text{Tyr}}$  with an unnatural amino acid, were isolated from a replica plate supplemented with the unnatural amino acid. The mutant TyrRS genes were isolated from these cells, recombined in vitro by DNA shuffling, and transformed back into *Escherichia coli* for further rounds of selection with increasing concentrations of chloramphenicol.

[0257] A tyrosine analogue with the para hydroxyl group substituted with the methoxy group was used in the selection. Optionally, other tyrosine analogues can also be used in selection, e.g., tyrosine analogues with different functional groups at the para position of the aryl ring (acetyl, amino, carboxyl, isopropyl, methyl, O-methyl and nitro, etc.). For example, the gene encoding  $\text{mtRNA}_{\text{CUA}}^{\text{Tyr}}$  was expressed in *Escherichia coli* DH10B cells under the control of the lpp promoter and rrnC terminator in plasmid pYC-J17, a pACYC184 derivative that also encodes the Asp<sub>112</sub> TAG CAT mutant. Supercoiled DNA encoding the TyrRS library was transformed into *Escherichia coli* DH10B competent cells containing pYC-J17 to yield a library of size greater than  $3 \times 10^9$  cfu, ensuring complete coverage of the original library. Cells were then plated on minimal media plates containing 1% glycerol and 0.3 mM leucine (GMML) with 17  $\mu\text{g/mL}$  tetracycline (Tet), 25  $\mu\text{g/mL}$  kanamycin (Kan), 50  $\mu\text{g/mL}$  of chloramphenicol (Cm), and 1 mM unnatural amino acid. After incubation at 37°C for 44 hours, colonies on plates supplied with O-methyl-L-tyrosine were pooled, plasmids were isolated and retransformed into *Escherichia coli* DH10B competent cells containing pYC-J17, and the transformed cells were positively selected on 50  $\mu\text{g/mL}$  of Cm. Colonies (96) were individually picked from the plate, diluted into 100  $\mu\text{L}$  of liquid GMML media, and streaked onto two sets of Kan/Tet GMML plates with various concentration of Cm. No O-methyl-L-tyrosine was added to plate set 1 and the concentration of Cm was varied from 10 – 25  $\mu\text{g/mL}$ ; plate set 2 contained 1mM O-methyl-L-tyrosine and 50  $\mu\text{g/mL}$  of Cm. Replicates of colonies that did not grow on 15  $\mu\text{g/mL}$  of Cm in plate set 1 were picked from plate set 2. Plasmids containing the TyrRS gene were purified and recombined in vitro by DNA shuffling using Stemmer's protocol with the exception of 10 mM Mn<sup>2+</sup> instead of Mg<sup>2+</sup> in the fragmentation reaction. See, W. P. C. Stemmer, *Nature* 370, 389-91 (1994); and, I. A. Lorimer, I. Pastan, *Nucleic Acids Res.* 23, 3067-8 (1995). The library was then religated into predigested pBK-JYA5 vector to afford a second generation TyrRS library with a typical size of  $8 \times 10^8$  to  $3 \times 10^9$  cfu. Thirty randomly selected members from the library

were sequenced. The mutagenic rate introduced by DNA shuffling was 0.35%. This library was transformed into the selection strain for the next round of selection followed by shuffling. The concentration of Cm in the positive selection and in plate set 2 was raised to 80 µg/mL for the second round and 120 µg/mL for the third round; the concentration of Cm in plate set 1 was unchanged. After three rounds of DNA shuffling, colonies began to grow on 20 – 25 µg/mL Cm in plate set 1, indicating that the TyrRS mutants were accepting natural amino acids as substrates. Therefore, the best clone selected after two rounds of DNA shuffling was characterized in detail.

[0258] Two rounds of selection and DNA shuffling were carried out and a clone was evolved whose survival in chloramphenicol was dependent on the addition of 1mM O-methyl-L-tyrosine to the growth media. In the absence of O-methyl-L-tyrosine, cells harboring the mutant TyrRS were not viable on minimal media plates containing 1% glycerol, 0.3 mM leucine (GMMML), and 15 µg/mL of chloramphenicol. Cells were able to grow on GMMML plates with 125 µg/mL chloramphenicol in the presence of 1mM O-methyl-L-tyrosine. Similar results were obtained in liquid GMMML. As a control, cells with the mtRNA<sup>Tyr</sup><sub>CUA</sub> and the inactive Ala<sub>5</sub> TyrRS did not survive at the lowest concentration of chloramphenicol used, either in the presence or absence of 1mM O-methyl-L-tyrosine. See Figure 14. Addition of 1mM O-methyl-L-tyrosine itself does not significantly affect the growth rate of *Escherichia coli*.

[0259] Analysis of the sequence of the mutant TyrRS that charges the mtRNA<sup>Tyr</sup><sub>CUA</sub> with O-methyl-L-tyrosine revealed the following mutations: Tyr<sup>32</sup>→Gln<sup>32</sup>, Asp<sup>158</sup>→Ala<sup>158</sup>, Glu<sup>107</sup>→Thr<sup>107</sup>, and Leu<sup>162</sup>→Pro<sup>162</sup>. See Figure 14. Based on the x-ray crystal structure of the homologous *B. stearothermophilus* TyrRS, the loss of the hydrogen-bonding network between Tyr<sup>32</sup>, Asp<sup>158</sup> and substrate tyrosine can disfavor binding of tyrosine to the mutant TyrRS. Indeed, mutation of Asp<sup>176</sup> (which corresponds to Asp<sup>158</sup> in *Methanococcus jannaschii*) of *B. stearothermophilus* TyrRS yields inactive enzyme. See, e.g., G.D.P. Gray, H.W. Duckworth, A. R. Fernst, FEBS Lett. 318:167 (1993). At the same time, the Asp<sup>158</sup>→Ala<sup>158</sup> and Leu<sup>162</sup>→Pro<sup>162</sup> mutations create a hydrophobic pocket that allows the methyl group of O-methyl-L-tyrosine to extend further into the substrate-binding cavity. Other important catalytic residues in the active site, which bind to the ribose or the phosphate group of the adenylate, were unchanged after two rounds of DNA shuffling.



[0260] Kinetics of adenylate formation of O-methyl-L-tyrosine and tyrosine with adenosine triphosphate (ATP) catalyzed by the mutant TyrRS were analyzed *in vitro* using a pyrophosphate-exchange assay at 37°C. For example, the mutant TyrRS gene with six histidines at its C-terminus was cloned into plasmid pQE-60 (Qiagen, CA) to generate  
5 plasmid pQE-mJYRS. Protein was purified by immobilized metal affinity chromatography according to manufacture's protocol (Qiagen, CA). Pyrophosphate (PPi) exchange was carried out at 37°C in a reaction mixture containing 100 mM TrisHCl (pH7.5), 10 mM KF, 5 mM MgCl<sub>2</sub>, 2 mM ATP, 2 mM NaPPi, 0.1 mg/mL bovine serum albumin, approximately 0.01 µCi/µL [<sup>32</sup>P]NaPPi, and various concentrations of tyrosine or  
10 O-methyl-L-tyrosine. Reactions were initiated with the addition of the purified mutant TyrRS, and aliquots were periodically taken and quenched with 0.2 M NaPPi, 7% perchloric acid, and 2% activated charcoal. The charcoal was filtered and washed with 10 mM NaPPi (pH2), then measured by scintillation counting to determine the <sup>32</sup>P levels in charcoal-adsorbed ATP. Values of  $k_{cat}$  and  $K_m$  were calculated by direct fitting of the  
15 Michaelis-Menten equation using nonlinear regression analysis.

[0261] The Michaelis constant ( $K_m$ ) for tyrosine (5833 +/- 902 µM) is approximately 13-fold higher than that for O-methyl-L-tyrosine (443 +/- 93 µM), and the catalytic rate constant ( $k_{cat}$ ) for tyrosine ( $1.8 \pm 0.2 \times 10^{-3} \text{ s}^{-1}$ ) is eightfold less than that for O-methyl-L-tyrosine ( $14 \pm 1 \times 10^{-3} \text{ s}^{-1}$ ). Thus, the value of  $k_{cat}/K_m$  of the mutant TyrRS  
20 for O-methyl-L-tyrosine is about 100-fold higher than that of tyrosine. The physiological concentration of tyrosine in *Escherichia coli* is about 80 µM, which is far below  $K_m$  value (5833 µM) of the mutant TyrRS for tyrosine. Presumably, the concentration of O-methyl-L-tyrosine in cells is comparable or greater than the  $K_m$  (443 µM).

[0262] This example shows that it is possible to augment the protein biosynthetic  
25 machinery of *Escherichia coli* to accommodate additional genetically encoded amino acids. The ability to introduce novel amino acids into proteins directly in living cells will provide new tools for studies of protein and cellular function and can lead to generation of proteins with enhanced properties compared to a naturally occurring protein. The methods described here can be applied to other amino acids with novel spectroscopic, chemical,  
30 structural or the like properties. The *Escherichia coli* ribosome has been shown to be able to incorporate amino acids with a wide array of side chains into proteins using *in vitro* protein synthesis. See, e.g., C. J. Noren, S. J. Anthony-Cahill, M. C. Griffith, P. G.

Schultz, Science 244, 182-8 (1989). Additional orthogonal tRNA/synthetase pairs, *see*, e.g., D. R. Liu, P. G. Schultz, Proc. Natl. Acad. Sci. USA 96, 4780-5 (1999); and, A. K. Kowal, C. Kohrer, U.L., RajBhandary, Proc. Natl. Acad. Sci. U.S.A., 98:2268 (2001), as well as four base codons, *see*, e.g., T. J. Magliery, J. C. Anderson, P. G. Schultz, J. Mol. Biol. 307:755 (2001); and, B. Moore, B. C. Persson, C. C. Nelson, R. F. Gesteland, J. F. Atkins, J. Mol. Biol., 298:195 (2000), and other selector codons described herein, can further expand the number and scope of amino acids that can be incorporated. Orthogonal pairs for eukaryotic cells can also be generated by the methods provided herein.

[0263] *See also* corresponding patent application "In vivo Incorporation of Unnatural Amino Acids" attorney docket number 54-000120PC/US which is incorporated herein by reference. This application describes an example of the generation of an O-methyl-L-tyrosine mutant of dihydrofolate reductase (DHFR) using the above-described system.

[0264] **Example 3- Mutating TyrRS so that it charges the mutRNA Tyr/CUA with an unnatural amino acid, L-3-(2-Naphthyl)alanine**

[0265] This example provides another orthogonal pair that can be used to incorporate a second unnatural amino acid, L-3-(2-Naphthyl)alanine into proteins in an organism, e.g., *Escherichia coli*. An example of the methods used to generate the orthogonal pair that incorporates the unnatural amino acid into proteins is described below. More details describing the incorporation of the unnatural amino acid into a protein can be found in corresponding patent application "In vivo incorporation of unnatural amino acid" attorney docket number 54-000120PC/US incorporated herein by reference.

[0266] An amber stop codon and its corresponding orthogonal amber suppressor tRNA, mu tRNA<sup>Tyr</sup><sub>CUA</sub>, were selected to encode an unnatural amino acid. As described above, and *see* Wang & Schultz, Chem. Biol. 8:883-890 (2001). The *Methanococcus jannaschii* tyrosyl-tRNA synthetase (TyrRS) was used as the starting point for the generation of an orthogonal synthetase with unnatural amino acid specificity. This TyrRS does not aminoacylate any endogenous *Escherichia coli* tRNAs, *see*, e.g., Steer & Schimmel, J. Biol. Chem., 274:35601-35606 (1999), but aminoacylates the mu tRNA<sup>Tyr</sup><sub>CUA</sub> with tyrosine. *See*, e.g., Wang, Magliery, Liu, Schultz, J. Am. Chem. Soc., 122:5010-5011 (2000). L-3-(2-naphthyl)-alanine was chosen for this study since it represents a significant structural

perturbation from tyrosine and may have novel packing properties. To change the amino acid specificity of the TyrRS so that it charges the mu tRNA<sup>Tyr</sup><sub>CUA</sub> with L-3-(2-naphthyl)-alanine and not any common 20 amino acids, a library of *Methanococcus jannaschii* TyrRS mutants was generated and screened. On the basis of an analysis of the crystal structure of the homologous TyrRS from *Bacillus stearothermophilus*, see, Brick, Bhat, Blow, J. Mol. Biol., 208:83-98 (1989), five residues (Tyr<sup>32</sup>, Asp<sup>158</sup>, Ile<sup>159</sup>, Leu<sup>162</sup>, and Ala<sup>167</sup>) in the active site of *Methanococcus jannaschii* TyrRS that are within 7 Å of the para position of the aryl ring of tyrosine were mutated. See Figure 15. No synthetases specific for L-3-(2-naphthyl)alanine were selected from the mutant TyrRS library reported in Wang, Brock, Herberich, Schultz, Science, 292:498-500 (2001). To reduce the wild-type synthetase contamination in the following selection, these residues (except Ala<sup>167</sup>) were first all mutated to alanine. The resulting inactive Ala<sub>5</sub> TyrRS gene was used as a template for polymerase chain reaction (PCR) random mutagenesis with oligonucleotides bearing random mutations at the corresponding sites.

[0267] The mutant TyrRS library was first passed through a positive selection based on suppression of an amber stop codon at a nonessential position (Asp<sup>112</sup>) in the chloramphenicol acetyltransferase (CAT) gene. Cells transformed with the mutant TyrRS library and the mu tRNA<sup>Tyr</sup><sub>CUA</sub> gene were grown in minimal media containing 1 mM L-3-(2-naphthyl)-alanine and 80 µg/mL chloramphenicol. Cells can survive only if a mutant TyrRS aminoacylates the mu tRNA<sup>Tyr</sup><sub>CUA</sub> with either natural amino acids or L-3-(2-naphthyl)-alanine. The surviving cells were then grown in the presence of chloramphenicol and the absence of the unnatural amino acid. Those cells that did not survive must encode a mutant TyrRS that charges the mu tRNA<sup>Tyr</sup><sub>CUA</sub> with L-3-(2-naphthyl)-alanine, and were picked from a replica plate supplied with the unnatural amino acid. After three rounds of positive selection followed by a negative screen, four TyrRS's were characterized using an in vivo assay based on the suppression of the Asp<sup>112</sup>TAG codon in the CAT gene.

[0268] Table 4 In vivo chloramphenicol acetyltransferase assay of mutant TyrRS.<sup>a</sup>

Mutant TyrRS	IC <sub>50</sub> (µg/mL of chloramphenicol)	
	No L-3-(2-naphthyl)-Ala	Add L-3-(2-naphthyl)-Ala

no TyrRS	4	4
wt TyrRS	240	240

*After selection*

5	S1-TyrRS	30	120
	S2-TyrRS	30	120
	S3-TyrRS	25	110
	S4-TyrRS	35	100

*After DNA shuffling*

SS12-TyrRS	9	150
------------	---	-----

10 <sup>a</sup> A pYC-J17 plasmid was used to express the mu tRNA<sup>Tyr</sup><sub>CUA</sub> gene and the chloramphenicol acetyltransferase gene with an amber stop codon at Asp112. A pBK plasmid was used to express TyrRS, and was cotransformed with pYC-J17 into *Escherichia coli* DH10B. Cell survival on GMML plates was titrated in the presence of different concentrations of chloramphenicol.

15 [0269] In the absence of L-3-(2-naphthyl)-alanine, cells expressing the selected TyrRS and the mu tRNA<sup>Tyr</sup><sub>CUA</sub> survived in 25 to 35 µg/mL chloramphenicol on minimal media plates containing 1% glycerol and 0.3 mM leucine (GMML plate); in the presence of L-3-(2-naphthyl)-alanine, cells survived in 100 to 120 µg/mL chloramphenicol on GMML plates. Compared to the IC<sub>50</sub> value in the absence of any TyrRS (4 µg/mL  
20 chloramphenicol), these results indicate that the selected TyrRS's accept L-3-(2-naphthyl)-alanine, but also still charge natural amino acids to some degree. See Table 4 above.

[0270] To further reduce the activity of the mutant TyrRS toward natural amino acids, one round of DNA shuffling was carried out using the above four mutant genes as templates. The resulting mutant TyrRS library was passed through two additional rounds  
25 of positive selections and negative screens. One mutant TyrRS (SS12-TyrRS) was evolved, whose activity for natural amino acids was greatly reduced (IC<sub>50</sub>=9 µg/mL chloramphenicol) while its activity toward L-3-(2-naphthyl)-alanine was enhanced (IC<sub>50</sub>=150 µg/mL chloramphenicol). See Table 4.

[0271] The evolved SS12-TyrRS has the following mutations: Tyr<sup>32</sup>→Leu<sup>32</sup>, Asp<sup>158</sup>→Pro<sup>158</sup>, Ile<sup>159</sup>→Ala<sup>159</sup>, Leu<sup>162</sup>→Gln<sup>162</sup>, and Ala<sup>167</sup>→Val<sup>167</sup>. See Figure 15. Based on the crystal structure of the homologous *B. stearothermophilus* TyrRS, the mutations of Tyr<sup>32</sup>→Leu<sup>32</sup> and Asp<sup>158</sup>→Pro<sup>158</sup> can result in the loss of hydrogen bonds between Tyr<sup>32</sup>, Asp<sup>158</sup>, and the native substrate tyrosine, thus disfavoring the binding of tyrosine to SS12-TyrRS. Most residues are mutated to amino acids with hydrophobic side chains, which are expected to favor binding of L-3-(2-naphthyl)-alanine. The crystal structure of the wild-type *Methanococcus jannaschii* TyrRS and the evolved SS12-TyrRS can be determined by available methods.

10 [0272] The mu tRNA<sup>Tyr</sup><sub>CUA</sub>/SS12-TyrRS pair was capable of selectively inserting L-3-(2-naphthyl)-alanine into proteins in response to the amber codon with fidelity rivaling that of the natural amino acids based on cell growth, protein expression and mass spectrometry examples described herein and in corresponding application "In vivo incorporation of unnatural amino acids" attorney docket number 54-000120PC/US. See also, Wang, Brock, and Schultz, *Adding L-3-(2-Naphthyl)alanine to the genetic code of E. coli*, *J. Am. Chem Soc.*, (2002) 124(9):1836-7. This result, which involves an amino acid that is structurally distinct from tyrosine, confirms that the methods described herein are generalizable to a variety of unnatural amino acids.

[0273] **Example 4- Mutating TyrRS so that it charges the mutRNA Tyr/CUA and screening for the mutated TyrRS with the desired properties by other methods, e.g., FACs and Phage display and panning**

[0274] Orthogonal pairs can also be selected by using reporter genes and proteins as described above, along with in vivo FACS screening, antibody detection, in vitro phage display and panning, or the like. See, Wang & Schultz, *Expanding the genetic code*, *Chem. Commun.*, 1:1-11 (2002).

[0275] For example, a general fluorescence-activated cell sorting (FACS) based screen has been developed with, e.g., green fluorescent protein (GFP) as the reporter, to screen for synthetases. See Figure 16, Panel A, and Panel B Synthetase activity is reported by suppression of the selector codon, e.g., an amber stop codon (TAG) within T7 RNA polymerase, which drives the expression of GFP. See, e.g., Figure 26 for another example of selection/screening methods of the invention. Only when the amber codons are suppressed can cells produce functional T7 RNA polymerase and express GFP,

rendering cells fluorescent. In the positive screen, fluorescent cells are collected which encode active synthetases charging the orthogonal tRNA with either natural or unnatural amino acids. The selected cells are then diluted and grown in the absence of the unnatural amino acid, and then sorted by FACS for cells without fluorescence, e.g., that express synthetases with specificities for unnatural amino acids only. **Figure 17, Panel A, Panel B Panel C and Panel D** illustrates suppression of a selector codon, e.g., an amber codon, using glutamine synthetase. By setting the collection threshold of the fluorescence intensity, the stringency of both positive and negative screen can be conveniently controlled.

10 **[0276]** A direct positive selection specific for a particular unnatural amino acid has also been developed which exploits the high affinity of a monoclonal antibody for an unnatural amino acid displayed on a phage surface. See **Figure 18**. See, M. Pastnak and P. G. Schultz, Bioorg. Med. Chem., 9:2373 (2001). For example, a C3 peptide with an amber mutation is fused to the N-terminus of VSCM13 phage coat protein pIII, such that  
15 phage production requires suppression of the amber stop codon. Cells harboring a phagemid that expresses an orthogonal suppressor tRNA and a synthetase library are infected with the C3TAG phage. An active synthetase results in suppression of C3TAG and display of its cognate amino acid on the phage surface. The phage pool is then incubated with immobilized monoclonal antibodies directed against the unnatural amino  
20 acid to isolate only those phage carrying the synthetase specific for the unnatural amino acid. In a simulated selection, phage displaying Asp were enriched over 300-fold from a pool of phage displaying Asn using antibodies raised against the Asp-containing epitope.

**[0277]** Several in vitro screen methods can also be used. In one such method, a library of mutant synthetases is displayed on the phage, and the phage particles are panned  
25 against immobilized aminoalkyl adenylate analogs of the aminoacyl adenylate intermediate. See **Figure 19**. For example, *Methanococcus jannaschii* TyrRS was fused to the pIII coat protein of M13 phage. This phage was enriched 1000-fold over a control phage displaying an unrelated antibody after panning against the aminoalkyl adenylate analog of tyrosyl adenylate. Given that only 0.1 to 1% of the starting TyrRS phage  
30 population displays the TyrRS protein, the actual enrichment factor can be as high as  $10^5$  to  $10^6$ .

**[0278]** **Example 5- Generating an archaeal leucyl-tRNA synthetase pair**

[0279] A leucyl-tRNA synthetase from an archaeobacterium, *Methanobacterium thermoautotrophicum*, was identified that can aminoacylate amber and frameshift suppressor tRNAs derived from archaeal leucyl tRNAs, but does not aminoacylate any tRNAs native to *Escherichia coli*. Using a selection strategy described in the present invention, highly active tRNA substrates were identified that are selectively charged by the synthetase. Mutant libraries of synthetases can be generated and selected for that are capable of selectively charging unnatural amino acids.

[0280]  $\beta$ -lactamase reporter genes were constructed with amber codons and suppressor tRNAs derived from five different archaeal leucyl tRNAs for which the anticodon was replaced with a CUA anticodon to make amber suppressor tRNAs. Seven different leucyl tRNA synthetases were cloned and were cotransformed with reporter constructs. Three synthetases gave higher levels of survival on ampicillin in the presence of the synthetase than controls lacking synthetase, and these systems were examined further. See, Figure 20.

[0281] The next step involved determination of a synthetase that charges the suppressor tRNA without interacting with host tRNA. The two chosen systems, *Methanobacterium thermoautotrophicum* and *Methanococcus jannaschii* were expressed, and aminoacylation was performed in vitro on purified tRNA from *Halobacterium* as a positive control, and for *Escherichia coli* total tRNA. It was found that the *Methanococcus jannaschii* synthetase was able to effectively charge *Escherichia coli* tRNA, but the *Methanobacterium thermoautotrophicum* synthetase was specific towards the *Halobacterium* tRNA.

[0282] Further improvements were made to increase the efficiency of the suppression system. The A<sup>37</sup> site of the anticodon loop was a G<sup>37</sup> in the leucyl tRNA synthetases. This mutation has been shown to be a negative determinant against aminoacylation by non-cognate synthetases in various eukaryotic cells and *Halobacterium*, and also a positive determinate for aminoacylation in yeast, but not in *Halobacterium*. A<sup>37</sup> was also shown to be a key requirement for efficient suppression. The anticodon loop was randomly mutagenized and selected for more efficient suppression. Mutating G<sup>37</sup> to A, resulted in a more efficient suppressor, which could suppress 20 fold higher concentrations of ampicillin compared to the un-mutated version. See, Figure 21.

[0283] To improve the tRNA so that is not preferentially charged by other synthetases in *Escherichia coli*, the acceptor stem of the tRNA was randomly mutagenized. A positive/negative selection was used to identify tRNAs that would not be charged in the absence of *Methanobacterium thermoautotrophicum* RS.

- 5 [0284] Amongst the selected mutated tRNAs observed, all conserved the discriminator base, A<sup>73</sup>, which has been shown in all previous systems to be a critical positive determinate for leucyl aminoacylation. Also conserved was a C<sup>3</sup>:G<sup>70</sup> base pair amongst all hits that had improved orthogonality. The best mutant tRNA observed gave about a 3-fold decrease in aminoacylation without synthetase and actually an increase in  
10 suppression in the presence of *Methanobacterium thermoautotrophicum* RS.

- [0285] Variants were also made that could suppress four-base codons instead of, e.g., three base codons. Four base codons offer the possibility of decoding the genetic code four bases at a time, for which 256 things could be encoded rather than 3 at a time, where only 64 amino acids can be encoded. The difficulty with using four-base codons is  
15 that they require expansion of the anticodon loop for the tRNA, a perturbation which most systems are unlikely to accept. However, a first generation AGGA suppressor for the leucyl system was identified. This was generated by randomly mutagenizing the anticodon loop with 8 bases and performing selection with an AGGA- $\beta$ -lactamase reporter system. See Figure 22.

- 20 [0286] The editing mechanism of the synthetase was also mutated to eliminate the editing function. The leucyl system, like several other synthetases has (at least) two active sites. One site performs activation of the amino acid with ATP to form an enzyme bound aminoacyl adenylate in complex with the synthetase, and then transfer of the amino acid onto the 3' terminus of the tRNA. A second site, however, is able to hydrolyze the amino  
25 acid from the tRNA if it is not leucine. The leucine system is known to perform this post-transfer editing function for methionine and isoleucine, and it optionally does this to unnatural amino acids as well.

- [0287] Initially, the editing domain was deleted. The editing domain was replaced with a library of 6 tandem random amino acids. A positive selection was used, which was  
30 based on suppression of a stop codon in  $\beta$ -lactamase. Many functional synthetases were obtained, but upon trying to purify the synthetases, no material in any cases could be



detected, and all of these synthetases displayed a temperature sensitive phenotype suggesting that the deletion of the editing domain resulted in a less stable protein.

[0288] Next, point mutations were made in the editing domain. The catalytic core of the editing domain is well conserved across species and even for different amino acids, at least for the family of branched chain amino acids. Several of these conserved sites have previously been mutated, for example a T→P mutation, and found to knock out editing function. Mutants of *Methanobacterium thermoautotrophicum* RS were constructed that were similar to several known mutants, and also a 20 member NNK library derived from T214 was made. Proteins were expressed and examined in vitro for aminoacylation with leucine and methionine. None of the previously identified mutations were transferable to our system, but a desirable mutation was identified from the T214 library. Two mutants were identified that were capable of charging with leucine, T214S and T214Q. Of these mutations, only T214Q was capable of charging methionine. The T214S mutant apparently retains the ability to edit out methionine whereas the Gln mutant has lost this function.

[0289] A library was then designed based on the crystal structure that has been solved for the *Thermus thermophilus* leucyl synthetase. The leucine side chain of the leucine aminoalkyl adenylate analog adenosine inhibitor was bound in the active site. Six sites surrounding the leucine side chain-binding pocket were replaced with randomized amino acids to create a larger library. The synthetases from this library can then be screened, e.g., by performing positive/negative double sieve selections, to identify synthetases capable of charging unnatural amino acids selectively.

[0290] **Example 6- Identification of tRNAs that efficiently suppress four-base codons**

[0291] A combinatorial approach was used to identify mutated tRNAs that efficiently suppress four-base codons. See, T. J. Magliery, J. C. Anderson and P. G. Schultz, J. Mol. Biol., 307:755 (2001). A reporter library was constructed in which a serine codon in the β-lactamase gene was replaced by four random nucleotides. A mutated tRNA, e.g., suppressor tRNA, suppressor library was then generated that consists of derivatives of *Escherichia coli* with the anticodon loop (7 nt) replaced with eight or nine random nucleotides. When these two libraries are crossed, an appropriate frameshift suppressor tRNA that decodes the four-base sequence as a single codon results in

translation of full-length  $\beta$ -lactamase, rendering the cells resistant to ampicillin. Survival at higher concentrations of ampicillin indicates that the corresponding tRNA has higher suppression efficiency for the four-base codon. Using this selection, four quadruplet codons AGGA, CUAG, UAGA, and CCCU and their cognate suppressor tRNAs were identified that decode only the canonical four-base codon with efficiencies close to that of natural triplet codon suppressors. Novel five- and six-base codon suppressors have also been selected using this strategy. *See*, Anderson, Magliery, Schultz, *Exploring the Limits of Codon and Anticodon Size*, Chemistry & Biology, 9:237-244 (2002). These extended codons, some of which are newly identified, can be useful for the incorporation of multiple unnatural amino acids in vitro and for in vivo protein mutagenesis.

**[0292] Example 7- Generation of an orthogonal tRNA-synthetase for *p*-aminophenylalanine**

**[0293]** To generate an orthogonal synthetase pair for *p*-aminophenylalanine (pAF), the *Methanococcus jannaschii* tyrosyl-tRNA synthetase (TyrRS) and mutant tyrosine amber suppressor tRNA (TyrCUA mutRNA ) pair were used as a starting point. *See*, Wang, L., Magliery, T. J., Liu, D. R. & Schultz, P. G. *A new functional suppressor tRNA/aminoacyl-tRNA synthetase pair for the in vivo incorporation of unnatural amino acids into proteins*. J. Am. Chem. Soc. 122:5010-5011 (2000); and, Wang, L. & Schultz, P. G. Chem. and Biol. 8:883 (2001). The pAF specific synthetase (pAFRS) was generated by modifying the amino acid specificity of the *Methanococcus jannaschii* TyrRS to accept pAF and not any of the common twenty amino acids. A combination of positive selections and negative screens was used to identify the pAFRS enzyme from a library of TyrRS variants 12 containing random amino acids at five positions (Tyr<sup>32</sup>, Glu<sup>107</sup>, Asp<sup>158</sup>, Ile<sup>159</sup>, and Leu<sup>162</sup>). *See*, Wang, L., Brock, A., Herberich, B. & Schultz, P. G. *Expanding the genetic code of Escherichia coli*. Science 292:498-500 (2001). A single reporter plasmid was used for both selection and screening. For example, the reporter plasmid is pREP(2)/YC-JYCUA, which contains the genes for CAT, T7 RNA polymerase, GFP, and TyrCUA mutRNA, and a selectable marker for Tet resistance. The CAT gene contains a TAG codon substitution at position D112. The T7 RNA polymerase gene contains a seven-amino acid N-terminal leader peptide and TAG substitutions at M1 and Q107.

**[0294]** The positive selection is based on suppression of a TAG codon at a permissive position within the chloramphenicol acetyltransferase (CAT) gene by either

pAF or an endogenous amino acid. See, e.g., Wang et al. (2001), *supra*; and, Pastrnak, M., Magliery, T. J. & Schultz, P. G. *A new orthogonal suppressor tRNA/aminoacyl-tRNA synthetase pair for evolving an organism with an expanded genetic code*. Helvetica Chimica Acta 83:2277 (2000). Cells containing the TyrRS library and reporter plasmid  
5 were grown in liquid culture containing pAF and selected for survival in the presence of chloramphenicol (Cm). For example, for the positive selection, cells were grown in GMML minimal media containing 35  $\mu\text{g/ml}$  Kn, 25  $\mu\text{g/ml}$  Tet, 75  $\mu\text{g/ml}$  Cm, and 1mM pAF (Sigma).

[0295] The negative screen is based on the inability to suppress in the absence of  
10 pAF two TAG stop codons at permissive positions within the T7 RNA polymerase gene. Expression of full length T7 RNA polymerase drives expression of green fluorescent protein (GFP). Cells from the positive selection were grown in the absence of pAF and Cm, and then screened using fluorescence activated cell sorting (FACS) for a lack of fluorescence. For example, for the negative screen, cells were grown in GMML media  
15 containing 35  $\mu\text{g/ml}$  Kn, 25  $\mu\text{g/ml}$  Tet, and 0.002 % arabinose. FACS was carried out using a BDIS FACVantage TSO cell sorter with a Coherent Enterprise II ion laser. The excitation wavelength was 351 nm and emission was detected using a 575/25 nm bandpass filter. Collected cells were diluted into at least 10 volumes of LB, containing Tet and Kn, and grown to saturation.

20 [0296] The desired pAFRS was identified following two rounds of positive selection in liquid media, one round of negative screening, another round of positive selection in liquid media, and one round of positive selection on plates. The pAFRS enzyme contains five mutations relative to the wild type TyrRS (Y32T, E107T, D158P, I159L, and L162A). In the absence of pAF, the  $\text{IC}_{50}$  of cells expressing the selected  
25 pAFRS and reporter plasmid was 10  $\mu\text{g/ml}$  Cm on GMML minimal media plates. The  $\text{Ic}_{50}$  was 120  $\mu\text{g/ml}$  Cm with 1 mM pAF. Thus, pAF is selectively suppressing the UAG codon.

[0297] **Example 8-Evolution of an Aminoacyl-tRNA Synthetase using fluorescence-activated cell sorting.**

30 [0298] A FACS based screening system was used to rapidly evolve three highly selective synthetase variants that accept amino-, isopropyl-, or allyl-containing tyrosine analogues. The system included a multipurpose reporter plasmid used for application of

both positive and negative selection pressure and for the facile and quantitative evaluation of synthetase activity. A chloramphenicol acetyl transferase (CAT) marker allowed positive selection for activity of the *M. jannaschii* tyrosyl-tRNA synthetase (TyrRS). A T7 polymerase/GFP reporter system allowed assessment of synthetase activity within cells  
5 grown in both the presence and absence of an unnatural amino acid. Fluorescence activated cell sorting (FACS) was used to screen against synthetase variants that accept natural amino acids, while visual and fluorimetric analyses were to assess synthetase activity qualitatively and quantitatively, respectively.

[0299]       **Design of an amplifiable fluorescence reporter system.** Efforts to  
10 develop a versatile screening system for the assessment of synthetase activity in living cells initially arose out of a desire for a greater degree of control over the selective pressure applied to populations of synthetase variants, especially negative selective pressure. As the system was to be used to assess the activities of large numbers of synthetase variants, a reporter was sought that would be amenable to high-throughput  
15 screening. In addition, a reporter that would allow for facile qualitative and quantitative evaluation of synthetase activity was desired. To meet these requirements, a fluorescence-based screen was designed. The system was based on the synthetase-dependent production of GFPuv, a variant of the green fluorescent protein that has been optimized for expression in *E. coli* (*see*, Cramer, A., Whitehorn, E. A., Tate, E. & Stemmer, W. P.,  
20 Nature Biotechnol. 1996, 14, 315-319). This fluorophore is amenable to use in FACS and fluorimetry, as well as visual inspection on plates and in liquid culture. The system was designed such that synthetase-dependent suppression of selector, e.g., amber nonsense codons would result in the production of a fluorescence signal. In order to maximize the sensitivity of the reporter, it was made amplifiable by placement of the amber codons  
25 within the gene for T7 RNA polymerase, which was designed to drive expression of the GFPuv reporter gene in analogy to other amplifiable intracellular reporter systems (*see*, Lorincz, M., Roederer, M., Diwu, Z., Herzenberg, L. A., Nolan, G. P. Cytometry, 1996, 24, 321-329; and Zlokarnik, G., Negulescu, P. A., Knapp, T. E., Mere, L., Burres, N., Feng, L., Whitney, M., Roemer, K. & Tsien, R. Y., Science, 1998, 279, 84-88). The T7  
30 RNA polymerase gene was placed under control of the arabinose promoter in order to allow facile optimization of the production of the RNA transcript for amber codon-containing T7 RNA polymerase.

[0300]       **Optimization of the T7 RNA polymerase/GFPuv reporter system.** A medium-copy reporter plasmid, pREP, was designed to express amber-containing T7 RNA polymerase variants under control of the arabinose promoter and the GFPuv gene under control of the T7 promoter (Figure 17a). A series of twelve T7 RNA polymerase variants, designed to optimize synthetase-dependent fluorescence enhancement (Figure 17b), were inserted into pREP to create plasmids pREP(1–12). All variants contained an N-terminal leader sequence of seven amino acids (MTMITVH) and 1–3 amber stop codons (TAG). Variants 1–3 contained one, two, and three amber stop codons, respectively, substituted for the original methionine at position one (M1), just downstream of the leader sequence. Variants 4–9 contained an amber codon substituted for D10, R96, Q107, A159, Q169, or Q232, respectively, which were predicted to be located in loop regions of the structure (see, Jeruzalmi, D. & Steitz, T. A., EMBO J., 1998, 17, 4101–4113). Variants 10–12 contained amber stop codons substituted at positions M1 and either Q107, A159, or Q232, respectively. Plasmid constructs were evaluated by fluorimetry and flow cytometry of live cells for fluorescence enhancement using a compatible plasmid containing the orthogonal glutamyl-tRNA synthetase and Glutamine tRNA<sub>CUA</sub> from *S. cerevisiae*. Plasmids pREP(1–12) were found to provide varying levels of synthetase-dependent fluorescence enhancement, with the best construct, pREP(10) exhibiting 220-fold greater fluorescence by fluorimetry (Figure 17c) and ~400-fold greater median fluorescence by cytometry (Figure 17d) in cells containing the wild type synthetase versus an inactive mutant. Substitution of a variety of functional groups at positions corresponding to the amber codons within pREP(10) demonstrate that position 107 within T7 RNA polymerase is highly permissive.

[0301]       **Construction of a multipurpose reporter plasmid.** In order to construct a multipurpose plasmid to be used both for selecting and screening variants of a *M. jannaschii* TyrRS, plasmid pREP(10) was combined with plasmid pYC-J17 (see, Wang, L, Brock, A., Herberich, B. & Schultz, P. G., Science, 2001, 292, 498–500) to obtain pREP/YC-JYCUA (Figure 25a). Plasmid pREP/YC-JYCUA was assayed for function with a compatible plasmid expressing a variant of *M. jannaschii* TyrRS (pBK-mJYRS; Wang, L, Brock, A., Herberich, B. & Schultz, P. G., Science, 2001, 292, 498–500) selective for incorporating *O*-Methyl-Tyrosine (OMY). Cells containing pREP/YC-JYCUA and pBK-mJYRS, grown in the presence of OMY, exhibited a chloramphenicol (Cm) IC<sub>50</sub> value of 120 µg/µl, identical to that obtained using plasmid pYC-J17, and a

fluorescence enhancement of 330-fold for cells grown in the presence versus the absence of OMY, as measured by fluorimetry.

[0302]       **Evolution of the substrate specificity of the *M. jannaschii* tyrosyl-tRNA synthetase.** Results have shown that the amino acid side chain binding pocket of the *M. jannaschii* TyrRS can be evolved to selectively accommodate chemical groups other than the phenol side chain of tyrosine (*see*, Wang, L, Brock, A., Herberich, B. & Schultz, P. G., *Science*, 2001, 292, 498-500; Wang, L., Brock, A. & Schultz, P. G. *J. Am. Chem. Soc.* 2002, 124, 1836-1837). We sought to further explore the generality of unnatural amino acid accommodation by *M. jannaschii* TyrRS by challenging the enzyme to accept four new functionalities: *p*-Isopropyl-Phenylalanine (*p*IF), *p*-Amino-Phenylalanine (*p*AF), *p*-Carboxyl-Phenylalanine (*p*CF), or *O*-Allyl-Tyrosine (*O*AT) (**Figure 25b**). A library of *M. jannaschii* TyrRS variants containing randomizations at positions Y32, E107, D158, I159, and L162 (Wang, L, Brock, A., Herberich, B. & Schultz, P. G., *Science*, 2001, 292, 498-500), residues thought to form the binding pocket for the *para* position of the tyrosyl ring, was introduced into cells containing plasmid pREP/YC-JYCUA. These cells, encompassing a library diversity of  $\sim 10^9$ , were used to begin four evolution experiments to identify synthetase variants selective for *p*IF, *p*AF, *p*CF, or *O*AT (**Figure 25b**). Two cycles of positive selection were carried out by allowing the cell cultures to grow to saturation in the presence of Cm and one of the four unnatural amino acids. Cell aliquots were removed following the second cycle of positive selection and used to inoculate a new culture containing no added amino acid or Cm, and the culture was again allowed to grow to saturation. At this point, cells that fluoresce are likely to contain synthetase variants that can accept one of the 20 natural amino acids. Approximately  $10^8$  cells from each line were subjected to negative screening using FACS in order to eliminate natural amino acid-accepting synthetase variants. The non-fluorescent cells were collected and amplified through growth to saturation. These amplified cells were used to inoculate a new culture for a final cycle of positive selection in liquid culture containing unnatural amino acid and Cm. Following growth to saturation, each population of cells was plated on media containing 0, 30, 60, or 100  $\mu$ g/mL Cm and either 0 or 1 mM of the appropriate unnatural amino acid.

[0303]       **Identification and characterization of evolved synthetase variants.** Cm plates supplemented with *p*IF, *p*AF, and *O*AT produced 10–100-fold greater numbers of

fluorescent colonies than plates containing no added amino acid. In contrast, plates for the *pCF* population produced the same number of fluorescent colonies with or without addition of *pCF*. The ten largest fluorescent colonies were picked for each of the *pIF*, *pAF*, and *OAT* populations from unnatural amino acid-containing plates and grown to saturation in liquid media with or without added unnatural amino acid. A qualitative assessment of fluorescence production was made visually with the use of a hand-held long-wavelength ultraviolet lamp (Figure 23a).

[0304] Synthetase variants corresponding to clones producing significant differences in fluorescence were sequenced. All ten clones from the *pIF* and *pAF* populations had identical sequences, while three different clones were identified from the *OAT* population. Amino acid changes occurred within the five randomized sites in all clones, with the exception of two additional substitutions within the *pIF*-tRNA synthetase (*pIF*-RS) variant. The activities of the different clones were quantitatively assessed. Fluorescence was measured fluorimetrically for cells grown in liquid culture in the presence or absence of unnatural amino acid (Figure 23b). The  $Cm$   $IC_{50}$ s were determined by plating the cells on varying concentrations of  $Cm$  in the presence or absence of unnatural amino acid (Figure 23c).

[0305] A myoglobin gene containing an amber codon in the fourth position was used to assess the production of unnatural amino acid-containing protein. The gene was expressed in cells, using the *pIF*-RS, *pAF*-RS, or *OMY*-RS variant, respectively, in either the presence or absence of *pIF*, *pAF*, or *OAT* (Figure 23d). Protein yields were comparable for all three variants, ranging from 1–2 milligrams of protein per liter of unnatural amino acid-containing cell culture. In contrast, protein production was virtually undetectable in cultures grown in the absence of unnatural amino acid. Proteins were analyzed by electrospray mass spectrometry, giving masses of  $18457.40 \pm 0.81$  (18457.28 expected) for the *pIF*-containing protein, and  $18430.30 \pm 0.27$  (18430.21 expected) for the *pAF*-containing protein. Activity measurements obtained using the  $Cm$   $IC_{50}$ , fluorimetry, and protein expression analyses correlated well, however the activity of the *pIF*-RS appears to be somewhat underestimated by fluorimetry. As compared to other assays, the disproportionately low fluorimetry measurement for the *pIF*-RS variant, suggests that T7 RNA polymerase may be partially destabilized upon incorporation of the *pIF* analogue,

despite the apparent permissivity of the amber positions within the reporter (*see*, Figure 17c).

[0306]       **Utility of the multipurpose reporter system.** The reporter system described here allows the use of a single multipurpose plasmid for both positive selection and negative screening, obviating the need to shuttle plasmids between alternating rounds of positive and negative selection. A total of only three rounds of positive selection and one round of negative screening were required to enable the identification of synthetase variants that selectively accept desired unnatural amino acids. These features allow evolution experiments to be carried out in a matter of days. The screening system can be used to readily identify active synthetase variants using agar plates containing unnatural amino acid and to individually assay the amino acid specificity of the variants.

[0307]       As described above, the T7 RNA polymerase/GFP system can be used to quantitatively compare the activities of synthetase variants. The availability of the three OAT-RS clones described here and a different OAT-RS clone derived independently from the same library using a positive/negative selection based on CAT and barnase allows the possibility of comparing the two different evolution systems in terms of the synthetase variants resulting from each. This analysis reveals that the three clones derived from positive selection and negative screening exhibit slightly lower levels of fluorescence in the presence of OAT, but ~10-fold lower background levels in the absence of the unnatural amino acid. The fluorescence enhancement for cells grown in the presence versus the absence of the unnatural amino acid is thus about 6-fold higher for cells expressing OAT-RS(1) from selection and screening than for cells expressing the OAT-RS clone derived from positive/negative selection using barnase. Although it is not clear whether this example is representative, these data suggest that the T7 RNA polymerase/GFP system may allow more stringency in selecting against synthetase variants that are promiscuous towards natural amino acid substrates. However, the fluorescence enhancement for cells grown in the presence versus the absence of an unnatural amino acid is expected to represent a lower limit for the fidelity of unnatural amino acid incorporation, as competition of unnatural amino acids for being bound by an evolved synthetase variant would reduce binding of natural amino acids. Moreover, although high fidelity is clearly desirable, there is likely to be a trade-off between fidelity and overall synthetase activity, which may depend on the desired application.



[0308]       **Generality of aminoacyl tRNA synthetase evolution.** Previous results and those presented here demonstrate that the amino acid side chain binding pocket of the *M. jannaschii* TyrRS is quite malleable. The enzyme can be evolved to accommodate a variety of functionalities in place of the phenol side chain of tyrosine and can do so with high selectivity. In this application it was demonstrated that enzyme can be evolved to accommodate an amine, isopropyl, or allyl ether functionality at the *para* position of the tyrosine ring, instead of hydroxyl. It was not possible to identify an enzyme variant that could accept the *p*CF unnatural amino acid. A second attempt to evolve a synthetase to accept the *p*CF amino acid was also unsuccessful. Using LC/MS analysis, *p*CF could not be detected upon toluenization of *E. coli* cells grown in the presence of the unnatural amino acid, suggesting that *p*CF is not transported into cells or that it is metabolized upon entry.

[0309]       Of the three successful evolution experiments described here, only the evolution of the OAT-RS resulted in the identification of more than one active clone. The OAT-RS evolution was also the experiment that produced the most active synthetase variant. These results suggest that some amino acid specificities may be easier to select for than others. This could be due, in part, to the relative difficulty of selectively recognizing different unnatural amino acids in the context of the 20 natural amino acids. It may be, for example, that *p*AF, due to its structural and electronic similarities to tyrosine, is more difficult to selectively recognize than OAT. This would explain why a greater number of OAT-RS clones were identified than *p*AF-RS clones and why the *p*AF-RS clone is less active than the best OAT-RS clone.

[0310]       **Plasmid Construction.** Plasmid pREP (Figure 17a) was constructed by insertion of a *Bam*HI/*Apa*LI overlap PCR fragment containing the T7 RNA polymerase gene upstream of an *rrnB* transcription termination region, followed by an *Apa*LI/*Ahd*I overlap PCR fragment containing the *araC* gene and *ara* promoter region from the pBAD/*Myc*-His A plasmid (Invitrogen; for transcriptional control of the T7 RNA polymerase gene) and the GFPuv gene (Clontech; upstream of the T7 terminator region and downstream of the T7 promoter) between the *Ahd*I/*Bam*HI sites of plasmid pACYC177 (New England Biolabs). Plasmids pREP(1-12) were constructed by replacement of an *Hpa*I/*Apa*LI fragment of T7 RNA polymerase with overlap PCR fragments containing amber mutations at the positions described. Plasmid pREP/YC-

JYCUA was constructed by ligation of an *AfeI/SacII* fragment from pREP(10) and an *EarI*(blunted)/*SacII* fragment from pYC-J17 (Wang, L, Brock, A., Herberich, B. & Schultz, P. G., Science, 2001, 292, 498-500). The desired construct was identified following transformation into cells containing plasmid pQ screening for fluorescence.

- 5 [0311] Plasmid pQ was constructed by triple ligation of a *AatII/SalI* overlap PCR fragment containing the *ScQRS* downstream of the *lac* promoter region and upstream of the *E. coli* QRS termination region, a *SalI/AvaI* overlap PCR fragment containing the *S. cerevisiae* tRNA(CUA)<sup>Gln</sup> downstream of the *lpp* promoter region and upstream of an *rrnC* termination region, and the *AvaI/AatII* fragment of pBR322 (New England Biolabs).
- 10 Plasmid pQD was constructed by replacement of pQ fragment between *Bam*HI and *Bgl*III with a *Bam*HI/*Bgl*III fragment of the *ScQRS* (D291A) mutant.

- [0312] Plasmid pBAD/JYAMB-4TAG was constructed by insertion of a PCR fragment of the S4Amber mutant of myoglobin, containing a C-terminal 6His-tag, into the pBAD/YC-JYCUA plasmid, a hybrid of plasmid pYC-J17 (Wang, L, Brock, A.,
- 15 Herberich, B. & Schultz, P. G., Science, 2001, 292, 498-500) and pBAD/Myc-His A (Invitrogen) containing the gene for *MjYtRNA*<sub>CUA</sub>, and the pBAD promoter and cloning regions for heterologous expression of an inserted gene.

- [0313] **Fluorimetric and cytometric analyses.** Single colonies containing desired plasmids were used to inoculate 2-mL GMMML cultures containing the appropriate
- 20 antibiotics, 0.002% Arabinose, and an appropriate unnatural amino acid, if desired. Cultures were grown to saturation and cells (200  $\mu$ L) were pelleted and resuspended in 1 mL phosphate-buffered saline (PBS). Cell concentrations were analyzed by absorbance at 600 nm and fluorescence levels were measured at 505 nm with excitation at 396 nm using a FluoroMax-2 fluorimeter. Cells suspended in PBS were analyzed cytometrically. To
- 25 evaluate the permissivity of the amber positions within the T7 polymerase gene of pREP(10), the reporter plasmid was transformed into a panel of suppressor strains, which were subsequently analyzed fluorimetrically.

- [0314] **Evolution of aminoacyl-tRNA synthetase variants.** *M. jannaschii* *TyrRS* variants randomized at positions Y32, E107, D158, I159, and L162 (Wang, L, Brock, A.,
- 30 Herberich, B. & Schultz, P. G., Science, 2001, 292, 498-500) were transformed into DH10B *E. coli* cells (Life Technologies) containing pREP/YC-JYCUA to generate a library with a diversity of  $\sim 10^9$ . Transformants were allowed to recover in SOC medium

for 60 min at 37°C, and were grown to saturation in LB medium. To begin an initial positive selection, 2 mL of library culture, pelleted and resuspended in GMML medium, was used to inoculate 500 mL of GMML containing 25 µg/mL Tetracycline (Tet), 35 µg/mL Kanamycin (Kn), and 1 mM *pIF*, *pAF*, *pCF*, or *OAY*. After incubation for 3 hours at 37°C, Cm was added to a final concentration of 75 µg/mL and cells were grown to saturation (~48 hours). For the second positive selection, a 100-mL GMML culture containing Tet, Kn, 75 µg/mL Cm, and 1 mM *pIF*, *pAF*, *pCF*, or *OAY* was inoculated with cells from the initial positive selection (500 µL) and grown to saturation at 37°C (~24–36 hours). In preparation for negative screening, a 25-mL GMML culture containing Tet, Kn, and 0.02% arabinose (Ara) was inoculated with cells from the second positive selection (100 µL, pelleted and resuspended in GMML) and grown to saturation at 37°C (~24 hours). Ara-induced cells grown in the absence of unnatural amino acids (1 mL) were pelleted and resuspended in 3 mL of phosphate-buffered saline (PBS). Cells were sorted for lack of expression of GFPuv using a BDIS FACVantage TSO cell sorter with a Coherent Enterprise II ion laser with excitation at 351 nm and emissions detected using a 575/25 nm bandpass filter. Collected cells were diluted in at least 10 volumes of LB, containing Tet and Kn, and grown to saturation. To begin the third round of positive selection, 100 µL of cells from the negative screen were pelleted, resuspended in GMML, and used to inoculate 25 mL of GMML containing Tet, Kn, and 1 mM *pIF*, *pAF*, *pCF*, or *OAY*. After incubation for 3 hours at 37°C, Cm was added to a final concentration of 75 µg/mL and cells were grown to saturation (~24 hours). Following the third positive selection, cells were plated on GMML/agar containing Tet, Kn, 0.002% Ara, 0, 75, or 100 µg/mL Cm, and 0 or 1 mM *pIF*, *pAF*, *pCF*, or *OAY*, and grown for 48 hours at 37°C.

**[0315] Expression and characterization of unnatural amino acid-containing proteins.** DH10B cells co-transformed with pBAD/JYAMB-4TAG and the appropriate pBK plasmid were used to inoculate a 100-mL GMML starter culture containing Kn and Tet, which was grown to saturation. A 500-mL culture containing Kn, Tet, 0.002% Ara, 5 µM FeCl<sub>3</sub>, and the desired unnatural amino acid (or none) was inoculated with 50 mL of the starter culture and grown to saturation (~18 hours). Cultures were pelleted, sonicated, and the myoglobin protein isolated according to the protocol of the QiaExpressionist (Qiagen) His-tag purification kit. Proteins were analyzed electrophoretically on a 12–20% gradient SDS polyacrylamide gel and by electrospray mass spectrometry.

**[0316] Example 9- Orthogonal tRNA/Threonyl-tRNA synthetase Pair.**

**[0317]** This example illustrates the generation of an orthogonal tRNA/Threonyl-tRNA synthetase pair. **Figure 27** illustrates a threonyl-tRNA synthetase from *Thermus thermophilus*. This synthetase has two N-terminal editing domains, a catalytic domain and a C-terminal anticodon binding domain (659 amino acids). To generate the orthogonal synthetase based on the *T. thermophilus* synthetase, the editing domain(s), N1 or N1 and N2 was deleted from the synthetase to generate an N-truncated *T. thermophilus* ThrRS (475 amino acids). This synthetase has the same catalytic activity but lacks the proofreading activity. The N-truncated synthetase was screened for activity. The N-truncated synthetase did not aminoacylate *Escherichia coli* tRNA.

**[0318]** Because, the *T. thermophilus* tRNA<sup>Thr</sup> was found to be a substrate for *Escherichia coli* Threonyl-tRNA synthetase, the *T. thermophilus* tRNA<sup>Thr</sup> was mutated in order to generate an orthogonal pair. **Figure 28** illustrates the mutations made in the tRNA. Specifically, C2G71 was mutated to A2U71. In vitro charging experiments demonstrate that this mutant is not a substrate for the *E. coli* Threonyl-tRNA synthetase but is a good substrate for the *T. thermophilus* Threonyl-tRNA synthetase. Another mutant was also constructed, which included the following mutations: C2G71→A2U71 and G34G35U36→C34G35U36 in order to generate an amber suppressor tRNA. Other mutant tRNAs with modified anticodon loops in addition to C2G71→A2U71 were also generated to suppress three and four base codons such as TGA, ACCA, ACAA, AGGA, CCCT, TAGA, and CTAG. All these tRNAs were not as good as substrate as the wild type tRNA<sup>Thr</sup> (with A2U71) but can be improved by mutating the anticodon binding site of the *T. thermophilus* Threonyl-tRNA synthetase.

**[0319] Example 10- Sequences of exemplary O-tRNAs and O-RSs.**

**[0320]** Exemplary O-tRNAs comprise a nucleic acid comprising a polynucleotide sequence selected from the group consisting of: SEQ ID NO:1-3 and/or a complementary polynucleotide sequence thereof. See, Table 5, Appendix 1. Similarly, example O-RS include polypeptides selected from the group consisting of: a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 35-66 and a polypeptide encoded by a nucleic acid comprising a polynucleotide sequence selected from the group consisting of: SEQ ID NO:4-34 and a complementary polynucleotide sequence thereof.

[0321] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and  
5 purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

CLAIMSWhat is claimed is:

1. A composition comprising an orthogonal aminoacyl-tRNA synthetase (O-RS), wherein the O-RS preferentially aminoacylates an orthogonal tRNA (O-tRNA) with an unnatural amino acid.
2. The composition of claim 1, wherein the O-RS comprises a nucleic acid comprising a polynucleotide sequence selected from the group consisting of: SEQ ID NO: 4-34 and a complementary polynucleotide sequence thereof.
3. The composition of claim 1, wherein the O-RS aminoacylates the O-tRNA with the unnatural amino acid in vivo.
4. The composition of claim 1, wherein the unnatural amino acid is selected from the group consisting of: an O-methyl-L-tyrosine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAc $\beta$ -serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a *p*-azido-L-phenylalanine, a *p*-acyl-L-phenylalanine, a *p*-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphoserine, a phosphotyrosine, a *p*-iodo-phenylalanine, a *p*-bromophenylalanine, a *p*-amino-L-phenylalanine, and an isopropyl-L-phenylalanine.
5. The composition of claim 1, wherein the unnatural amino acid is selected from the group consisting of: an unnatural analogue of a tyrosine amino acid; an unnatural analogue of a glutamine amino acid; an unnatural analogue of a phenylalanine amino acid; an unnatural analogue of a serine amino acid; an unnatural analogue of a threonine amino acid; an alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkynyl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine, keto, or amino substituted amino acid, or any combination thereof; an amino acid with a photoactivatable cross-linker; a spin-labeled amino acid; a fluorescent amino acid; an amino acid with a novel functional group; an amino acid that covalently or noncovalently interacts with another molecule; a metal binding amino acid; a metal-containing amino acid; a radioactive amino acid; a photocaged amino acid, a photoisomerizable amino acid;

a biotin or biotin-analogue containing amino acid; a glycosylated or carbohydrate modified amino acid; a keto containing amino acid; an amino acid comprising polyethylene glycol; an amino acid comprising polyether; a heavy atom substituted amino acid; a chemically cleavable or photocleavable amino acid; an amino acid with an  
 5 elongated side chain; an amino acid containing a toxic group; a sugar substituted amino acid; a sugar substituted serine; a carbon-linked sugar-containing amino acid; a redox-active amino acid; an  $\alpha$ -hydroxy containing acid; an amino thio acid containing amino acid; an  $\alpha,\alpha$  disubstituted amino acid; a  $\beta$ -amino acid; and a cyclic amino acid other than proline.

10 6. The composition of claim 1, wherein the O-RS has one or more improved or enhanced enzymatic properties, selected from the groups consisting of:  $K_m$  and  $K_{cat}$ , for the unnatural amino acid as compared to a natural amino acid.

7. A polypeptide comprising an amino acid sequence encoded by a coding polynucleotide sequence, the coding polynucleotide sequence selected from the  
 15 group consisting of:

- a) a coding polynucleotide sequence selected from SEQ ID NO:4-34;
- b) a coding polynucleotide sequence that encodes a polypeptide selected from SEQ ID NO:35-66;
- c) a polynucleotide sequence which hybridizes under highly stringent  
 20 conditions over substantially an entire length of a polynucleotide sequence of (a) or (b); and,
- d) a complementary sequence of (a), (b), or (c).

8. The polypeptide of claim 7, wherein the encoded polypeptide encodes an orthogonal aminoacyl tRNA synthetase.

25 9. A polypeptide comprising an amino acid sequence selected from SEQ ID NO:35-66.

10. A nucleic acid comprising: a polynucleotide sequence selected from the group consisting of:

- a) a polynucleotide sequence selected from SEQ ID NO:1 to SEQ ID NO:3, or a complementary polynucleotide sequence thereof; and,
- b) a polynucleotide sequence which hybridizes under highly stringent conditions over substantially the entire length of polynucleotide sequence (a).

11. The nucleic acid of claim 10, wherein the polynucleotide sequence comprises an orthogonal tRNA.

12. The nucleic acid of claim 10; wherein the polynucleotide sequence forms a complementary pair with an orthogonal aminoacyl-tRNA synthetase.

13. The nucleic acid of claim 12, wherein the polypeptide sequence of the orthogonal aminoacyl-tRNA synthetase is selected from the group consisting of SEQ ID:35 to SEQ ID NO:66.

14. A composition comprising an orthogonal tRNA (O-tRNA), wherein the O-tRNA recognizes a selector codon and wherein the O-tRNA is preferentially aminoacylated with an unnatural amino acid by an orthogonal aminoacyl-tRNA synthetase.

15. The composition of claim 14, wherein the O-tRNA comprises a nucleic acid comprising a polynucleotide sequence selected from the group consisting of: SEQ ID NO: 1-3 and a complementary polynucleotide sequence thereof.

16. The composition of claim 14, wherein the selector codon comprises a unique three base codon, a nonsense codon, a rare codon, an unnatural codon, or at least a four base codon.

17. The composition of claim 14, further comprising the orthogonal aminoacyl-tRNA synthetase (O-RS).

18. The composition of claim 17, wherein the O-tRNA and the O-RS are complementary.



19. The composition of claim 17, wherein the composition comprises a mutRNATyr-mutTyrRS pair.
20. The composition of claim 19, wherein the composition comprises a mutRNATyr-SS12TyrRS pair.
- 5 21. The composition of claim 17, wherein the composition comprises a mutRNA<sup>Leu</sup>-mut<sup>Leu</sup>RS pair.
22. The composition of claim 17, wherein the composition comprises a mutRNA<sup>Thr</sup>-mut<sup>Thr</sup>RS pair.
23. The composition of claim 17, wherein the composition comprises a  
10 mutRNA<sup>Glu</sup>-mut<sup>Glu</sup>RS pair
24. The composition of claim 17, wherein the O-tRNA and the O-RS are derived by mutation of a naturally occurring tRNA and an RS from at least one organism, wherein the at least one organism is a prokaryotic organism.
25. The composition of claim 24, wherein the at least one organism is  
15 selected from the group consisting of: *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, and a *Halobacterium*.
26. The composition of claim 17, wherein the O-tRNA and the O-RS are derived by mutation of a naturally occurring tRNA and RS from at least one organism, wherein the at least one organism is a eukaryotic organism.
- 20 27. The composition of claim 26, wherein the at least one organism is selected from the group consisting of: yeasts, mammals, fungi, insects, plants and protists.
28. The composition of claim 17, wherein the O-tRNA is derived by mutation of a naturally occurring tRNA from a first organism and the O-RS is derived by mutation of a naturally occurring RS from a second organism.
- 25 29. The composition of claim 17, wherein the O-tRNA and the O-RS are isolated from at least one organism, wherein the at least one organism is a prokaryotic organism.

30. The composition of claim 29, wherein the at least one organism is selected from the group consisting of: *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, and a *Halobacterium*.

5 31. The composition of claim 17, wherein the O-tRNA and the O-RS are isolated from at least one organism, wherein the at least one organism is a eukaryotic organism.

32. The composition of claim 31, wherein the at least one organism is selected from the group consisting of: yeasts, mammals, fungi, insects, plants and protists.

10 33. The composition of claim 17, wherein the O-tRNA is isolated from a first organism and the O-RS is isolated from a second organism.

34. The composition of claim 17, wherein one or more of the O-tRNA and the O-RS is isolated from one or more library, which one or more library comprises an O-tRNA or an O-RS from one or more organism.

15 35. The composition of claim 34, wherein the one or more organism comprises a prokaryote or a eukaryote.

36. The composition of claim 17, wherein the composition is in a cell.

37. The composition of claim 17, wherein the composition comprises an in vitro translation system.

20 38. A method for producing at least one recombinant orthogonal aminoacyl-tRNA synthetase (O-RS), the method comprising:

(a) generating a library of RSs derived from at least one aminoacyl-tRNA synthetase (RS) from a first organism;

(b) selecting or screening the library of RSs for members that aminoacylate an orthogonal tRNA (O-tRNA) in the presence of an unnatural amino acid and a natural amino acid, thereby providing a pool of active RSs; and,

25

(c) selecting or screening the pool for active RSs that preferentially aminoacylate the O-tRNA in the absence of the unnatural amino acid, thereby providing

the at least one recombinant O-RS; wherein the at least one recombinant O-RS preferentially aminoacylates the O-tRNA with the unnatural amino acid.

39. The method of claim 38, wherein the first organism is a prokaryotic organism.

5 40. The method of claim 38, wherein the first organism is selected from the group consisting of: *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, and a *Halobacterium*.

41. The method of claim 38, wherein the at least one RS is an inactive RS.

10 42. The method of claim 41, where the inactive RS is generated by mutating an active RS.

43. The method of claim 42, wherein the inactive RS comprises at least about 1, at least about 2, at least about 3, at least about 4, about 5, at least about 6, or at least about 10 or more amino acids mutated to alanine amino acids.

15 44. The method of claim 38, wherein the library of RSs comprises a library of mutant RS.

45. The method of claim 44, wherein step (a) comprises random mutation.

46. The method of claim 38, wherein the step (b) comprises:  
20 introducing a positive selection or screening marker and the library of RSs into a plurality of cells, wherein the positive selection or screening marker comprises at least one selector codon;

growing the plurality of cells in the presence of a selection or screening agent;

25 identifying cells that survive or show a specific screening response in the presence of the selection or screening agent by suppressing the at least one selector codon

in the positive selection or screening marker, thereby providing a subset of positively selected or screened cells that contains the pool of active RSs.

47. The method of claim 46, wherein the selection or screening agent concentration is varied.

5 48. The method of claim 46, wherein the at least one selector codon comprises an amber codon, an ochre codon, or an opal stop codon.

49. The method of claim 46, wherein the positive selection marker is a chloramphenicol acetyltransferase (CAT) gene and wherein the at least one selector codon is an amber stop codon in the CAT gene.

10 50. The method of claim 46, wherein the positive selection marker is a  $\beta$ -lactamase gene and wherein the at least one selector codon is an amber stop codon in the  $\beta$ -lactamase gene.

51. The method of claim 46, wherein the positive screening marker comprises a fluorescent or luminescent screening marker.

15 52. The method of claim 46, wherein the positive screening marker comprises an affinity based screening marker.

53. The method of claim 38, wherein the step (c) comprises:

introducing a negative selection or screening marker with the pool of active RSs from step (b) into a plurality of cells of a second organism, wherein the negative  
20 selection or screening marker gene comprises at least one selector codon;

identifying cells that survive or show a specific screening response in a 1<sup>st</sup> media supplemented with the unnatural amino acid and a selection or screening agent, but fail to survive or to show the specific screening response in a 2<sup>nd</sup> media not supplemented with the unnatural amino acid and the selection or screening agent, thereby providing  
25 surviving or screened cells with the at least one recombinant O-RS.

54. The method of claim 53, wherein concentration of the selection or screening agent is varied.

55. The method of claim 53, wherein the first and the second organism are different.

56. The method of claim 53, wherein the first and second organism comprise a prokaryote, a eukaryote, a mammal, an *Escherichia coli*, a fungi, a yeast, an  
5 archaeobacterium, a eubacterium, a plant, an insect, or a protist.

57. The method of claim 53, wherein the negative selection marker comprises a chloramphenicol acetyltransferase (CAT) gene comprising at least one selector codon.

58. The method of claim 53, wherein the screening marker comprises a  
10 fluorescent or luminescent screening marker.

59. The method of claim 53, wherein the screening marker comprises an affinity based screening marker.

60. The method of claim 38, wherein step (c) comprises:

isolating the pool of active RSs from step (b);

15 introducing a negative selection or screening marker, wherein the negative selection or screening marker gene comprises at least one selector codon, and the pool of active RSs into a plurality of cells of a second organism;

identifying cells that survive or show a specific screening response in a 1<sup>st</sup> media not supplemented with the unnatural amino acid, but fail to survive or to show the  
20 specific screening response in a 2<sup>nd</sup> media supplemented with the unnatural amino acid, thereby providing surviving or screened cells with the at least one recombinant O-RS, wherein the at least one recombinant O-RS is specific for the unnatural amino acid.

61. The method of claim 60, wherein the at least one selector codon comprises two or more selector codons.

25 62. The method of claim 60, wherein the first and the second organism are different.

63. The method of claim 60, wherein the first and second organism comprise a prokaryote, a eukaryote, a mammal, an *Escherichia coli*, a fungi, a yeast, an archaeobacteria, a eubacteria, a plant, an insect, or a protist.
- 5 64. The method of claim 60, wherein the negative selection marker comprises a ribonuclease barnase gene comprising at least one selector codon.
65. The method of claim 60, wherein the screening marker comprises a fluorescent or luminescent screening marker.
66. The method of claim 60, wherein the screening marker comprises an affinity based screening marker.
- 10 67. The method of claim 38, wherein step (b), (c) or both steps (b) and (c), comprise varying a selection or screening stringency.
68. The method of claim 38, further comprising:
- (d) isolating the at least one recombinant O-RS;
- (e) generating a second set of O-RS derived from the at least one  
15 recombinant O-RS, wherein the second set of O-RS comprises a set of mutated O-RS; and,
- (f) repeating steps (b) and (c) until a mutated O-RS is obtained that comprises an ability to preferentially aminoacylate the O-tRNA.
69. The method of claim 68, further comprising repeating steps (d)-(f) at least about two times.
- 20 70. The method of claim 68, wherein step (e) comprises random mutagenesis, site-specific mutagenesis, recombination or any combination thereof.
71. The method of claim 38, wherein step (b), (c) or both steps (b) and (c) comprise using a reporter, wherein the reporter is detected by fluorescence-activated cell sorting (FACS) or wherein the reporter is detected by luminescence.

72. The method of claim 38, wherein the step (b), (c) or both steps (b) and (c) comprise using a reporter, wherein the reporter is displayed on a cell surface or on a phage display.

73. The method of claim 38, wherein the unnatural amino acid is  
5 selected from the group consisting of: an O-methyl-L-tyrosine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAc $\beta$ -serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a *p*-azido-L-phenylalanine, a *p*-acyl-L-phenylalanine, a *p*-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphoserine, a phosphotyrosine, a *p*-iodo-phenylalanine, a *p*-  
10 bromophenylalanine, a *p*-amino-L-phenylalanine, and an isopropyl-L-phenylalanine.

74. The at least one recombinant O-RS produced by the method of claim 38.

75. A method for producing a recombinant orthogonal tRNA (O-tRNA), the method comprising:

15 (a) generating a library of tRNAs derived from at least one tRNA from a first organism;

(b) selecting or screening the library for tRNAs that are aminoacylated by an aminoacyl-tRNA synthetase (RS) from a second organism in the absence of a RS from the first organism, thereby providing a pool of tRNAs; and,

20 (c) selecting or screening the pool of tRNAs for members that are aminoacylated by an introduced orthogonal RS (O-RS), thereby providing at least one recombinant O-tRNA; wherein the at least one recombinant O-tRNA recognizes at least one selector codon and is not efficiently recognized by the RS from the second organism and is preferentially aminoacylated by the O-RS.

25 76. The method of claim 75, wherein the at least one tRNA is a suppressor tRNA.

77. The method of claim 75, wherein the selector codon comprises a unique three base codon of natural or unnatural bases, a nonsense codon, a rare codon, an unnatural codon or at least a four base codon.
78. The method of claim 75, wherein the selector codon comprises an  
5 amber codon, an ochre codon, or an opal stop codon.
79. The method of claim 75, wherein the at least one recombinant O-tRNA possesses an improvement of orthogonality.
80. The method of claim 75, wherein the first organism is a prokaryotic organism.
- 10 81. The method of claim 80, wherein the prokaryotic organism is selected from the group consisting of: *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, and a *Halobacterium*.
82. The method of claim 75, wherein the first and second organism comprise a prokaryote, a eukaryote, a mammal, an *Escherichia coli*, a fungi, a yeast, an  
15 archaeobacteria, a eubacteria, a plant, an insect, or a protist.
83. The method of claim 75, wherein the first and the second organism are different.
84. The method of claim 75, wherein the recombinant tRNA is aminoacylated by an unnatural amino acid, wherein the unnatural amino acid is  
20 biosynthesized in vivo either naturally or through genetic manipulation.
85. The method of claim 75, wherein the unnatural amino acid is added to a growth media of one or more of the first or second organism.
86. The method of claim 75, wherein the step (b) comprises:  
introducing a toxic marker gene or a gene that leads to the production of a  
25 toxic or static agent or a gene essential to the organism, wherein the marker gene comprises the at least one selector codon and the library of mutant tRNAs into a plurality of cells from the second organism; and,



selecting surviving cells, wherein the surviving cells contain the pool of tRNAs comprising at least one orthogonal tRNA or nonfunctional tRNA.

87. The method of claim 86, wherein selecting surviving cells comprises a comparison ratio cell density assay.

5 88. The method of claim 86, wherein the selector codon comprises two or more selector codons.

89. The method of claim 86, wherein the marker gene is a ribonuclease barnase gene, wherein the ribonuclease barnase gene comprises at least one amber codon.

90. The method of claim 89, wherein the ribonuclease barnase gene  
10 comprises two or more amber codons.

91. The method of claim 75, wherein the step (c) comprises:

introducing a positive selection or screening marker gene, wherein the positive marker gene comprises a drug resistance gene or a gene essential to the organism, or a gene that leads to detoxification of a toxic agent, comprising at least one of the  
15 selector codons, the O-RS, and the pool of tRNAs into a plurality of cells from the second organism; and,

identifying surviving or screened cells grown in the presence of a selection or screening agent, thereby providing a pool of cells possessing the at least one recombinant tRNA, wherein the at least recombinant tRNA is aminoacylated by the O-RS  
20 and inserts an amino acid into a translation product encoded by the positive marker gene, in response to the at least one selector codons.

92. The method of claim 91, wherein the selection agent is an antibiotic.

93. The method of claim 91, wherein concentration of the selection or screening agent is varied.

25 94. The method of claim 91, wherein the drug resistance gene is a  $\beta$ -lactamase gene.

95. The method of claim 94, wherein the  $\beta$ -lactamase gene comprises at least one amber stop codon.

96. The at least one recombinant O-tRNA produced by the method of claim 75.

5 97. A method for producing at least one specific O-tRNA/O-RS pair, the method comprising:

(a) generating a library of tRNAs derived from at least one tRNA from a first organism;

(b) negatively selecting or screening the library for tRNAs that are  
10 aminoacylated by an aminoacyl-tRNA synthetase (RS) from a second organism in the absence of a RS from the first organism, thereby providing a pool of tRNAs;

(c) selecting or screening the pool of tRNAs for members that are aminoacylated by an introduced orthogonal RS (O-RS), thereby providing at least one  
15 recombinant O-tRNA; wherein the at least one recombinant O-tRNA recognizes a selector codon and is not efficiently recognized by the RS from the second organism and is preferentially aminoacylated by the O-RS;

(d) generating a library of RSs derived from at least one aminoacyl-tRNA synthetase (RS) from a third organism;

(e) selecting or screening the library of RSs for members that preferentially  
20 aminoacylate the at least one recombinant O-tRNA in the presence of an unnatural amino acid and a natural amino acid, thereby providing a pool of active RSs; and,

(f) negatively selecting or screening the pool for active RSs that preferentially aminoacylate the at least one recombinant O-tRNA in the absence of the unnatural amino acid, thereby providing the at least one specific O-tRNA/O-RS pair,  
25 wherein the at least one specific O-tRNA/O-RS pair comprises at least one recombinant O-RS that is specific for the unnatural amino acid and the at least one recombinant O-tRNA.

98. The specific O-tRNA/O-RS pair produced by the method of claim 97.

99. The method of claim 97, wherein the at least one specific O-tRNA/O-RS pair is a mutRNATyr-mutTyrRS pair.

5 100. The method of claim 97, wherein the first and the third organism are same.

101. The method of claim 97, wherein the first organism and the third organism are *Methanococcus jannaschii*.

102. A method for identifying an orthogonal tRNA-tRNA synthetase pair  
10 for use in an in vivo translation system of a second organism, the method comprising:

introducing a marker gene, a tRNA and an aminoacyl-tRNA synthetase (RS) isolated or derived from a first organism into a first set of cells from the second organism;

15 introducing the marker gene and the tRNA into a duplicate cell set from the second organism; and

selecting or screening for surviving cells or for cells showing a specific screening response in the first set that fail to survive or show said response in the duplicate cell set, wherein the first set and the duplicate cell set are grown in the presence of a selection or screening agent, wherein the surviving or screened cells comprise the  
20 orthogonal tRNA-tRNA synthetase pair for use in the in vivo translation system of the second organism.

103. The method of claim 102, wherein the comparing and selecting or screening comprises an in vivo complementation assay.

104. The method of claim 102, wherein concentration of the selection or  
25 screening agent is varied.

105. The method of claim 102, wherein the first organism is a prokaryotic organism.

106. The method of claim 102, wherein the second organism is a prokaryotic organism.

107. The method of claim 102, wherein the first and second organism are different.

5 108. The method of claim 102, wherein the first organism is selected from the group consisting of: *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum*, and a *Halobacterium*.

109. The method of claim 102, wherein the second organism is *Escherichia coli*.

10 110. The method of claim 38, 75, 97, or 102, wherein the selecting or screening comprises one or more positive or negative selection or screening chosen from the groups consisting of: a change in amino acid permeability, a change in translation efficiency, and a change in translational fidelity, and wherein the one or more change is based upon a mutation in one or more gene in an organism in which an orthogonal tRNA-  
15 tRNA synthetase pair are used to produce protein.

111. The method of claim 38, 75, 97, or 102, wherein the selecting or screening comprises selecting or screening at least 2 selector codons within one or more selection gene or within one or more screening gene.

112. The method of claim 111, wherein the at least 2 selector codons are  
20 in the same selection gene or the same screening gene.

113. The method of claim 111, wherein the at least 2 selector codons are in different selection or screening genes.

114. The method of claim 111, wherein the at least 2 selector codons comprise different selector codons.

25 115. The method of claim 111, wherein the at least 2 selector codons comprise the same selector codons.

1/35




Fig. 1

2/35




Fig. 2A

3/35





Fig. 2B

4/35



Wild Type	32	67	70	107	155	160	167
Library	Tyr --	Ala Asp Leu His	-- Glu	-- Gln Val Asn Asp Ile His Tyr Leu Gly Val Asp Val Ala			
Library	1 NNN --	Ala Asp Leu His	-- NNN	-- Gln Val Asn NNN NNN His Tyr NNN Gly Val Asp Val Ala			
Library	2 NNN --	Ala Asp Leu His	-- Glu	-- Gln Val Asn NNN NNN His Tyr NNN Gly Val Asp Val NNN			
Library	3 NNN --	NNN Asp Leu NNN	-- Glu	-- NNN Val Asn NNN Ile His Tyr Leu Gly Val Asp Val NNN			

Fig. 3



5/35

	32	67	70	107	155	160	167
<b>Wild Type</b>	Tyr	-- Ala Asp	Leu His	-- Glu	-- Gln Val	Asn Asp Ile His Tyr	Leu Gly Val Asp Val Ala
<b>Library 1</b>	NNN	-- Ala Asp	Leu His	-- NNN	-- Gln Val	Asn NNN NNN His Tyr	NNN Gly Val Asp Val Ala
<b>Library 2</b>	NNN	-- Ala Asp	Leu His	-- Glu	-- Gln Val	Asn NNN NNN His Tyr	NNN Gly Val Asp Val NNN
<b>Library 3</b>	NNN	-- NNN Asp	Leu NNN	-- Glu	-- NNN Val	Asn NNN Ile His Tyr	Leu Gly Val Asp Val NNN

### Consensus sequence

Ile -- Gln Asp Leu Tyr -- Glu -- Ala Val Asn Ala Ile His Tyr Leu Gly Val Asp Val Leu

Fig. 4

6/35




Fig. 5

7/35

<b>EcTyrRS</b>	<b>1</b>	<b>WFGNMNVLTFFLRDIGKHF</b>	<b>SVNQMINKEAVKQRLNREDQGISTE</b>
<b>HsTyrRS</b>	<b>1</b>	<b>-LSKEYTLDVYRLS---</b>	<b>SVVTQHDSKKAGAEVVKQVEHPLLSG-</b>
<b>MjTyrRS</b>	<b>1</b>	<b>LDKDYTLNVYRLALKTT</b>	<b>KKRARRSMELIAREDENPKVAE</b>
<b>HsTyrRS</b>	<b>1</b>	<b>LSKEYTLDVYRLSSVVT</b>	<b>QHDSKKAGAEVVKQVEHPLLSG</b>

*M. jannaschii*

*E. coli*

*Chimera #1*

*Chimera #2*

*Chimera #3*

Fig. 6

8/35




Fig. 7

9/35




Fig. 8



The figure displays chemical structures for two different systems. The top section, labeled **3MN:3MN**, shows two 3-methyl-1-naphthyl groups (3MN) and a complex of a central black sphere (representing a metal or cluster) coordinated by two 3MN ligands and two 2,6-pyridinedicarboxylate (Dipic:Py) ligands. The bottom section, labeled **7Al:7Al**, shows two 7-alkynyl-1H-benzimidazole-2-one (PICS) ligands and a complex of a central black sphere coordinated by two PICS ligands and two 7-alkynyl-1H-benzimidazole (7Al) ligands.

**Fig. 10**

12/35




Fig. 11



13/35




Fig. 12

**Mutant tRNAs selected from anticodon-loop library**

ATL LIB	-----NN-----NN-----
JY	CCGCGGTAGTTCAGCCTGGTAGAACGGCGGACTCTAGATCCGCATGTCGCTGGTTCAAATCCGGCCCCCGCGGCCA
AA2	CCGCGGTAGTTCAGCCTGGTAGAACGGCGGACACTAAATCCGCATGTCGCTGGTTCAAATCCGGCCCCCGCGGCCA
AA3	CCGCGGTAGTTCAGCCTGGTAGAACGGCGGACACTAAATCCGCATGTCGCTGGTTCAAATCCGGCCCCCGCGGCCA
AA4	CCGCGGTAGTTCAGCCTGGTAGAACGGCGGAATCTAAATCCGCATGTCGCTGGTTCAAATCCGGCCCCCGCGGCCA

**Mutant tRNAs selected from all-loop library**

**Mutant tRNAs surviving both selections**

AL LIB	-----NNN--N-----N-----NN-----N-N-----NN-----
JY	CCGCGGTAGTTCAGCCTGGTAGAACGGCGGACTCTAGATCCGCATGTCGCTGGTTCAAATCCGGCCCCCGCGGCCA
J15	CCGCGGTAGTTCAGTGAAGGAAGAACGGCGGAOTCTAAATCCGCAAGGCGCTGGTTCAAAGTCCGGCCCCCGCGGCCA
J17	CCGCGGTAGTTCAGCAGGGCAGAACGGCGGACTCTAAATCCGCATGGCGCTGGTTCAAATCCGGCCCCCGCGGCCA
J18	CCGCGGTAGTTCAGATAGGGAGAACGGCGGACTCTAACTCCGCATGGCGCTGGTTCAAATCCGGCCCCCGCGGCCA
J22	CCGCGGTAGTTCAGGTAGGGAGAACGGCGGACTCTAACTCCGCATGTCGCTGGTTCAAAGTCCGGCCCCCGCGGCCA

**Mutant tRNAs surviving negative selection only**

AL LIB	-----NNN--N-----N-----NN-----N-N-----NN-----
JY	CCGCGGTAGTTCAGCCTGGTAGAACGGCGGACTCTAGATCCGCATGTCGCTGGTTCAAATCCGGCCCCCGCGGCCA
N11	CCGCGGTAGTTCAGTAGGGAGAACGGCGGACTCTAAATCCGCACGTCGCTGGTTCAAAGTCCGGCCCCCGCGGCCA
N12	CCGCGGTAGTTCAGGGTGGAGAACGGCGGAGTCTAGTCCGCATGCCGCTGGTTCAATACCGGCCCCGCGGCCA
N13	CCGCGGTAGTTCAGTTCGGCAGAACGGCGGAGTCTATATCCGCACGCTGCTGGTTCAACCCCGGCCCGCGGCCA
N16	CCGCGGTAGTTCAGTGTGGAAGAACGGCGGATCTATCTCCGCACGCTGCTGGTTCAAGGCCGCCCGCGGCCA

Fig. 13

15/35




Fig. 14

16/35




Fig. 15

Fig. 16B





Fig. 16A



18/35




Figure 17A

19/35













Construct Number		Fluorescence Enhancement (fold)
1		12
2		-
3		-
4		4
5		-
6		32
7		6
8		-
9		20
10		220
11		48
12		82

Figure 17B

20/35




Figure 17C



21/35




Figure 17D

22/35




Fig. 18

23/35




Fig. 19

24/35




Fig. 20

25/35

Fig. 21A




Fig. 21B

Alone	With MLRS	Original Amber Mutant	Optimized Anticodon Loop	Optimized Acceptor Stem
5	25	25	500	600
		5	25	7.5

26/35






Fig. 22

**Fig. 23A**




**Fig. 23B**



**Fig. 23C.**

Cm IC <sub>50</sub> (μg/mL)	pIF-RS	pAF-RS	OAY-RS(1)
- Unnatural	< 5	< 5	< 5
+ Unnatural	75	100	120

**Fig. 23D**



28/35





Figure 24



29/35



**B**




Figure 25

30/35




Figure 26

31/35




Fig. 27

32/35




Fig. 28

33/35




Fig. 29

34/35





Fig. 30

Fig. 31



SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
1	CCGGCGGTAGTT CAGCAGGGCAGAACGGCGGACTCTAAATCCGCATGGCGCTGGTTC AAATCCGGCCCCCGGACCA	<i>M. jannaschii</i> mtRNA <sup>Tyr</sup> <sub>CUA</sub>	tRNA
2	CCCAGGGTAG CCAAGCTCGG CCAACGGCGA CGGACTCTAA ATCCGTTCTC GTAGGAGTTC GAGGGTTCGA ATCCCTTCCC TGGGACCA	HLAD03; an optimized amber suppressor tRNA	tRNA
3	GCGAGGGTAG CCAAGCTCGG CCAACGGCGA CGGACTTCTT AATCCGTTCT CGTAGGAGTT CGAGGGTTCG AATCCCTCCC CTCGCACCA	HL325A; an optimized AGGA frameshift suppressor tRNA	tRNA
4	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCAGATAGGTTTGAACCAAGT GGTAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCTATTTAAACAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTACCTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA ATAATGCAGGTTAATGCAATTCATTATCCTGGCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTGTA ATTACACAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATACGCCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG GTTAGTAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATGCAATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACCTTATAAAGATTTTAGAGCCAATTAGAAAG AGATTATAA	mutant TyrRS (LWJ16)	RS
5	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTGGGATAGGTTTGAACCAAGT GGTAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCTATTTAAACAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGCTTATGGAAGTCTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATGTTTATCATTATCTTGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTGTA TTCACAAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGAAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG GTTAGTAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATGCAATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACCTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -iPr-PheRS	RS
6	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCAGATAGGTTTGAACCAAGT GGTAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCTATTTAAACAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTCTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATGTTTCTCATTATATGCGGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTGTA TTCACAAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGAAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG GTTAGTAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATGCAATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACCTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -NH <sub>2</sub> -PheRS(1)	RS
7	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACTATAGGTTTGAACCAAGT GGTAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCTATTTAAACAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTACCTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATCCGTTGCAATTATGCTGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTGTA TTCACAAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGAAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG GTTAGTAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATGCAATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACCTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -NH <sub>2</sub> -PheRS(2)	RS
8	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCATATAGGTTTGAACCAAGT GGTAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCTATTTAAACAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTACCTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATCCGTTGCAATTATGCTGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTGTA TTCACAAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGAAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG GTTAGTAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATGCAATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACCTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -NH <sub>2</sub> -PheRS(3a)	RS



SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGTGAAGCA ATGGGGTTAAAGGCAAAATATGTTTATGGAAGTGAGTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATCGGCCGATTATCTGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTGTGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAAATATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA		
9	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTTATATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGGATATAAATTATATTGTTGGCTGATTTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGTGAAGCA ATGGGGTTAAAGGCAAAATATGTTTATGGAAGTCCCTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATCAGAGTCAATTATGATGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTGTGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAAATATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -NH <sub>2</sub> -PheRS(3b)	RS
10	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTTCGATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGGATATAAATTATATTGTTGGCTGATTTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGTGAAGCA ATGGGGTTAAAGGCAAAATATGTTTATGGAAGTACGTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATACGATATCATTTATGCTGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTGTGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAAATATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	<i>O</i> -Allyl-TyrRS(1)	RS
11	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCCTATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGGATATAAATTATATTGTTGGCTGATTTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGTGAAGCA ATGGGGTTAAAGGCAAAATATGTTTATGGAAGTATGTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATACGATATCATTTATGCTGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTGTGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAAATATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	<i>O</i> -Allyl-TyrRS(3)	RS
12	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACGATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGGATATAAATTATATTGTTGGCTGATTTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGTGAAGCA ATGGGGTTAAAGGCAAAATATGTTTATGGAAGTCAATTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATCAGACTCAATTATGAGGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTGTGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAAATATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	<i>O</i> -Allyl-TyrRS(4)	RS

SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
13	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCATATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTTACAAAAT GCTGGATTGGATATAAATTATATGTTGGCTGATTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTAAGTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATCCGTGTCATTATCATGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCCCTGTCTTAAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAGATTATTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -Br-PheRS	RS
14	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTGCTATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTTACAAAAT GCTGGATTGGATATAAATTATATGTTGGCTGATTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTCCGTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATGCTGATTATGATGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCCCTGTCTTAAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAGATTATTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -Az-PheRS(1)	RS
15	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTGGGATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTTACAAAAT GCTGGATTGGATATAAATTATATGTTGGCTGATTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTACTTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATACGTATTATATGCTGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCCCTGTCTTAAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAGATTATTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -Az-PheRS(3)	RS
16	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTGATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTTACAAAAT GCTGGATTGGATATAAATTATATGTTGGCTGATTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTCCGTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATCAGATTCTAGTGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCCCTGTCTTAAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAGATTATTAGAGCCAATTAGAAAGA GATTA	<i>p</i> -Az-PheRS(5)	RS
17	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTGACATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTTACAAAAT GCTGGATTGGATATAAATTATATGTTGGCTGATTACACGCCCTATTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTCCGTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAATGCAGGTTAATGGAATGCATTATCAAGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTACCAAAAAAGGTTGTTTGT TTCACAACCCCTGTCTTAAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATGCTGTAGCTGAAGAACTTATAAGATTATTAGAGCCAATTAGAAAGA GATTA	Mutant synthetases to incorporate m-acyl phenylalanine into proteins (Ketone 3-4)	RS

SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAAG AGATTATAA		
18	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTTACATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTTACACGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAAATATGTTTATGGAAGTCTATTCCAGCTTGATAAGGATTAT ACACTGAATGCTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCAGGTTAATGATATTCAATTATACAGGCCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTCACAACCCCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATACCTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAAG AGATTATAA	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 3-7)	RS
19	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCTAATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGACAGATTAAACGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAAATATGTTTATGGAAGTGAATTCAGCTTGATAAGGATTAT ACACTGAATGCTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCAGGTTAATGATATTCAATTATTAGGCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTCACAACCCCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATACCTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAAG AGATTATAA	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 4-1)	RS
20	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCTAATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGACAGATTAAAGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAAATATGTTTATGGAAGTGAATTCAGCTTGATAAGGATTAT ACACTGAATGCTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCAGGTTAATGATATTCAATTATTAGGCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTCACAACCCCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATACCTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAAG AGATTATAA	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 5-4)	RS
21	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCTAATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGCCAGATTATCAGCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAAATATGTTTATGGAAGTGAATTCAGCTTGATAAGGATTAT ACACTGAATGCTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCAGGTTAATGATATTCAATTATTAGGCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTCACAACCCCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATACCTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCCTTGAATATCCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAAAG AGATTATAA	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 6-8)	RS
22	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACAATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTTACACGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAAATATGTTTATGGAAGTGAATTCAGCTTGATAAGGATTAT ACACTGAATGCTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCAGGTTAATGATATTCAATTATGCAGGCCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTCACAACCCCTGTCTTAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 1-6)	RS

SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATAGTCCAGCTGGAGTTGTTGAAGGAAATCCAAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAA AGATTATAA		
23	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACAAATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGCTCCGATTACACGCTATTAAACCGAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTGAATTCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCGAGTTAATGATATTTCATTATTAGGCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTACACACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATAGTCCAGCTGGAGTTGTTGAAGGAAATCCAAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAA AGATTATAA	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 1-8)	RS
24	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACAAATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGCTGATTACACGCTATTAAACCGAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTATGTTCCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCGAGTTAATTCATCATTATGACGGCTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTACACACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATAGTCCAGCTGGAGTTGTTGAAGGAAATCCAAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAA AGATTATAA	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 2-7)	RS
25	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCAAAATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGCCAGATTACACGCTATTAAACCGAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTGAATTCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCGAGTTAATGATATTTCATTATTAGGCGTTGATGTTGACGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTACACACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATAGTCCAGCTGGAGTTGTTGAAGGAAATCCAAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAA AGATTATAA	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 4-1)	RS
26	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCTATTAAACCGAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTGCATTCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCGAGTTAATGGACACCATTATATAGGCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTACACACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATAGTCCAGCTGGAGTTGTTGAAGGAAATCCAAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAA AGATTATAA	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 4-8)	RS
27	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCTATTAAACCGAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAGTTTGAAGCA ATGGGGTTAAAGGCCAAAATATGTTTATGGAAGTGCATTCAGCTTGATAAGGATTAT ACACTGAATGTCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACCTTATAGCAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAGTTATCTATCCA ATAATGCGAGTTAATGGACACCATTATATAGGCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTACACACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATAGTCCAGCTGGAGTTGTTGAAGGAAATCCAAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAACTTATAAAGATTTTAGAGCCAATTAGAAA AGATTATAA	Mutant synthetase to incorporate p-O-allyl tyrosine into proteins (Allyl)	RS

SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	ATAATGCAGGTTAAATGCGCACATTATTTAGGCGTTGATGTTGCAGTTGGAGGGATG GAGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT ATTTCACAACCCCTGCTTAAACGGGTTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAA GGGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAA GCATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATAC TTCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACA GTTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATG GATTTAAAAAATGCTGTAGCTGAAGAATCTATAAAGATTTTAGAGCCAATTAGAAAAG AGATTATAA		
28	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTGGTATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTTCCCTCCAGCTTGATAAGGATTAT ACACTGAATGCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAGGAGT ATGGAATCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATACGAGTCATTATCTGGCGCTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT TTACAAACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAGATGAGTTCTTCAAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTAAAAAATGCTGTAGCTGAAGAATCTATAAAGATTTTAGAGCCAATTAGAAAAG GATTA	Aminoacyl tRNA synthetase for the incorporation of p- benzoyl-L- phenylalanine (p- BpaRS(H6))	RS
29	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACGATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTAAATTTCCAGCTTGATAAGGATTAT ACACTGAATGCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAATCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATCCGCTTCATTATCAGGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT TTACAAACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAGATGAGTTCTTCAAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTAAAAAATGCTGTAGCTGAAGAATCTATAAAGATTTTAGAGCCAATTAGAAAAG GATTA	Aminoacyl tRNA synthetase for the incorporation of p- azido-phenylalanine (p- Az-PheRS(3))	RS
30	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACGATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTCTGTTCCAGCTTGATAAGGATTAT ACACTGAATGCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAATCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATCCCTTCATTATGAGGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT TTACAAACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAGATGAGTTCTTCAAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTAAAAAATGCTGTAGCTGAAGAATCTATAAAGATTTTAGAGCCAATTAGAAAAG GATTA	Aminoacyl tRNA synthetase for the incorporation of p- azido-phenylalanine (p- Az-PheRS(6))	RS
31	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTCTTATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTCTTCCAGCTTGATAAGGATTAT ACACTGAATGCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAATCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATCCGCTTCATTATCAGGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT TTACAAACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAGATGAGTTCTTCAAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTAAAAAATGCTGTAGCTGAAGAATCTATAAAGATTTTAGAGCCAATTAGAAAAG GATTA	Aminoacyl tRNA synthetase for the incorporation of p- azido-phenylalanine (p- Az-PheRS(20))	RS
32	ATGGACGAATTTGAAATGATAAAGAGAAACACATCTGAAATTATCAGCGAGGAAGAG TTAAGAGAGGTTTAAAAAAGATGAAAAATCTGCTACTATAGGTTTGAACCAAGT GGTAAAAATACATTTAGGGCATTATCTCCAAATAAAAAAGATGATTGATTACAAAAAT GCTGGATTGATATAATTATATTGTTGGCTGATTACACGCCCTATTTAAACCAGAAA GGAGAGTTGGATGAGATTAGAAAAATAGGAGATTATAACAAAAAAGTTTGAAGCA ATGGGGTTAAAGGCAAAAATATGTTTATGGAAGTCTTCCAGCTTGATAAGGATTAT ACACTGAATGCTATAGATTGGCTTTAAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAATCTTATAGAAGAGAGGATGAAAAATCCAAAGGTTGCTGAAAGTTATCTATCCA TAATGCAGGTTAATCCGCTTCATTATCAGGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTTGT TTACAAACCCCTGCTTAAACGGGTTGGATGGAGAAGGAAGATGAGTTCTTCAAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAAG CATACTGCCAGCTGGAGTTGTTGAAGGAAATCCAATAATGGAGATAGCTAAATACT TCCTTGAATATCCTTTAACCATAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTTATTTAAAAATAAGGAATTGCATCCAATGG ATTAAAAAATGCTGTAGCTGAAGAATCTATAAAGATTTTAGAGCCAATTAGAAAAG GATTA	Aminoacyl tRNA synthetase for the incorporation of p- azido-phenylalanine (p- Az-PheRS(20))	RS

SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	ATGGGGTTAAAGGCAAAATATGTTTATGGAAGTTCGTTCCAGCTTGATAAGGATTAT ACACCTGAATGTCTATAGATTGGCTTTAAAACTACCTTAAAAAGAGCAAGAAGGAGT ATGGAACTTATAGAAGAGAGGATGAAATCCAAAGGTTGCTGAAGTTATCTATCCAA TAAATGCAGGTTAATCCACTGCATTATCAGGGCGTTGATGTTGCAGTTGGAGGGATGG AGCAGAGAAAAATACACATGTTAGCAAGGGAGCTTTTACCAAAAAAGGTTGTTGTA TTCACAAACCTGTCTTAACGGGTTGGATGGAGAAGGAAAGATGAGTTCTTCAAAAG GGAATTTTATAGCTGTTGATGACTCTCCAGAAGAGATTAGGGCTAAGATAAAGAAAG CTAAGTGCACAGCTGGAGTTGTTGAAGGAAATCCAAATATGGAGATAGCTAAATACT TCCTTGAATATCTTTAACCATAAAAAAGGCCAGAAAAATTTGGTGGAGATTGACAG TTAATAGCTATGAGGAGTTAGAGAGTTATTTAAAAATAAGGAATTGCATCCAATGG ATTTAAAAAATCTGTAGCTGAAGAACCTATAAAGATTTTAGAGCCAATTAGAAAGA GATTA	Az-PheRS(24))	
33	ATGAGCGATT TCAGGATAAT TGAGGAGAAG TGGCAGAAGG CGTGGGAGAA GGACAGAATT TTTGAGTCCG ATCCTAATGA GAAGGAGAAG TTTTCTCTCA CAATTCCCTA TCCTTACCTT AATGGAATC TTCACGCAGG TCACACGAGA ACCCTTCACAA TTGGCGATGC CTTGCCCAGA TACATGAGAA TGAAGGGCTA CAACGTTCTC TTTCCCTCCG GCTTTCATGT TACGGGCACC CCAATCATTTG GCCTTGGCGA GCTCATAGCC AAGAGGGACG AGAGGACGAT AGAGGTTTAC ACCAAATACC ATGACGTTCC GCTGGAGGAC TTGCTTCAGC TCACAACTCC AGAGAAATC GTTGAGTACT TCTCAAGGGA GGCCTGTCAG GCTTTGAAGA GCATAGGCTA CTCCATTGAC TGGAGGAGGG TTTTACCAC AACCGATGAA GAGTATCAGA GATTTCATCGA GTGGCAGTAC TGAAGCTCA AGGAGCTTGG CCTGATTGTG AAGGGCACCC ACCCCGTCAG ATACTGCCCC CACGACCAGA ATCCTGTGTA AGACCAAGAC CTTCTCGCTG GGGAGGAGGC AACTATTGTT GAATTTACCG TTATAAAGTT CAGGCTTGAA GATGGAGACC TCATTTTCCC CTGTGCAACT CTCCGTCCTG AAACCGTGT TGGCGTCACG AACATCTGGG TAAAGCCGAC AACCTACGTA ATTGCCGAGG TGGATGGGGA AAAGTGGTTT GTGAGCAAAG AGGCTTACGA GAAGCTCACC TACACGGAGA AAAAAGTCAG GCTGCTGGAG GAGGTTGATG CGTCGCAGTT CTTCCGCAAG TACGTCTAG TCCCGCTGGT AAACAGAAAA GTGCCAATTC TGCCCTGCAGA GTTTGTTGAC ACCGACAACG CAACAGGAGT TGTGATGAGC GTTCCCGCAC ACGCTCCTTT TGACCTGGCT GCCATTGAGG ACTTGAAGAG AGACGAGGAA ACGCTGGCGA AGTACGGAAT TGACAAAAGC GTTGTAGAGA GCATAAAGCC AATAGTTCTG ATTAAGACCG ACATTGAAGG TGTCTCTGCT GAGAAGCTAA TAAGAGAGCT TGGAGTGAAG AGCCAGAAGG ACAAGGAGCT GCTGGATAAG GCAACCAAGA CCCCTACAA GAAGGAGTAC CACACGGGAA TCATGCTGGA CAACACGATG AACTATGCTG GAATGAAAGT TTCTGAGGCG AAGGAGAGAG TTCATGAGGA TTTGGTTAAG CTTGGCTTGG GGGATGTTT CTACGAGTTC AGCGAGAAGC CCGTAATCTG CAGGTGCGGA ACGAAGTCCG TTGTTAAGGT TGTTAGGGAC CAGTGGTTCC TGAATACTC CAACAGAGAG TGAAGGAGA AGGTTCTGAA TCACCTTGAA AAGATGCGAA TCATCCCCGA CTACTACAAG GAGGAGTTCA GGAACAAGAT TGAGTGGCTC AGGGACAAGG CTTGTGCCAG AAGGAAGGGG CTTGGAACGA GAATCCGCTG GGATAAGGAG TGGCTCATCG AGAGCCTTTC AGACTCAACA ATCTACATGG CCTACTACAT CCTTGCCAAG TACATCAACG CAGGATTGCT CAAGGCCGAG AACATGACTC CCGAGTTCTC CGACTACGTG CTGCTGGGCA AAGGTGAGGT TGGGAAAAGT CGCGAAGCTT CAAAACCTAG CGTGGAGTTA ATCCAGCAGA TCAGGGACGA CTTGAGTAC TGGTATCCCG TTGACCTAAG AAGCAGTGGC AAGGACTTGG TTGCAAAACCA CCTGCTCTTC TACCTCTTCC ACCACGTCGC CATTTTCCCG CCAGATAAGT GGCCGAGGGC AATTGCCGTA AACGGATACG TCAGCCTTGA GGGCAAGAAG ATGAGCAAGA GCAAGAGGCC CTTGCTAACG ATGAAGAGGG CGGTGCAGCA GTATGGTGCG GATGTGACGA GGCTCTACAT CCTCCACGCT GCAGAGTACG ACAGCGATGC GGACTGGAAG AGCAGAGAGG TTGAAGGGCT TGCAAAACAC CTCAGGAGGT TCTACAACCT CGTGAAGGAG AACTACCTGA AAGAGTGGG AGAGCTAACA ACCCTCGACC GCTGGCTTGT GAGCAGGATG CAGAGGGCAA TAAAGGAAAT GAGGAGAGCT ATGGACAACC TGCAGACGAG GAGGGCCGTG AATGCCGCCCT TCTTCGAGCT CATGAACGAC GTGAGATGGT ATCTGAGGAG AGGAGGTGAG AACCTCGCTA TAATACTGGA CGACTGGATC AAGCTCCTCG CCCCTTTTGC TCCGCACATT TGCGAGGAGC TGTGGCACTT GAAGCATGAC AGCTACGTCA GCCTCGAAAG CTACCCAGAA TACGACGAAA CCAGGGTTGA CGAGGAGGCG GAGAGAAATT AGGAATACCT CCGAAACCTT GTTGAGGACA TTCAGGAAT CAAGAAGTTT GTTAGCGATG CGAAGGAGGT TTACATTGCT CCCGCCGAAG ACTGGAAGGT TAAGGCAGCA AAGGTCGTTG CTGAAAGCGG GATGTTGGG GAGGCGATGA AGCAGCTTAT GCAGGACGAG GAGCTTAGGA AGCTCGGCAA AGAAGTGCTA AATTTCGTCA AGAAGATTTT CAAAGACAGA AAGAAGCTGA TGCTAGTTAA GGAGTGGGAA GTTCTGCAGC AGAACCTGAA ATTTATTGAG AATGAGACCG GACTGAAGGT TATTTCTTGT ACTCAGAGAG TTCTTGAGGA GAAGAGGAGG CAGGCAGTTC CGGGCAAGCC CGCGATTAT GTTGTCTAA	Archaeoglobus fulgidus leucyl tRNA-synthetase (AFLRS)	RS
34	GTGGATATTG AAAGAAAATG GCGTGATAGA TGGAGAGATG CTGGCATATT TCAGGCTGAC CCTGATGACA GAGAAAAGAT ATTCTCTACA GTCGCTTACC CCTACCCAG TGGTGGCATG CACATAGGAC ACGGGAGGAC CTACACTGTC CCTGATGCT ATGCACGGTT CAAGAGGATG CAGGGCTACA ACGTCCGTGT TCCC ATGGCC TGGCATGTC JAGGGGCCCT GTTCATAGGG ATAGCGCGGA GGATTCAGAG GAAGGATCCC TGGACCTCA AAATCTACAG GGAGGTCCAC AGGGTCCCG AGGATGAGCT TGAACGTTTC AGTGACCCTG AGTACATAGT TGAATACTTC AGCAGGGAAT ACCGGTCTGT TATGGAGGAT ATGGGCTACT CCTACGACTG GAGGCGTGAA TTCAAAACCA CGGATCCAC CTACAGCAGG TTATACAGT GGCAGATAAG GAAGCTGAGG GACCTTGGCC TCGTAAGGAA GGGCGCCCAT CCTGTTAAGT ACTGCCCTGA ATGTGAAAC CCTGTGGGTG ACCATGACCT CCTTGAGGTT GAGGGGGTTG CCATAAACCA GCTCACACTC CTCAAATTC AACTTGGAGA CTCATACCTG GTCGAGCCCA CCTTCAGGCC CGAGACAATC TATGGGGCCA CCAACCTCTG GCTGAACCTT GATGAGGATT	Methanobacterium thermoautotrophicum leucyl tRNA-synthetase (MLRS)	RS

SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	ATGTGAGGGT TGAACAGGT GGTGAGGAGT GGATAATAAG CAGGGCTGCC GTGGATAATC TTTCACACCA GAAACTGGAC CTCAAGGTTT CCGGTGACGT CAACCCCGGG GACCTGATAG GGATGTGCGT GGAGAATCCT GTGACGGGCC AGGAACACCC CATACTCCCG GCTTCCTTCG TTGACCCTGA ATATGCCACA GGTGTTGTGT TCTCTGTCCC TGCACATGCC CCTGCAGACT TCATAGCCCT TGAGGACCTC AGGACAGACC ATGAATCTCT TGAAGGTAC GGTCTTGAGG ATGTGGTTGC TGATATTGAG CCCGTGAATG TCATAGCAGT GGATGGCTAC GGTGAGTTCC CGGCGGCCGA GGTATAGAG AAATTTGGTG TCAGAAACCA GGAGGACCC CGCCTTGAGG ATGCCACCGG GGAGCTATAC AAGATCGAGC ATGCGAGGGG TGTATGAGC AGCCACATCC CTGTCTATGG TGGTATGAAG GTCTCTGAGG CCCGTGAGGT CATCGCTGAT GAACCTGAAG ACCAGGGCTT TGACAGATGAG ATGTATGAAT TCGCTGAGCG ACCTGTTATA TGCCGCTGCG GTGGCAGGTG CGTTGTGAGG GTCATGGAGG ACCAGTGGTT CATGAAGTAC TCTGATGAGC CCTGGAAGGA CCTCGCCAC AGGTGCCTCG ATGGCATGAA GATAATACCC GAGGAGGTCC GGGCCAACCT TGAATACTAC ATCGACTGGC TCAATGACTG GGCATGTTCA AGGAGGATAG GCCTTGGAAAC AAGGCTGCC TGGGATGAGA GGTGGATCAT CGAACCCCTC ACAGACTCAA CAATCTACAT GGCATATTAC ACCATCGCAC ACCGCCTCAG GGAGATGGAT GCCGGGAGA TGGACGATGA GTTCTTTGAT GCCATATTCC TAGATGATTG AGGAACCTTT GAGGATCTCA GGGAGGAATT CCGGTACTGG TACCCCTTGG ACTGGAGGCT CTCTGCAAG GACCTCATAG GCAATCACCT GACATTCCAT ATATTCCACC ACTCAGCCAT ATTCCTGAG TCAGGGTGGC CCCGGGGGCG TGTGGTCTTT GGTATGGGCC TTCTTGAGGG CAACAAGATG TCATCTCCA AGGGCAACGT CATACTCTCG AGGGATGCCA TCGAGAAGCA CGGTGCAGAC GTGGTCCGGC TCTTCTCAT GTCTCAGCA GAGCCATGGC AGGACTTTGA CTGGAGGAG AGTGAGGTCA TCGGACCCG CAGGAGGATT GAATGGTTCA GGAATTCCGG AGAGAGGGTC TCAGGTATCC TGGATGGTAG GCCAGTCTC AGTGAGGTTA CTCAGACTGA ACCTGAAAGC TTCATTGGA GGTGGATGAT GGTCAGCTG AACCAGAGGA TACGTGAAGC CACAAGGGCC CTTGAATCAT TCCAGACAAG AAAGGCAGTT CAGGAGGCAC TCTATCTCCT TAAAGAGGAT GTTGACCACT ACCTTAAGCG TGTGAGGGT AGAGTTGATG ATGAGGTTAA ATCTGTCTTT GCAACGGTTC TGCAGGCTG GATAAGGCTC ATGGCTCCAT TCATACCCTA CACTGCTGAG GAGATGTGGG AGAGGTATGG TGGTGAGGGT TTTGTAGCAG AAGCTCCATG GCCTGACTTC TCAGATGATG CAGAGAGCAG GGATGTGCAG GTTGCAGAGG AGATGGTCCA GAATACCGTT AGAGACATTC AGGAAATCAT GAAGATCCTT GGATCCACCC CGGAGAGGGT CCACATATAC ACCTCACCA AATGAAATG GGATGTGCTA AGGTCGCAG CAGAGGTAGG AAACTAGAT ATGGCTCCA TAATGGGAAG GGTTCAGCT GAGGGCATCC ATGATAACAT GAAGGAGGTT GCTGAATTTG TAAGGAGGAT CATCAGGAC CTTGGTAAAT CAGAGGTTAC GGTGATAGAC GAGTACAGCG TACTCATGGA TGCATCTGAT TACATTGAAT CAGAGGTTGG AGCCAGGTTG GTGATACACA GCAAACAGA CTATGACCTT GAAACAAGG CTGTGAATGC CGTTCCTCTG AAGCCAGCCA TATACCTTGA ATGA		
35	MDEFEMIKRNTSEIISEELREVLKKDEKSAQIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIILLADLHAYLNQKGLDEIRKIGDYNKKVFEAMGLKAKYVVGSTFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPALHYPGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELSLFKNKELHPM DLKNAVAEELIKILEPIRKRL	mutant TyrRS (LWJ16)	RS
36	MDEFEMIKRNTSEIISEELREVLKKDEKSAQIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIILLADLHAYLNQKGLDEIRKIGDYNKKVFEAMGLKAKYVVGSEFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPALHYPGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELSLFKNKELHPM DLKNAVAEELIKILEPIRKRL	TyrRS (SS12)	RS
37	MDEFEMIKRNTSEIISEELREVLKKDEKSAQIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIILLADLHAYLNQKGLDEIRKIGDYNKKVFEAMGLKAKYVVGSTFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPALHYPGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELSLFKNKELHPM DLKNAVAEELIKILEPIRKRL	<i>p</i> -iPr-PheRS	RS
38	MDEFEMIKRNTSEIISEELREVLKKDEKSAQIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIILLADLHAYLNQKGLDEIRKIGDYNKKVFEAMGLKAKYVVGSTFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPALHYPGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELSLFKNKELHPM DLKNAVAEELIKILEPIRKRL	<i>p</i> -NH <sub>2</sub> -PheRS(1)	RS
39	MDEFEMIKRNTSEIISEELREVLKKDEKSAQIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIILLADLHAYLNQKGLDEIRKIGDYNKKVFEAMGLKAKYVVGSTFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPALHYPGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELSLFKNKELHPM DLKNAVAEELIKILEPIRKRL	<i>p</i> -NH <sub>2</sub> -PheRS(2)	RS
40	MDEFEMIKRNTSEIISEELREVLKKDEKSAQIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIILLADLHAYLNQKGLDEIRKIGDYNKKVFEAMGLKAKYVVGSEFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPALHYPGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELSLFKNKELHPM DLKNAVAEELIKILEPIRKRL	<i>p</i> -NH <sub>2</sub> -PheRS(3a)	RS
41	MDEFEMIKRNTSEIISEELREVLKKDEKSAQIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIILLADLHAYLNQKGLDEIRKIGDYNKKVFEAMGLKAKYVVGSTFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPALHYPGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELSLFKNKELHPM DLKNAVAEELIKILEPIRKRL	<i>p</i> -NH <sub>2</sub> -PheRS(3b)	RS



SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL		
42	MDEFEMIKRNTSEIISEEELREVLKKDEKSASIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSTFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNTYHYAGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	O-Allyl-TyrRS(1)	RS
43	MDEFEMIKRNTSEIISEEELREVLKKDEKSAPIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSMFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNTYHYAGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	O-Allyl-TyrRS(3)	RS
44	MDEFEMIKRNTSEIISEEELREVLKKDEKSATIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSHFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNTYHYAGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	O-Allyl-TyrRS(4)	RS
45	MDEFEMIKRNTSEIISEEELREVLKKDEKSAHIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNPCHYAGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	p-Br-PheRS	RS
46	MDEFEMIKRNTSEIISEEELREVLKKDEKSAAGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNVHYDGDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	p-Az-PheRS(1)	RS
47	MDEFEMIKRNTSEIISEEELREVLKKDEKSAGIFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNTYYLGVDAVAGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	p-Az-PheRS(3)	RS
48	MDEFEMIKRNTSEIISEEELREVLKKDEKSALIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNVYHSGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	p-Az-PheRS(5)	RS
49	MDEFEMIKRNTSEIISEEELREVLKKDEKSADIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNMHYQGVDAVAGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 3-4)	RS
50	MDEFEMIKRNTSEIISEEELREVLKKDEKSAYIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNDIHYTGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 3-7)	RS
51	MDEFEMIKRNTSEIISEEELREVLKKDEKSALIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNDIHYLGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 4-1)	RS
52	MDEFEMIKRNTSEIISEEELREVLKKDEKSALIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMSVNVHYLGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 5-4)	RS
53	MDEFEMIKRNTSEIISEEELREVLKKDEKSALIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNDIHYLGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-acyl phenylalanine into proteins (Ketone 6-8)	RS
54	MDEFEMIKRNTSEIISEEELREVLKKDEKSATIGFEPGSKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGELDEIRKIGDYNKKVFEAMGLKAKYVYGSFQLDKDY TLNVYRLALKTTTKRARRSMELIAREDENPKVAEVIYPIMQVNDIHYAGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK	Mutant synthetase to incorporate m-methoxy phenylalanine into	RS



SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	proteins (OMe 1-6)	
55	MDEFEMIKRNTSEIISEEELREVLKKDEKSATIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLSDLPAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSEFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNDIHYLGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 1-8)	RS
56	MDEFEMIKRNTSEIISEEELREVLKKDEKSATIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSEFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNSHYDGVDAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 2-7)	RS
57	MDEFEMIKRNTSEIISEEELREVLKKDEKSAIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLPDLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSEFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNDIHYLGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 4-1)	RS
58	MDEFEMIKRNTSEIISEEELREVLKKDEKSAHIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSAFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNGHHYIGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate m-methoxy phenylalanine into proteins (OMe 4-8)	RS
59	MDEFEMIKRNTSEIISEEELREVLKKDEKSATIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSAFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNCAYHVGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL#	Mutant synthetase to incorporate p-O-allyl tyrosine into proteins (Allyl)	RS
60	MDEFEMIKRNTSEIISEEELREVLKKDEKSAGIFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSSFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNTSHYLGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	Aminoacyl tRNA synthetase for the incorporation of p-benzoyl-L-phenylalanine (p-BpaRS(H6))	RS
61	MDEFEMIKRNTSEIISEEELREVLKKDEKSATIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSEFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPPLHYQGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	Aminoacyl tRNA synthetase for the incorporation of p-azido-phenylalanine (p-Az-PheRS(3))	RS
62	MDEFEMIKRNTSEIISEEELREVLKKDEKSATIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSSFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPPLHYQGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	Aminoacyl tRNA synthetase for the incorporation of p-azido-phenylalanine (p-Az-PheRS(6))	RS
63	MDEFEMIKRNTSEIISEEELREVLKKDEKSALIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSTFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPVHYQGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	Aminoacyl tRNA synthetase for the incorporation of p-azido-phenylalanine (p-Az-PheRS(20))	RS
64	MDEFEMIKRNTSEIISEEELREVLKKDEKSATIGFEPGSGKIHLGHYLQIKKMIDLQN AGFDIIILLADLHAYLNQKGEDEIRKIGDYNKKVFEAMGLKAKYVYGSSFQLDKDY TLNVYRLALKTTTLKRARRSMELIAREDENPKVAEVIYPIQVNPVSHYQGVDVAVGGM EQRKIHMLARELLPKKVVCIHNPVLTGLDGEKMSSSKGNFIAVDDSPPEIRAKIKK AYCPAGVVEGNPIMEIAKYFLEYPLTIKRPEKFGGDLTVNSYEELESFKNKELHPM DLKNAVAEELIKILEPIRKRL	Aminoacyl tRNA synthetase for the incorporation of p-azido-phenylalanine (p-Az-PheRS(24))	RS
65	MSDFRIIEEK WQKAWEKDRI FESDPNEAEK FFLTIYPYPL NGNLHAGHTR TFITIGDAPAF YMRMGYNVL PPLGFHVGT PIIGLAELIA KRDETTIEVY TKYHDVPLED LLQUTTEPKI VEYFSREALQ ALKSIGYSID WRRVFTTDE EYQRFIEWQY WKLELGLIV KGTHPVRYCP HDQNPVEDHD LLAGERATIV EFTVIKFRLE DGDLIFFCAT LRPETVFGVT NIWVKPTTYV IALVDGEKWF VSKEAYEKL YTEKKVRLLE EVDASQFFGK YVIVPLVNRK VPILPAEPVD TDNATGVVMS VPAHAPFLA AIEDLKRDEE TLAKYGIDKS VVESIKPIVL IKTDIEGVPA EKLIRELGVK SQDKELLDK ATKTYKKEY HTGIMLDNTM NYAGMKVSEA KERVHEDLVK LGLGDVFYEF SEKPVICRG TKCVVKVVRD QWFLNYSNR WKEKVLNHL KMRIIPDYK EEFNKIEWL RDKACARRKG	Archaeoglobus fulgidus leucyl trna-synthetase (AFLRS)	RS

SEQ ID #	Appendix 1: Table 5: Sequences	Notes	tRNA or RS
	LGTRIPWDKE WLIESLSDST IYMAYYILAK YINAGLLKAE NMTPEFLDYV LLGKGEVGKV AEASKLSVEL IQQIRDDFEY WYPVDLRSSG KDLVANHLLF YLFHHVAIFP PDKWPRAIAV NGVVSLEGKK MSKSKGPLLT MKRAVQQYGA DVTRLYILHA AEYDSADAWK SREVEGLANH LRRFYNLVKE NYLKEVGELT TLDRLVSRM QRAIKEVREA MDNLQTRRAV NAAFFELMND VRWYLRGGE NLAILDDWI KLLAPPAPHI CEELWHLKHD SYVSLETYPE YDETRVDEEA ERIEYLRNL VEDIQEIKKF VSDAKEVYIA PAEDWKVKAA KVAESGDVG EAMKQLMQDE ELRKLGEKVS NFVKKIFKDR KKLMLVKWE VLQONLKPIE NETGLKVILD TQRPPEEKRR QAVPGKPAIY VA*		
66	VDIERKWRDR WRDAGIFQAD PDDREKIFLT VAYPYPSGAM HIGHGRITYTV PDVYARFKRM QGYNVLPFMA WHVTGAPVIG IARRIQKDP WTLKIYREVH RVPEDLERF SDPEYIVEYF SREYRSVMED MGYSIDWRRE FRITDPTYSR FIQWQIRKLR DLGLVRKAH PVKYCPECEN PVGDHDLLEG EGVAINQLTL LKFKLGDSYL VAATFRPETI YGATNLWLN DEDYVRVETG GEEWIIISRAA VDNLSHQKLD LKVSQDVNPG DLIGMCVENP VTQGEHPILP ASFVDPEYAT GUVFSVPAHA PADFIALEDL RTDHELLERY GLEDVVADIE PWNVIAVDGY GEFPAAEVIE KFGVRNQEDP RLEDATGELY KIEHARGVMS SHIPVYGGMK VSEAREVIAD ELKDQGLADE MYEFAERPVI CRCGGRCVVR VMEDQWFMKY SDDAWKDLAH RCLDGMKIIP EEVRANFEY IDWLNWACS RRIGLSTRLP WDERWIEPL TDSTIYMAY TIAHRLREMD AGEMDDEFFD AIFLDDSGTF EDLREEFRYW YPLDWRLSAK DLIGNHLTFH IFHHSATFPE SGWPRGAVVF CMGLLEGKMK SSSKGNVILL RDAIEKHGAD VVRLFLMSSA EPWQDFDWRE SEVIGTRRRRI EWFREFGERV SGILDGRPVL SEVTPAEPES FIGRNMGGQL NQRIREATRA LESFQTRKAV QEALYLLKKD VDHYLKRVEG RVDDDEVKSVL ANVLHAWIRL MAPFIPTAE EMWERYGEG FVAEAPWPDF SDDAESRDVQ VAEEMVQNTV RDIQEIMKIL GSTPERVHIY TSPKWKVDVL RVAAEVGKLD MGSIMGRVSA EGIHNDMKEV AEFVRRRIIRD LGKSEVTVID EYSVLMDASD YIESEVGARV VIHSPDYDF ENKAVNAVPL KPAIYLE*	Methanobacterium thermoautotrophicum leucyl tna-synthetase (MtLRS)	RS